

COLD SPRING HARBOR SYMPOSIA
ON QUANTITATIVE BIOLOGY

VOLUME XLI—PART 2

COLD SPRING HARBOR SYMPOSIA
ON QUANTITATIVE BIOLOGY

VOLUME XLI

Origins of Lymphocyte Diversity

COLD SPRING HARBOR LABORATORY

1977

COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY
VOLUME XLI

© 1977 by The Cold Spring Harbor Laboratory
International Standard Book Number 0-87969-040-2 (clothbound)
Library of Congress Catalog Card Number 34-8174

Printed in the United States of America
All rights reserved

COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY

Founded in 1933 by



REGINALD G. HARRIS

Director of the Biological Laboratory 1924 to 1936

Previous Symposia Volumes

- | | |
|---|--|
| I (1933) Surface Phenomena | XXI (1956) Genetic Mechanisms: Structure and Function |
| II (1934) Aspects of Growth | XXII (1957) Population Studies: Animal Ecology and Demography |
| III (1935) Photochemical Reactions | XXIII (1958) Exchange of Genetic Material: Mechanism and Consequences |
| IV (1936) Excitation Phenomena | XXIV (1959) Genetics and Twentieth Century Darwinism |
| V (1937) Internal Secretions | XXV (1960) Biological Clocks |
| VI (1938) Protein Chemistry | XXVI (1961) Cellular Regulatory Mechanisms |
| VII (1939) Biological Oxidations | XXVII (1962) Basic Mechanisms in Animal Virus Biology |
| VIII (1940) Permeability and the Nature of Cell Membranes | XXVIII (1963) Synthesis and Structure of Macromolecules |
| IX (1941) Genes and Chromosomes: Structure and Organization | XXIX (1964) Human Genetics |
| X (1942) The Relation of Hormones to Development | XXX (1965) Sensory Receptors |
| XI (1946) Heredity and Variation in Microorganisms | XXXI (1966) The Genetic Code |
| XII (1947) Nucleic Acids and Nucleoproteins | XXXII (1967) Antibodies |
| XIII (1948) Biological Applications of Tracer Elements | XXXIII (1968) Replication of DNA in Microorganisms |
| XIV (1949) Amino Acids and Proteins | XXXIV (1969) The Mechanism of Protein Synthesis |
| XV (1950) Origin and Evolution of Man | XXXV (1970) Transcription of Genetic Material |
| XVI (1951) Genes and Mutations | XXXVI (1971) Structure and Function of Proteins at the Three-dimensional Level |
| XVII (1952) The Neuron | XXXVII (1972) The Mechanism of Muscle Contraction |
| XVIII (1953) Viruses | XXXVIII (1973) Chromosome Structure and Function |
| XIX (1954) The Mammalian Fetus: Physiological Aspects of Development | XXXIX (1974) Tumor Viruses |
| XX (1955) Population Genetics: The Nature and Causes of Genetic Variability in Population | XL (1975) The Synapse |

The Symposium Volumes are published by the Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, and may be purchased directly from the Laboratory or through booksellers. Price of Volume XLI—2-part set \$60.00 (inc. postage). May be purchased only as a complete set. Price subject to change without notice.



First Row: A. and B. Benacerraf/N. K. Jerne, G. J. Thorbecke
Second Row: R. Riblet/H. O. McDevitt, W. Bodmer/R. J. Poljak
Third Row: E. Haber, K. Rajewsky/N. A. Mitchison, B. A. Askonas
Fourth Row: D. Dressler, H. Potter/H. Wigzell, G. M. Shearer



First Row: A. E. Bussard/P. Doherty/W. E. Paul/D. W. Scott
 Second Row: J. F. A. P. Miller/O. Mäkelä/C. Milstein/L. Hood
 Third Row: J. Schrader, G. J. V. Nossal/H. Cantor, P. Matzinger/ . and F. Haurowitz
 Fourth Row: D. R. Davies, M. Potter/J. J. van Rood, M. Raff

Contents

Part 1

Symposium Participants	v
Foreword	xv

Introduction

The Common Sense of Immunology <i>N. K. Jerne</i>	1
---	---

LYMPHOCYTE FUNCTION

T-cell Markers and Differentiation

Thymopoiectin and Bursopoiectin: Induction Signals Regulating Early Lymphocyte Differentiation <i>G. Goldstein, M. Scheid, E. A. Boyse, A. Brand and D. G. Gilmour</i>	5
Normal and Neoplastic Maturation of T-lineage Lymphocytes <i>I. L. Weissman, S. Baird, R. L. Gardner, V. E. Papaioannou and W. Raschke</i>	9
Regulation of Cellular and Humoral Immune Responses by T-cell Subclasses <i>H. Cantor and E. A. Boyse</i>	23
Surface Markers and Functional Relationships of Cells Involved in Murine B-lymphocyte Differentiation <i>L. A. Herzenberg, L. A. Herzenberg, S. J. Black, M. R. Loken, K. Okumura, W. van der Loo, B. A. Osborne, D. Hewgill, J. W. Goding, G. Gutman and N. L. Warner</i>	33
An Unusual Kappa Immunoglobulin Antigen Present on the Membrane of T and B Lymphocytes <i>A. B. Gottlieb, M. Engelhard, H. G. Kunkel and S. M. Fu</i>	47
Rat Thy-1 Antigens from Thymus and Brain: Their Tissue Distribution, Purification, and Chemical Composition <i>A. F. Williams, A. N. Barclay, M. Letarte-Muirhead and R. J. Morris</i>	51
Specialized DNA Polymerases in Lymphoid Cells <i>D. Baltimore, A. E. Silverstone, P. C. Kung, T. A. Harrison and R. P. McCaffrey</i>	63
Studies on the Interactions between Viruses and Lymphocytes <i>B. R. Bloom, A. Senik, G. Stoner, G. Ju, M. Nowakowski, S. Kano and L. Jimenez</i>	73

Helper and Suppressor T Cells and Their Products

The Hermaphrocyte: A Suppressor-Helper T Cell <i>R. K. Gershon, D. D. Eardley, K. F. Naidorf and W. Ptak</i>	85
Suppressor T Cells in Tolerance to Non-self and Self Antigens <i>A. Basten, R. Loblay, E. Chia, R. Callard and H. Pritchard-Briscoe</i>	93
Tolerance: Two Pathways of Negative Immunoregulation in Contact Sensitivity to DNFB <i>H. N. Claman, S. D. Miller and J. W. Moorhead</i>	105

Current Concepts of the Antibody Response: Heterogeneity of Lymphoid Cells, Interactions, and Factors <i>M. Feldmann, P. Beverley, P. Erb, S. Howie, S. Kontiainen, A. Maoz, M. Mathies, I. McKenzie and J. Woody</i>	113
Suppressive and Enhancing T-cell Factors as I-region Gene Products: Properties and the Subregion Assignment <i>T. Tada, M. Taniguchi and C. S. David</i>	119
<i>B-cell Differentiation and Commitment</i>	
In Vitro Studies on the Generation of Lymphocyte Diversity <i>J. J. T. Owen, R. K. Jordan, J. H. Robinson, U. Singh and H. N. A. Willcox</i>	129
Studies of Generation of B-cell Diversity in Mouse, Man, and Chicken <i>M. D. Cooper, J. F. Kearney, P. M. Lydyard, C. E. Grossi and A. R. Lawton</i>	139
Ontogeny of Murine B Lymphocytes: Development of Ig Synthesis and of Reactivities to Mitogens and to Anti-Ig Antibodies <i>F. Melchers, J. Andersson and R. A. Phillips</i>	147
Development and Modulation of B Lymphocytes: Studies on Newly Formed B Cells and Their Putative Precursors in the Hemopoietic Tissues of Mice <i>M. C. Raff</i>	159
Induction of Immunoglobulin Synthesis in Abelson Murine Leukemia Virus-transformed Mouse Lymphoma Cells in Culture <i>B. J. Weimann</i>	163
The Interplay of Evolution and Environment in B-cell Diversification <i>N. R. Klinman, N. H. Sigal, E. S. Metcalf, S. K. Pierce and P. J. Gearhart</i>	165
Synthesis of Multiple Immunoglobulin Classes by Single Lymphocytes <i>B. Pernis, L. Forni and A. L. Luzzati</i>	175
Immunoglobulin Receptors on Murine B Lymphocytes <i>E. S. Vitetta, J. Cambier, J. Forman, J. R. Kettman, D. Yuan and J. W. Uhr</i>	185
Functional and Structural Characterization of Immunoglobulin on Murine B Lymphocytes <i>R. M. E. Parkhouse, E. R. Abney, A. Bourgois and H. N. A. Willcox</i>	193
Origin and Differentiation of Lymphocytes Involved in the Secretory IgA Response <i>J. J. Cebra, P. J. Gearhart, R. Kamat, S. M. Robertson and J. Tseng</i>	201
Mechanism of B-cell Activation and Self-Non-self Discrimination <i>G. Möller</i>	217
Growth and Maturation of Single Clones of Normal Murine T and B Lymphocytes In Vitro <i>J. Andersson, A. Coutinho, F. Melchers and T. Watanabe</i>	227
Hapten-specific B Lymphocytes: Enrichment, Cloning, Receptor Analysis, and Tolerance Induction <i>G. J. V. Nossal, B. L. Pike, J. W. Stocker, J. E. Layton and J. W. Goding</i>	237
Regulation of Clonal B-lymphocyte Proliferation by Anti-immunoglobulin or Anti-Ia Antibodies <i>P. W. Kincade and P. Ralph</i>	245
Cellular and Molecular Interactions in Control of B-cell Immunity and Tolerance <i>E. Diener, C. Shiozawa, B. Singh and K.-C. Lee</i>	251
<i>Receptors</i>	
Lymphocyte Surface Immunoglobulins: Evolutionary Origins and Involvement in Activation <i>J. J. Marchalonis, J. M. Decker, D. DeLuca, J. M. Moseley, P. Smith and G. W. Warr</i>	261
Antigen-binding, Idiotypic Receptors from T Lymphocytes: An Analysis of Their Biochemistry, Genetics, and Use as Immunogens To Produce Specific Immune Tolerance <i>H. Binz and H. Wigzell</i>	275
On the Structure of the T-cell Receptor for Antigen <i>U. Krawinkel, M. Cramer, C. Berek, G. Hämmerling, S. J. Black, K. Rajewsky and K. Eichmann</i>	285
The Immune Response to Staphylococcal Nuclease: A Probe of Cellular and Humoral Antigen-specific Receptors <i>D. H. Sachs, J. A. Berzofsky, C. G. Fathman, D. S. Pisetsky, A. N. Schechter and R. H. Schwartz</i>	295
Functional Characterization of Rabbit Lymphocytes Carrying Fc Receptor <i>P.-A. Cazenave, D. Juy and C. Bona</i>	307
Structural and Functional Heterogeneity of Fc Receptors <i>H. M. Grey, C. L. Anderson, C. H. Heusser, B. K. Borthistle, K. B. Von Eschen and J. M. Chiller</i>	315

THE MAJOR HISTOCOMPATIBILITY COMPLEX

Structure of the Molecular Products of the MHC

Structure of HL-A A and B Antigens Isolated from Cultured Human Lymphocytes <i>J. L. Strominger, D. L. Mann, P. Parham, R. Robb, T. Springer and C. Terhorst</i>	323
Structural Studies of β_2 -Microglobulin-associated and Other MHC Antigens <i>P. A. Peterson, H. Anundi, B. Curman, L. Klareskog, S. Kvist, L. Östberg, L. Rask, L. Sandberg and K. Sege</i>	331
Comparative Chemical Analyses and Partial Amino Acid Sequences of the Heavy Chains of HL-A Antigens <i>E. Appella, N. Tanigaki, O. Henriksen, D. Pressman, D. F. Smith and T. Fairwell</i>	341
Structural Differences between Parent and Variant H-2K Glycoproteins from Mouse Strains Carrying H-2 Gene Mutations <i>S. G. Nathenson, J. L. Brown, B. M. Ewenstein, T. Nisizawa, D. W. Sears and J. H. Freed</i>	343
Structure of Murine Histocompatibility Antigens <i>B. A. Cunningham, R. Henning, R. J. Milner, K. Reske, J. A. Ziffer and G. M. Edelman</i>	351
Structural Studies of H-2 and TL Alloantigens <i>J. W. Uhr, E. S. Vitetta, J. Klein, M. D. Poulík, D. G. Klapper and J. D. Capra</i>	363
Chemical Characterization of Products of the H-2 Complex <i>J. Silver, J. M. Cecka, M. McMillan and L. Hood</i>	369
Human Ia Antigens—Purification and Molecular Structure <i>D. Snary, C. Barnstable, W. F. Bodmer, P. Goodfellow and M. J. Crumpton</i>	379
Chemical and Immunological Characterization of HL-A-linked B-lymphocyte Alloantigens <i>T. A. Springer, J. F. Kaufman, L. A. Siddoway, M. Giphart, D. L. Mann, C. Terhorst and J. L. Strominger</i>	387
The Guinea Pig MHC: Functional Significance and Structural Characterization <i>B. D. Schwartz, A. M. Kask and E. M. Shevach</i>	397
Partial Amino Acid Sequences of MHC Products <i>J. Silver</i>	405
Analysis of Lymphocyte Surface Antigen Expression by the Use of Variant Cell Lines <i>R. Hyman and I. Trowbridge</i>	407

Part 2

Genetics of the MHC and Associated Products

- Polymorphic B-cell Determinants in Man *J. J. van Rood, A. van Leeuwen, M. Jonker, A. Termijtelen and B. A. Bradley* 417
- Cellular Recognition of Major Histocompatibility Complex Antigens *F. H. Bach, M. L. Bach, O. J. Kuperman, H. W. Sollinger and P. M. Sondel* 429
- Genetics and Serology of HL-A-linked Human Ia Antigens *C. J. Barnstable, E. A. Jones, W. F. Bodmer, J. G. Bodmer, B. Arce-Gomez, D. Snary and M. J. Crumpton* 443
- Histocompatibility-2 System of Wild Mice. IV. Ia and Ir Typing of Two Wild Mouse Populations *J. Klein, C. F. Merryman, P. H. Maurer, M. Hauptfeld and M. B. Gardner* 457
- Genetic Control of Specific Immune Responses and Immune Suppressions by *I*-region Genes *B. Benacerraf and M. E. Dorf* 465
- Serological and Functional Evidence for Further Subdivision of the *I* Regions of the *H-2* Gene Complex *D. C. Shreffler, C. S. David, S. E. Cullen, J. A. Frelinger and J. E. Niederhuber* 477
- Functional and Genetic Analysis of Ia Antigens *H. O. McDevitt, T. L. Delovitch and J. L. Press* 489
- Selective Expression of Separate *I*-region Loci in Functionally Different Lymphocyte Subpopulations *D. B. Murphy, K. Okumura, L. A. Herzenberg, L. A. Herzenberg and H. O. McDevitt* 497

Role of Histocompatibility Gene Products in T-cell Cytolysis

- The Concept That Surveillance of Self Is Mediated Via the Same Set of Genes That Determines Recognition of Allogenic Cells *R. M. Zinkernagel and P. C. Doherty* 505
- F₁ Hybrid Antiparental Cell-mediated Lympholysis: A Comparison with Bone Marrow Graft Rejection and with Cell-mediated Lympholysis to Alloantigens *G. M. Shearer, G. Cudkowicz, A.-M. Schmitt-Verhulst, T. G. Rehn, H. Waksal and P. D. Evans* 511
- Cytotoxic T-cell Response to Histocompatibility Antigens: The Role of H-2 *M. J. Bevan* 519
- Recognition of Alterations Induced by Early Vaccinia Surface Antigens and Dependence of Virus-specific Lysis on H-2 Antigen Concentration on Target Cells *U. Koszinowski, H. Ertl, H. Wekerle and R. Thomssen* 529
- The Influence of *H-2* Gene Products on Cell-mediated and Humoral Immune Responses *H. von Boehmer, J. Sprent and W. Haas* 539
- The Recognition of H-2 and Viral Antigens by Cytotoxic T Cells *J. W. Schrader, R. Henning, R. J. Milner and G. M. Edelman* 547
- On the Possibility of Multiple T-cell Receptors *D. B. Wilson, E. Heber-Katz, J. Sprent and J. C. Howard* 559

Antigen Presentation and T-B Cell Interactions

Genetic Restriction of Macrophage-Lymphocyte Interactions in Secondary Antibody Responses In Vitro <i>C. W. Pierce, J. A. Kapp and B. Benacerraf</i>	563
Genetic Restriction in T-lymphocyte Activation by Antigen-pulsed Peritoneal Exudate Cells <i>W. E. Paul, E. M. Shevach, D. W. Thomas, S. F. Pickeral and A. S. Rosenthal</i>	571
Antigen Activation of T Lymphocytes: Influence of Major Histocompatibility Complex <i>J. F. A. P. Miller and M. A. Vadas</i>	579
Regulatory Mechanisms in the Immune Response to Cell-surface Antigens <i>P. Lake and N. A. Mitchison</i>	589
The Significance of T-B Collaboration across Haplotype Barriers <i>S. L. Swain, P. E. Trefts, H. Y.-S. Tse and R. W. Dutton</i>	597
The Role of the Histocompatibility Gene Complex in Lymphocyte Differentiation <i>D. H. Katz</i>	611
Comparison of B-cell Activation Factors <i>J. Klein</i>	625

IMMUNOGLOBULINS

Antibody Combining Site

Model-building Studies of Antigen-binding Sites: The Hapten-binding Site of MOPC-315 <i>E. A. Padlan, D. R. Davies, I. Pecht, D. Givol and C. Wright</i>	627
Three-dimensional Structure and Diversity of Immunoglobulins <i>R. J. Poljak, L. M. Amzel, B. L. Chen, Y. Y. Chiu, R. P. Phizackerley, F. Saul and X. Ysern</i>	639
Origins of Antibody Diversity: Insights Gained from Amino Acid Sequence Studies of Elicited Antibodies <i>E. Haber, M. N. Margolies and L. E. Cannon</i>	647
Primary Structural Differences in Myeloma Proteins That Bind the Same Haptens <i>M. Potter, S. Rudikoff, M. Vrana, D. N. Rao and E. B. Mushinski</i>	661
Folding, Association, and Interactions of Domains in the Antibody Molecule <i>D. Givol, J. Sharon, J. Hochman, M. Gavish, D. Inbar, I. Pecht, I.-Z. Steinberg and J. Schlessinger</i>	667

Allotypes and Idiotypes

Rabbit Immunoglobulin Allotypes: Complexities of Their Genetics, Expression, Structural Basis, and Evolution <i>R. G. Mage, G. O. Young-Cooper, J. Rejnek, A. A. Ansari, C. B. Alexander, E. Appella, M. Carta-Sorcini, S. Landucci-Tosi and R. M. Tosi</i>	677
V-region Genes for Rabbit Ig Heavy Chains <i>K. L. Knight, W. J. Horng and S. Dray</i>	687
The Response of Rabbits to Streptococcal Hyperimmunization <i>B. A. Fraser, A. P. Johnstone, S. M. Gordon and T. J. Kindt</i>	689
Structure and Immunosuppression of a Cross-reactive Idiotypic Antibody Associated with Anti- <i>p</i> -azophenylarsonate Antibodies of Strain-A Mice <i>S.-T. Ju, F. L. Owen and A. Nisonoff</i>	699
Idiotypes and Anti-idiotypes as Probes in Analysis of Immunoregulation <i>H. Cozenza, A. A. Augustin and M. H. Julius</i>	709
Immune Responses of BALB/c Mice to the Idiotypic Protein of T15 and of Other Myeloma Proteins of BALB/c Origin: Implications for an Immune Network and Antibody Multispecificity <i>N. Sakato, C. A. Janeway, Jr. and H. N. Eisen</i>	719
Uniformity in a Clonal Repertoire: A Case for a Germ-line Basis of Antibody Diversity <i>J. L. Claflin and S. Rudikoff</i>	725
Inheritance of Antibody Specificity. IV. Control of Related Molecular Species by One V _H Gene <i>O. Mäkelä and K. Karjalainen</i>	735
On the Genetic Dissection of a Specific Humoral Immune Response to $\alpha(1,3)$ Dextran <i>W. Geckeler, B. Blomberg, C. de Preval and M. Cohn</i>	743

Generation of Diversity: 1. Biological Aspects

- The Life Style of B Cells—Cellular Proliferation and the Invariancy of IgG *B. A. Askonas and J. R. North* 749
- Evolution in Microcosm: The Rapid Somatic Diversification of Lymphocytes *A. J. Cunningham* 761
- The Ontogenesis of Lymphocyte Diversity in Anuran Amphibians *L. Du Pasquier and M. R. Wabl* 771
- Regulation of Immunoglobulin Expression in Mouse Myeloma Cells *D. H. Margulies, W. Cieplinski, B. Dharmgrongartama, M. L. Gefter, S. L. Morrison, T. Kelly and M. D. Scharff* 781
- Somatic Cell Genetics of Antibody-secreting Cells: Studies of Clonal Diversification and Analysis by Cell Fusion *C. Milstein, K. Adetugbo, N. J. Cowan, G. Köhler, D. S. Secher and C. D. Wilde* 793
- The I_B-peptide Marker and the Ly-3 Surface Alloantigen: Structural Studies of a V_κ-region Polymorphism and a T-cell Marker Determined by Linked Genes *P. D. Gottlieb and P. J. Durda* 805

Generation of Diversity: 2. Structural Aspects

- The Structure and Genetics of Mouse Immunoglobulins: An Analysis of NZB Myeloma Proteins and Sets of BALB/c Myeloma Proteins Binding Particular Haptens *L. Hood, E. Loh, J. Hubert, P. Barstad, B. Eaton, P. Early, J. Fuhrman, N. Johnson, M. Kronenberg and J. Schilling* 817
- Genetic Control of Antibody Variable Regions *M. Weigert and R. Riblet* 837
- Identical Hypervariable Regions in Light Chains of Differing V_κ Subgroups *J. D. Capra, D. G. Klapper, A. S. Tung and A. Nisonoff* 847
- Origin of Immunoglobulin Gene Diversity: The Evidence and a Restriction-Modification Model *P. Leder, T. Honjo, J. Seidman and D. Swan* 855
- The Significance of Hybridization Kinetic Experiments for Theories of Antibody Diversity *G. P. Smith* 863
- Somatic Changes in the Content and Context of Immunoglobulin Genes *S. Tonogawa, N. Hozumi, G. Matthysens and R. Schuller* 877

Summary

- Understanding Selective Molecular Recognition *G. M. Edelman* 891

Name Index 1i

Subject Index 17i

Recognition of Alterations Induced by Early Vaccinia Surface Antigens and Dependence of Virus-specific Lysis on H-2 Antigen Concentration on Target Cells

U. KOSZINOWSKI, H. ERTL, H. WEKERLE* AND R. THOMSEN

*Hygiene-Institut der Universität, Kreuzbergweg 57, D-34 Göttingen, West Germany; *Max-Planck-Institut für Immunbiologie, Stübweg 51, D-78 Freiburg, West Germany*

Mice generate cytolytic T lymphocytes (CTL) after sensitization with infective virus (Zinkernagel and Doherty 1974; Gardner et al. 1975; Koszinowski and Thomssen 1975; Ertl and Koszinowski 1976). CTL lyse virus-infected target cells in vitro. The reaction is specific for the sensitizing virus; there is no cross-reactivity against cells infected with viruses of another group. In addition to virus specificity, H-2 homology of antigenic products of the K or D region is required for specific lysis (Zinkernagel and Doherty 1975). The same requirements have been found in the effector phase against chemically modified cells (Shearer 1974; Shearer et al. 1975; Forman 1975; Rehn et al. 1976) and cells bearing the male-specific antigen (H-Y) (Gordon et al. 1975) as well as in the reactivity against minor histocompatibility antigens (Bevan 1975). The question arose whether this restriction is due to a dual recognition process of syngenic H-2 structures and viral antigens or to a single T-cell receptor which recognizes a virus-specific altered H-2 antigen. Recent experiments with radiation chimeras favor the second possibility since reaction against "modified" alloantigens is possible provided the CTL is tolerant to the alloantigen which is present during the sensitization phase (Pfeizenmaier et al. 1976).

It must be considered, however, that determination of ^{51}Cr -release in certain combinations reflects only the requirements of the lethal-hit stage (Golstein and Smith 1976). The inference as to recognition requirements can only be drawn indirectly from cytolysis data. Requirements for recognition can be tested by specific absorption on monolayers (Wekerle et al. 1972; Golstein et al. 1972). Data presented here show that absorption is possible only on monolayers bearing "modified" H-2 determinants present during the sensitization phase. Another question is whether CTL can lyse virus-specific infected cells which lack H-2 antigenic determinants. To investigate the relationships between H-2 antigenic concentration and degree of virus-specific lysis, infected target cells treated with proteolytic enzymes were tested. In a third approach, we looked for the minimal changes that must be induced on cells by the vaccinia virus infection to sensitize CTL in vivo and to enable cytolysis in vitro. Our data demonstrate that induction

of early vaccinia virus surface antigens is sufficient for sensitization and specific lysis.

MATERIALS AND METHODS

Mice. Mice of the inbred strains C3H (H-2^k), DBA/2 (H-2^d), and C57BL/6J (H-2^b) at the age of 6–10 weeks were used throughout. These were purchased from Bomholtgard, Denmark.

Viruses and sensitization. Stocks of vaccinia virus strains WR and Elstree were grown in VERO (*Cercopithecus aethiops*) kidney cells. Virus titrations were performed on the same cells. Stock solutions of vaccinia virus strains WR and Elstree (Lister strain) contained 1×10^6 TCID₅₀ (tissue-culture infective dose) per milliliter. Strain DIs, an attenuated vaccinia virus mutant which derived from the Dairen 1 (DIE) strain (Tagaya et al. 1961), was provided by Dr. Ueda, Tokyo. DIs was propagated in 12-day-old fertile eggs at 35–36°C for 2 days. Titrations were done on primary chicken fibroblasts (Tagaya et al. 1974). DIs was used in a concentration of 1×10^5 TCID₅₀ per milliliter. Purification of strain WR was performed according to the method of Joklik (1962). Inactivation of vaccinia virus WR was obtained by incubation at 56°C for 120 minutes, three times interrupted by a short sonication procedure.

LCM virus strain WE-3, kindly provided by Dr. Lehmann-Grube, Hamburg, was propagated in L929 cells.

Virus of vesicular stomatitis (VSV) strain Indiana was propagated in VERO cells; stock solutions contained 10^6 TCID₅₀ per milliliter. Mice were sensitized by intraperitoneal injection of the 1-ml virus suspension. Spleen cells were harvested 6 days later.

Antisera. Antiserum to strain WR (No. 8) was obtained from rabbits immunized with WR strain vaccinia virus. The animals were injected intradermally, and, after a period of 2 weeks, three booster injections were given at intervals of 10 days. Sera were inactivated and stored at -70°C. The cytolysis titer of the sera measured in a ^{51}Cr -release assay, using infected L929 cells as targets

and guinea pig serum as complement source, was about 1024–2048. An anticomplementary activity of the sera was demonstrable to a dilution of about 1:8.

Antiserum to late vaccinia virus surface antigens (anti-LS): serum No. 8 was extensively absorbed with DIs-infected primary chicken fibroblasts. Antiserum to early vaccinia virus surface antigens (anti-ES): rabbit serum against early vaccinia virus surface antigens was prepared by injection of crude soluble early antigens of DIs-infected rabbit kidney cells into rabbits (Ueda et al. 1972; Ueda and Tagaya 1973). Antiserum to structural antigens of the virion (anti-VA) was obtained from rabbits injected with purified inactivated vaccinia virus. One optical density unit (ODU) (Joklik 1962), containing about 64 μg viral protein, was injected intramuscularly, and a booster injection of the same dose was given 14 days later. Neutralizing antibody titers were determined by 80% plaque reduction in VERO cell cultures.

Anti-H-2 serum was obtained from D. J. G. Ray, Transplantation and Immunology Branch, NIAID, NIH Bethesda, Maryland. We used charge 3b (Snell 1974), raised in recipient-donor strains (C3H-H-2⁰ \times 129) anti-C3H, genotypes (H-2^{dk} \times H-2^b) anti-H-2^k. The serum is directed mainly against specificities coded by H-2 K genes. No cross-reactivity with other private H-2 specificities could be observed by immunofluorescence or complement-dependent antibody-mediated cytotoxicity.

Demonstration of viral surface and intracellular antigens. Indirect immunofluorescence was performed as reported previously (Koszinowski and Ertl 1975). Demonstration of DNA synthesis in vaccinia-virus-infected cells was performed with DAPI (4,6-diamidino-2-phenylindol) (Russell et al. 1975).

Early and late surface antigens of cells infected with vaccinia virus were studied by mixed hemagglutination technique (Ito and Barron 1972) and by cytolytic antibody assay.

Target cells: L929 cells (haplotype H-2^k) and mastocytoma P-815-X2 cells were cultivated in Eagle's MEM supplemented with 10% inactivated calf serum and 100 $\mu\text{g}/\text{ml}$ streptomycin and penicillin (1% SP). For infection of target cells, about 5×10^6 to 1×10^7 L929 cells growing as monolayer cells in glass bottles were washed with fresh serum-free medium and then incubated with 10–15 ml virus suspension on a rocker platform at 37°C. After 2 hours, the virus dilution was discarded and fresh serum-free medium was added. The cells were used 3–12 hours later, depending on virus and test conditions.

Enzymatic treatment: The following enzymes were used: (1) papain, water-soluble, 3.5 mAnson units per milligram (Merck, Darmstadt, W. Germany,

lot 7144); and (2) neuraminidase from vibrio comma (VCN), 500 neuraminidase units per milliliter (Behringwerke, Marburg/Lahn, W. Germany). The enzymes were dissolved and diluted in serum-free MEM.

Cells prepared for enzymatic treatment were washed twice with serum-free medium and diluted to a concentration of 2.5×10^6 cells/ml. The enzymatic treatment was performed at 37°C, pH 6.5–7.0, with intermittent shaking for 20 (papain) or 30 minutes (VCN). Treatment with papain was carried out in the presence of 0.01 M cysteine (L(+)-cysteine chloride, Merck, lot 2839). Following enzymatic treatment, the cells were washed three times with MEM supplemented with 20% fetal calf serum (FCS).

Cells were counted and viability was determined by the trypan blue exclusion test. With the enzyme concentrations used, viability did not fall below 70–80%. The cells were stored before use in Eagle's MEM supplemented with 20% FCS. For virus-specific cytotoxic assays, carried out 4 hours after enzymatic treatment, cells were labeled 1 hour before with 100 μCi ⁵¹Cr (sodium chromate; Amersham, Buchler, Braunschweig, W. Germany; No. CJS1P, specific activity 100–200 mCi/mg Cr) per 5×10^6 cells. For allogenic cell-mediated cytotoxicity (CMC), cells were labeled before enzymatic treatment and used as targets immediately after treatment.

Sensitization to alloantigens. Mitomycin-C-treated stimulator cells, 1×10^6 , were incubated with 4×10^6 responder cells in 3 ml Dulbecco's modified medium supplemented with 5% FCS and 100 $\mu\text{g}/\text{ml}$ penicillin and streptomycin in a CO₂ atmosphere at 37°C. Allogenic spleen cells or tumor cells were used as stimulator cells. Five or six days later, the cells were harvested, and their effect on the appropriate ⁵¹Cr-labeled target cells was tested in a 5–10-hour assay. The ratio of attacker to target cells ranged between 20:1 and 50:1.

Adsorption of effector cells on monolayers. Mouse peritoneal exudate cells were harvested after thioglycolate stimulation and plated in plastic petri dishes (100-mm diameter, Greiner, Nürtingen, W. Germany). Confluent monolayers were infected 24 hours later. The medium containing virus was replaced by fresh medium after an adsorption time of 1 hour. About 6–12 hours later, monolayers were washed carefully and used for lymphocyte adsorption. Spleen-cell suspensions, treated for 10 minutes with ammonium chloride solution (0.14 M, pH 7.5), were added to the monolayers in a quantity of 2×10^7 cells in 2 ml medium. The separation procedure was performed according to the method of Wekerle et al. (1972). Adsorption time was 3 hours at 37°C. Controls were run at 4°C.

Antibody-mediated cytotoxicity. Antibody-mediated lysis of virus-infected cells was performed as described by Kibler and ter Meulen (1975).

Cold-cell inhibition assay. The assay was performed according to the method of Herberman et al. (1976). Inhibition was calculated as follows:

$$\% \text{ Inhibition of specific lysis} = \frac{\% \text{ specific lysis in immune control} - \% \text{ specific lysis in presence of inhibitory cells}}{\% \text{ specific lysis in immune control}} \times 100.$$

Cell-mediated cytotoxicity. Various numbers of lymphocytes from sensitized mice and control mice were incubated with a constant number (1×10^4) of ^{51}Cr -labeled target cells (Wagner 1973). Specific ^{51}Cr -release was determined (Koszinowski and Thomssen 1975) using the formula:

$$\% \text{ Specific lysis} = \frac{{}^{51}\text{Cr-release by immune cells} - {}^{51}\text{Cr-release by normal control}}{\text{maximal } {}^{51}\text{Cr-release}} \times 100.$$

The standard deviation (s.d.) was calculated from at least a triplicate assay. Some data are given without s.d. because, under the test conditions used, the s.d. values of percent lysis were less than 5%.

RESULTS

Cold-cell Inhibition and Monolayer Adsorption

Inhibition tests with cold target cells were performed to test which antigens have to be expressed for specific lysis. To the test assay consisting of 1×10^4 ^{51}Cr -labeled target cells and 1×10^6 effector cells, different amounts of nonlabeled target cells infected with different viruses were added. In the concentration of 50 inhibitory cells to one target cell, inhibition of 91.0% could be achieved when syngenic cells infected with the sensitizing virus were added (Table 1). Normal syngenic cells or syngenic cells infected with unrelated viruses showed no inhibitory activity. Allogenic cells infected with the sensitizing virus had only slight inhibitory activity.

Since in cold third-party cell experiments blocking of specific lysis is measured, a hypothetical recognition process without subsequent lysis cannot be tested. Requirements for specific recognition can be tested by adsorption of sensitized effector cells on monolayers; this has been shown after sensitization to alloantigens (Golstein et al. 1972).

Table 1. Inhibition of Specific Lysis by Cold Inhibitory Cells

Third-party cells infected with virus	Percent inhibition of lysis ^a of vaccinia-virus-WR-infected L929 cells
L929	7.1 ± 3.2
L929 vaccinia virus WR	91.0 ± 1.4
L929 vesicular stomatitis virus	3.8 ± 2.8
L929 LCM virus	14.8 ± 1.6
P-815-X2 vaccinia virus WR	18.7 ± 3.1

^a Effector cells derived from a pool of six C3H mice sensitized to vaccinia virus strain WR 6 days previously. Mean of percentage ^{51}Cr -release ± s.d. of four tubes per group. Specific lysis of target cells without cold cells added, 52.0%. Ratio of attacker to target cells, 100:1; ratio of cold inhibitory cells to target cells, 50:1.

Results show that adsorption of virus-sensitized T cells is possible on syngenic monolayers infected with the sensitizing virus (Table 2). If virus-specific effector cells have two receptors, one for syngenic H-2 and one for the viral antigen, adsorption should be possible on normal syngenic monolayers as well as on allogenic vaccinia-virus-infected cells. However, specific adsorption on normal syngenic monolayers or allogenic vaccinia-virus-infected monolayers was not seen, which favors the modified-self hypothesis.

Enzymatic Treatment of Target Cells and Anti-viral CMC

Target cells were treated with enzymes to investigate the necessity of H-2 antigenic determinants for anti-viral CMC. The effect of papain and VCN on the amount of surface antigens directly after treatment and 4 and 24 hours later was controlled by indirect immunofluorescence. H-2, as well as virus-specific fluorescence, was reduced or even abolished directly after treatment. Repetition of immuno-

Table 2. Adsorption of Vaccinia-virus-specific Effector Cells

Macrophage monolayers used for adsorption	Percent specific lysis of vaccinia-virus-infected C3H macrophages	Percent change relative to control
Control	17.4 ± 1.3	100
C3H	16.3 ± 2.4	94
C3H vaccinia-virus-infected	8.1 ± 2.9	47
DBA/2 vaccinia-virus-infected	18.9 ± 1.6	109
C3H vaccinia-virus-infected (4°C control)	18.6 ± 2.3	107

Supernatant (nonadherent) lymphocytes were collected from macrophage monolayers after 3 hr incubation at 37°C on a rocker platform. Attacker-to-target-cell ratio, 50:1; assay time 8 hr.

Table 3. Antibody-mediated Lysis of Vaccinia-virus-infected Cells after Treatment with Enzymes

Enzyme concentration ^a	Papain	VCN
Control	13.6 ± 1.8	8.8 ± 1.3
5	24.6 ± 0.2	13.9 ± 2.4
10	33.7 ± 1.4	9.3 ± 2.3
20	24.4 ± 1.8	14.2 ± 2.4
50	23.4 ± 0.3	15.6 ± 3.6
100	29.1 ± 2.5	66.8 ± 2.1

L929 were infected 6 hr before enzymatic treatment; ⁵¹Cr-release test was performed 4 hr after treatment; antiserum to vaccinia virus (No. 8) originated from rabbits, and complement originated from guinea pigs. Assay time was 4 hr. Spontaneous ⁵¹Cr-release of enzymatically treated cells, 20–25%. Each value represents the mean of four tubes ± s.d.

^a Papain, μg/ml; VCN, u/ml.

fluorescence (IF) after 4 and 24 hours indicated resynthesis of viral antigens but, due to host-cell protein synthesis inhibition, not of H-2 antigens. Enzymatic treatment of noninfected target cells was followed by resynthesis of H-2 antigenic determinants 4 to 24 hours later. VCN treatment had no effect on either H-2 or virus-specific determinants; IF was even found intensified.

Results of IF were repeated in complement-dependent antibody-mediated lysis using an anti-vaccinia serum and infected target cells 4 hours after enzymatic treatment. The results verify the IF observations (Table 3). Virus-specific antigens are resynthesized and lysis is even increased after treatment with high doses of enzymes, especially in the case of VCN.

Enzymatic activity on H-2 antigenic determinants was tested. Absorption studies were performed because concentration differences of surface antigens cannot be distinguished easily by antibody-mediated lysis (Lesley et al. 1974). Equal numbers of nontreated and enzyme-treated (4 hr previously) infected target cells were used for absorption of an H-2 alloantiserum. Absorbing capac-

ity was demonstrated by comparing the cytolytic activity of the alloantiserum before and after absorption. The nearly identical slopes of cytolytic activity of absorbed and nonabsorbed serum after papain treatment of absorbing cells (Fig. 1) demonstrated the reduced capacity of these cells to adsorb H-2 alloantiserum. VCN-treated cells, however, had nearly the same absorbing capacity as non-enzyme-treated cells. This means that papain is effective in reducing H-2 antigenic sites. The reduction of H-2 antigenic determinants is constant when vaccinia-virus-infected target cells are treated.

T cells sensitized to vaccinia virus were incubated with enzyme-treated or nontreated infected and noninfected target cells. Enzymatic treatment influenced lysis of syngenic infected cells. Removal of sialic acid resulted in enhanced CMC. Digestion of target cells with papain diminished the lysis of target cells (Fig. 2).

To prove the efficiency of enzymatic digestion on H-2 antigenic determinants and to exclude possible toxic activities of enzymes on the effector cells, uninfected L929 cells were subjected to papain treatment in both the same and higher concentrations than those of infected target cells. These cells were incubated with allogenic anti-H-2^b killer T cells for either 5 or 10 hours. The results (Fig. 3) show that papain treatment does in fact reduce the sensitivity of target cells to lysis by T cells directed to H-2 antigens. Since noninfected L929 cells are less fragile than infected cells, higher concentrations of papain could be used. Nonspecific effects of enzyme on effector cells could be excluded by the 10-hour assay. During this incubation period, H-2 antigenic determinants are resynthesized (Schwartz and Nathenson 1971), and effector cells are effective under these conditions. This means that T-cell-mediated lysis of virus-infected cells is dependent on expression of H-2 antigenic determinants on these cells. Viral surface antigens do not suffice for virus-specific CMC.





Figure 1. Residual cytotoxicity of anti-H-2^b alloantiserum after absorption on enzymatically treated cells. (□—□) Cytotoxic activity of the nonabsorbed serum control; (△—△) residual cytotoxic activity after absorption of 0.5 ml serum on 5×10^7 vaccinia-virus-infected L929 cells; (○—○) absorption on 200 U/ml VCN-treated infected L929 cells; (■—■) absorption on 200 μg/ml papain-treated infected L929 cells. The plateau activity of the anti-H-2^b serum (44.8 ± 3.2) was taken as 100%. Data represent the mean of at least four tubes ± s.d.

Figure 2. Alteration of cell-mediated lysis after enzymatic treatment of target cells. The figure represents data from four tubes \pm s.d. (○—○) VCN-treated target cells (background lysis of enzyme-treated cells, 18–23%; specific lysis of nontreated infected L929 cell controls, 37.2%); (■—■) papain-treated target cells (background lysis of treated cells, 29.3%; specific lysis of nontreated infected L929 cell controls, 44.0%). Ratio of attacker cells to target cells was 100:1; assay time, 16 hr.



Role of Early Viral Surface Antigens in Cellular Immune Response to Vaccinia Virus

Experiments were performed to test the minimal "alterations" that must be induced on cell surfaces to induce specific sensitization or to render cells sensitive to virus-specific T-cell-mediated lysis. The




Figure 3. Influence of target-cell treatment with papain on allogenic CMC: (●—●) 5-hr assay (background lysis, 12.5–18.3%; percent specific lysis of nontreated control target L929 cells, 56.4%); (□—□) 10-hr assay (background lysis, 17.5–23.9%; percent specific lysis of nontreated control target L929 cells, 63.6%). Attacker cells were DBA/2 lymphocytes sensitized in vitro to C3H lymphocytes for 5 days. Ratio of attacker cells to target cells was 20:1.

virus strains we put into test varied in the expression of viral surface antigens. Characteristics of the three strains used are given in Table 4. Strain WR was positive for early and late surface antigens, strain DIs did not propagate in mouse cells but it did induce early surface antigens, and strain Elstree gave mixed hemagglutination of the single-cell type (Ito and Barron 1972) with an anti-early-surface-antigen serum.

Spleen lymphocytes of C3H mice sensitized to any of the three virus strains killed all infected target cells (Table 5). Also, lymphocytes from mice sensitized with a low dose of DIs were active, despite the fact that virus propagation did not take place in vivo. This means that DNA replication and production of late surface antigens is not a prerequisite for cellular anti-vaccinia-virus sensitization. Lymphocytes from mice sensitized to DIs or Elstree showed cross-killing of their relevant infected target cells. Although early antigen expression is sufficient, our data give no clear-cut results about the role of late surface antigens, since strain Elstree is only partially defective in production of early surface antigens.

Inhibition of Antiviral CMC by Specific Antibodies

Cytolytic activities against DIs-infected cells suggest CTL activities against virus-induced early surface antigens. Different antiviral sera were prepared to control these results in inhibition assays. These antibodies were tested for inhibitory activities in the antiviral CMC using L929 cells infected with vaccinia virus strain WR as targets and spleen cells from strain-WR-sensitized C3H mice. Table 6 gives the characterization of the antisera and their activity on antiviral CMC. Significant inhibition of CMC was seen with a serum obtained from rabbits after virus infection (No. 8) and anti-ES serum. Anti-LS serum and

Table 4. Characteristics of Vaccinia Virus Strains

Strain	DNA replication in L929 cells ^a	Cytopathic effects in L929 cells	Titer of virus in test ^b (TCID ₅₀)	Indirect hemagglutination with anti-ES	Indirect IF on surfaces	
					anti-ES	anti-LS
WR	yes	yes	10 ⁶	positive	+++	+++
Elstree	yes	yes	10 ⁶	single-cell type	+	++
DIs	no	no	10 ⁵	positive	++	-

^a Tested with DAPI and by indirect IF with anti-VA.

^b Strains WR and Elstree were propagated and titrated in VERO cells; strain DIs was propagated in embryonated eggs (chorioallantois membrane) and titrated on primary fibroblasts of 6-day-old chicken embryos.

serum directed against antigens of the virus particle (anti-VA) had no significant inhibitory activities. The inhibition test with 1 ODU of inactivated vaccinia antigen, after addition of about 1.2×10^{10} inactivated vaccinia elementary bodies, was negative. Therefore, the virus-specific antigen receptor site on the cytolytic T cell does not seem to recognize antigens of the virus particle.

Table 5. Antiviral CMC of CTL from Mice Sensitized with Different Vaccinia Strains

Sensitization	Percent specific release ^a from L929 cells infected with		
	DIs	WR	Elstree
1×10^6 TCID ₅₀ WR	45.0	41.8	15.7
1×10^6 TCID ₅₀ Elstree	18.8	27.3	15.1
1×10^5 TCID ₅₀ DIs	27.6	14.2	N.D.

Lymphocytes were derived from C3H mice sensitized 6 days previously.

^a Background lysis ranged between 20-25%; assay time was 14 hr; ratio of attacker cells to target cells was 100:1; N.D. = not done.

Table 6. Activities of Anti-vaccinia Serum

Serum	Indirect cell- surface IF ^a				Percent specific lysis ^d
	WR	DIs	CA ^b	NT ^c	
Anti-vaccinia (No. 8)	+	+	1:1024	1:32	15.0 ^e
Anti-ES	+	+	1:1024	1:<4	17.0 ^e
Anti-LS	+	-	1:512	N.D.	23.7
Anti-VA	-	-	1:<4	1:256	25.8
Normal serum					24.8
None					27.4
1.2×10^{10} vaccinia particles					32.4

^a Indirect IF was tested on L929 cells infected with vaccinia strains WR and DIs 8 hr previously.

^b CA = cytolytic antibody assay. Cytolytic activity was tested on L929 cells infected with vaccinia strain WR in a 4-hr ⁵¹Cr-release assay.

^c N.D. = Neutralizing test. Neutralizing activity was tested on VERO cell monolayers.

^d Lymphocytes were derived from C3H mice sensitized 6 days previously with vaccinia virus strain WR. Ratio of attacker cells to target cells, 50:1; incubation time, 12 hr; background lysis, 22.8%.

^e Significantly reduced specific ⁵¹Cr-release ($P < 0.05$).

DISCUSSION

Cold-cell inhibition experiments were performed to look for blocking activities of cells bearing different virus-induced "modifications." Only syngenic vaccinia-virus-infected cells had blocking activities. No effect was produced by adding allogenic vaccinia-virus-infected cells or syngenic cells infected with other viruses. The necessity of H-2 homology for effective blocking of CMC of "modified" cells has also been shown by others (Shearer et al. 1975; Rehn et al. 1976). The aim of the absorption studies was to discriminate between cytolysis and recognition. Monolayer absorption can effectively fractionate antigen-sensitive cells (Wekerle et al. 1972; Golstein et al. 1972). If virus-specific CTL have two antigen receptors, one for syngenic H-2 and one for the viral antigen, specific adsorption should be possible on normal syngenic monolayers or on allogenic vaccinia-virus-infected cells. Lysis would occur only if both antigens are expressed on the same cell. The finding that specific adsorption takes place only on vaccinia-virus-infected monolayers sharing K and D structures with the effector cells is very much in accord with the altered-self hypothesis (Doherty et al. 1976), which requires only one antigen receptor site on T cells for recognition and cytolysis. There is no independent recognition of both single antigenic determinants, or at least a very low affinity of the receptors.

It was next of interest to investigate the reactivity against target cells bearing viral antigens but reduced or even abolished H-2 antigenic sites. These target cells could be prepared since vaccinia virus infection inhibits the host-cell protein synthesis (Moss 1968). H-2 antigenic sites were not reexpressed after enzymatic treatment while synthesis of viral surface antigens took place. The main results from these experiments were that viral antigenic determinants which are detectable by humoral antibodies (immunofluorescence, antibody-mediated antiviral cytotoxicity) did not suffice for the effector function of antiviral CTL.

CMC of virus-infected target cells was found reduced after papain treatment but not after VCN treatment. As has been shown by Sandford and Codrington (1971), removal of sialic acid has no

inhibitory activity on cellular recognition of H-2 antigenic determinants while H-2 can be dissolved from cell membranes by papain treatment (Nathenson and Davies 1966; Yamane and Nathenson 1970). It could be demonstrated that the inhibition of CMC acts on the target-cell level. After treatment of normal L929 cells with papain, cytotoxicity by allogenic killer cells sensitized against H-2^b antigens was found reduced, but under test conditions allowing resynthesis of H-2 antigens (Schwartz and Nathenson 1971), there was no inhibition of effector-cell activity. This rules out unspecific inhibitory effects of any active enzyme possibly remaining on the effector cells.

These results do not support the finding (Dennert 1975) that the T cell recognizes the modifying hapten on the cell surface. Cytolytic T cells specific for new antigens on cells also need H-2 antigenic sites on the target cell for their effector function. Reduction of H-2 by enzymatic treatment or by capping with alloantiserum (Koszinowski and Ertl 1975; Schmitt-Verhulst et al. 1976) decreases the ability of virus-infected target cells to be lysed by antiviral CTL. This corresponds to observations (Lightbody and Bach 1973; Brondz et al. 1973) that proteolytic treatment reduced allogenic CMC. Thus the virus-specific CTL act in an analogous way to the alloantigen-specific CTL, which are dependent on the concentration of K- or D-region products on the target cell (Alter et al. 1973). One can assume that CTL can only be sensitized to and recognize new antigenic determinants which interact with antigens coded by genes of the K or D region of the major histocompatibility complex (MHC).

Investigating the minimal requirements of cell-surface alterations by a virus infection, it was found that early surface antigens, induced by vaccinia virus, give rise to the generation of anti-vaccinia CTL. This could be demonstrated using a conditional lethal mutant strain of vaccinia virus (Tagaya et al. 1961) which does not replicate in mice. The essential role of early viral antigens for induction of cellular and humoral immune mechanisms has been suggested previously (Ueda and Tagaya 1973). Also, in the effector phase, target-cell infection with strain DIs was sufficient for induction of cell-mediated specific lysis.

The inhibition experiments with different antiviral sera outline the significance of early antigens. Using sera against different viral antigens, the neutralizing activity could be separated from CTL inhibitory properties. Contact with complete virus particles is not necessary; they do not inhibit the cytotoxic interaction, nor does the injection of inactivated virus particles give rise to CTL production (unpubl.). CTL recognition is therefore specific for plasma membrane alterations but not for antigens of the virus surface.

If CTL have biological functions *in vivo*, sensitization and reactivity against virus-induced early

antigens seem to be advantageous. They are expressed as early as 1 hour after infection (Ueda et al. 1969), whereas maturation of complete infective virus needs several hours. In the reaction against alterations of the cell membrane induced by early antigens, the CTL could prevent synthesis of virus particles and, in later stages of infection, the spreading of virus.

Vaccinia-virus-specific early surface antigens, whose role in virus replication is not clear, perform the functional H-2 antigenic alteration which gives rise to vaccinia-virus-specific CMC. Characterization of the relevant polypeptides (Esteban and Metz 1973; Polisky and Kates 1975) that are synthesized very early after infection will help to clarify the biochemical basis of H-2 antigen "alteration."

SUMMARY

Specific recognition of antigens by cytolytic T lymphocytes sensitized to vaccinia virus was tested by monolayer adsorption. Adsorption was possible only on monolayers also expressing syngenic H-2 as viral antigens present during the sensitization phase.

Vaccinia-virus-infected target cells were subjected to papain and neuraminidase treatment. H-2 antigenic determinants could be removed by papain treatment. Due to virus-specific inhibition of host-cell protein synthesis, reexpression of H-2 antigenic determinants did not take place, but viral surface antigens were resynthesized. Susceptibility of target cells to T-cell-mediated lysis was decreased after papain treatment.

Substrains of vaccinia virus were used in order to define the minimal changes induced by vaccinia virus necessary for T-cell sensitization *in vivo* and target-cell lysis *in vitro*. When the immune response to a conditional lethal mutant strain of vaccinia virus was investigated, it could be demonstrated that expression of early surface antigens is sufficient for induction of the cellular immune reactions. These data were confirmed by inhibition studies with virus-specific antisera.

Acknowledgments

We thank Dr. Y. Ueda, Tokyo, for supplying us with DIs virus and anti-ES serum, and Dr. C. Jungwirth, Würzburg, for purification of vaccinia virus WR.

The technical assistance of Ms. K. B. Henderson and Mrs. S. Siebels is greatly appreciated. We thank Mrs. I. Dreyer for preparation of the manuscript.

This work was supported by the Deutsche Forschungsgemeinschaft, Grant Ko 571/2.

REFERENCES

- ALTER, B. J., D. J. SCHENDEL, M. L. BACH, F. H. BACH, J. KLEIN and J. H. STIMPFLING. 1973. Cell mediated lympholysis: Importance of serologically defined H-2 regions. *J. Exp. Med.* **137**: 1303.
- BEVAN, M. J. 1975. Interaction antigens detected by cytotoxic T cells with the major histocompatibility complex as modifier. *Nature* **256**: 419.
- BRONZD, B. D., A. E. SNEGEROVA, Y. A. RASSULIN and O. G. SHAMBORANT. 1973. Modification of in vitro immune lymphocyte target cell interaction by some biologically active drugs. *Immunochemistry* **10**: 175.
- DENNERT, G. 1975. Cell mediated immunity to hapten modified self and non-self antigens. *Nature* **255**: 712.
- DOHERTY, P. C., R. V. BLANDEN and R. M. ZINKERNAGEL. 1976. Specificity of virus-immune effector T cells for H-2K or H-2D compatible interactions: Implications for H-antigen diversity. *Transplant. Rev.* **29**: 89.
- ERTL, H. and U. KOSZINOWSKI. 1976. Cell mediated cytotoxicity against sendai virus infected cells. *Z. Immun. Forsch.* **152**: 128.
- ESTEBAN, M. and D. H. METZ. 1973. Early virus protein synthesis in vaccinia virus-infected cells. *J. Gen. Virol.* **19**: 201.
- FORMAN, J. 1975. On the role of the H-2 histocompatibility complex in determining the specificity of cytotoxic effector cells sensitized against syngeneic trinitrophenyl modified targets. *J. Exp. Med.* **142**: 403.
- GARDNER, I. D., N. A. BOWERN and R. V. BLANDEN. 1975. Cell mediated cytotoxicity against ectromelia virus infected target cells. III. Role of the H-2 gene complex. *Eur. J. Immunol.* **5**: 122.
- GOLSTEIN, P. and E. T. SMITH. 1976. Mechanism of T cell mediated cytotoxicity: The lethal hit stage. *Contemp. Topics Immunobiol.* **7**: (in press).
- GOLSTEIN, P., E. A. J. SVEDMYR and H. BLOMGREN. 1972. Specific adsorption of cytotoxic thymus-processed lymphocytes (T cells) on glutaraldehyde-fixed fibroblast monolayers. *Eur. J. Immunol.* **2**: 380.
- GORDON, R. D., E. SIMPSON and L. E. SAMELSON. 1975. In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice. *J. Exp. Med.* **142**: 1108.
- HERBERMAN, R. B., N. E. NUNN and H. T. HOLDEN. 1976. Cytotoxicity inhibition assay for analysis of specificity of cell-mediated ⁵¹Cr release cytotoxicity. In *In vitro methods in cell-mediated and tumor immunity* (ed. B. R. Bloom and J. R. David). Academic Press, New York. (In press.)
- ITO, M. and A. L. BARRON. 1972. Studies on a strain of vaccinia virus defective in surface antigen production. *Proc. Soc. Biol. Med.* **140**: 374.
- JOKLIK, W. H. 1962. The purification of four strains of poxvirus. *Virology* **18**: 9.
- KIBLER, R. and V. TER MEULEN. 1975. Antibody mediated cytotoxicity after measles virus infection. *J. Immunol.* **114**: 93.
- KOSZINOWSKI, U. and H. ERTL. 1975. Lysis mediated by T-cells and restricted by H-2 antigen of target cells infected with vaccinia virus. *Nature* **255**: 552.
- KOSZINOWSKI, U. and R. THOMSEN. 1975. Target cell dependent T cell mediated lysis of vaccinia infected cells. *Eur. J. Immunol.* **5**: 245.
- LESLEY, J., R. HYMAN and G. DENNERT. 1974. Effect of antigen density on complement-mediated lysis, T-cell mediated killing and antigenic modulation. *J. Nat. Cancer Inst.* **53**: 1759.
- LIGHTBODY, J. J. and F. H. BACH. 1973. Cell mediated lympholysis. Effect of papain on effector and target cells. *Ann. Immunol. (Inst. Pasteur)* **124c**: 311.
- MOSS, K. 1968. Inhibition of HeLa cell protein synthesis by the vaccinia virion. *J. Virol.* **2**: 1028.
- NATHENSON, S. G. and D. A. L. DAVIES. 1966. Solubilization and partial purification of mouse histocompatibility antigens from membrane lipoprotein fraction. *Proc. Nat. Acad. Sci.* **56**: 476.
- PFIZENMAIER, K., A. STARZINSKI-POWITZ, H. RODT, M. RÖLLINGHOFF and H. WAGNER. 1976. Virus and TNP-hapten specific T-cell mediated cytotoxicity against H-2 incompatible target cells. *J. Exp. Med.* **143**: 999.
- POLISKY, B. and J. KATES. 1975. Viral specific polypeptides associated with newly replicated vaccinia DNA. *Virology* **66**: 128.
- REHN, T. G., G. M. SHEARER, H. S. KOREN and J. K. INMAN. 1976. Cell-mediated lympholysis of N-(3-nitro-4-hydroxy-5-iodophenylacetyl)-β-alanyl-glycylglycyl-modified autologous lymphocytes. Effector cell specificity to modified cell surface components controlled by the H-2 K and H-2 D serological regions of the murine major histocompatibility complex. *J. Exp. Med.* **143**: 127.
- RUSSELL, W. C., C. NEWMAN and D. H. WILLIAMSON. 1975. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses. *Nature* **253**: 461.
- SANDFORD, B. H. and J. F. CODINGTON. 1971. Further studies on the effect of neuraminidase on tumor cell transplantability. *Tissue Antigens* **1**: 153.
- SCHMITT-VERHULST, A. M., D. H. SACHS and G. M. SHEARER. 1976. Cell mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Confirmation of genetic control of response to trinitrophenyl-modified H-2 antigens by the use of anti-H-2 and anti-Ia antibodies. *J. Exp. Med.* **143**: 211.
- SCHWARTZ, B. D. and S. G. NATHENSON. 1971. Regeneration of transplantation antigens on mouse cells. *Transplant. Proc.* **3**: 180.
- SHEARER, G. M. 1974. Cell mediated cytotoxicity to trinitrophenyl modified syngeneic lymphocytes. *Eur. J. Immunol.* **4**: 527.
- SHEARER, G. M., G. R. REHN and C. A. GARBARINO. 1975. Cell mediated lympholysis of trinitrophenyl modified autologous lymphocytes. Effector cell specificity to modified cell surface components controlled by the H-2 K and H-2 D regions of the murine major histocompatibility complex. *J. Exp. Med.* **141**: 1348.
- SNELL, G. D. 1974. Catalogue of mouse alloantisera. *Transplantation Immunology Branch Publication*, NIAID, NIH, Bethesda, Maryland. (1968, Supplement.)
- TAGAYA, I., H. AMANO and T. YUSSA. 1974. Improved plaque assay of a mutant of vaccinia virus, strain DIs in chick embryo cell cultures. *Japan. J. Med. Sci. Biol.* **27**: 245.
- TAGAYA, I., T. HITAMURA and Y. SANO. 1961. A new mutant of dermovaccinia virus. *Nature* **192**: 381.
- UEDA, Y. and I. TAGAYA. 1973. Induction of skin resistance to vaccinia virus in rabbits by vaccinia-soluble early antigens. *J. Exp. Med.* **138**: 1033.
- UEDA, Y. A., M. ITO and I. TAGAYA. 1969. A specific surface antigen induced by poxvirus. *Virology* **38**: 180.
- UEDA, Y., I. TAGAYA, H. AMANO and M. ITO. 1972. Studies on the early antigens induced by vaccinia virus. *Virology* **49**: 794.
- WAGNER, H. 1973. Synergy during in vitro cytotoxic allograft responses. *J. Exp. Med.* **138**: 1379.
- WEKERLE, H., P. LONAI and M. FELDMAN. 1972. Fractionation of antigen reactive cells on a cellular immunosorbant: Factors determining recognition of antigens by T lymphocytes. *Proc. Nat. Acad. Sci.* **69**: 1620.
- YAMANE, K. and S. G. NATHENSON. 1970. Murine histocompatibility-2 (H-2) alloantigens. Purification and some chemical properties of a second class of fragments (class II) solubilised by papain from cell membranes of H-2^b and H-2^d mice. *Biochemistry* **8**: 1336.

ZINKERNAGEL, R. M. and P. C. DOHERTY. 1974. Restriction of in vitro T-cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogenic system. *Nature* **248**: 701.

———. 1975. H-2 compatibility requirement for T cell

mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T cell specificities are associated with structures coded for in H-2 K or H-2 D. *J. Exp. Med.* **141**: 1427.

Name Index

A

- Aaskov, J. G., 251, 253, 257, 259
- Aasted, B., 692, 694, 696
- Abbas, A. K., 249, 249
- Abbot, A., 259
- Abbot, J., 8, 136, 137
- Abelson, H. T., 163, 164
- Abelson, L., 386, 396, 427, 454, 455
- Abney, E. R., 39, 40, 44, 143, 144, 176, 182, 185, 186, 187, 190, 190, 191, 193-200, 193, 194, 195, 199, 266, 270, 271, 365, 368
- Abola, E. E., 339, 636, 645, 674
- Abraham, R., 314, 321, 587
- Abrahams, S., 321
- Ackers, G. K., 353, 361
- Acton, R. T., 51, 52, 53, 61
- Ada, G. L., 182, 252, 259, 791
- Adams, H., 891, 901
- Adelberg, E. A., 782, 787, 789, 790, 791
- Aden, D. P., 377
- Adetugbo, K., 645, 665, 793-803, 795, 796, 797, 802, 803
- Adler, R. H., 215
- Adler, S., 454
- Aellen, M.-F., 852, 862, 888
- Agrawal, B. B. L., 228, 236
- Ahlstedt, S., 214
- Ainsworth, C. F., 645
- Albert, E., 427
- Albertini, R. J., 429, 439
- Albrecht, P., 82
- Albrechtsen, D., 426
- Aldo-Benson, M., 251, 259
- Alexander, C. B., 677-686, 686, 698, 845
- Alexander, R. J., 773, 778
- Alford, C. A., 144
- Alkins, R. C., 284
- Allan, D., 379, 385
- Allderdice, P. W., 444, 449, 453
- Allen, F. H., 426, 427
- Allen, J. M. V., 51, 52, 53, 59, 61, 163, 164, 407, 414
- Allfrey, V. G., 269, 273
- Allison, A. C., 102
- Alter, B. J., 236, 349, 351, 361, 426, 429, 434, 439, 440, 441, 535, 536, 609
- Amano, H., 536
- Amante, L., 44, 47, 50, 164, 183, 791
- Ambrosius, H., 272
- Amkraut, A. A., 598, 609
- Amos, D. B., 343, 377, 386, 396, 426, 427, 454
- Amzel, L. M., 377, 635, 636, 637, 639-645, 641, 644, 645, 654, 658, 659, 666, 818, 834, 834, 835
- Ancona, A., 50
- Abney, E. R., 39, 40, 44, 143, 144, 176, 182, 185, 186, 187, 190, 190, 191, 193-200, 193, 194, 195, 199, 266, 270, 271, 365, 368
- Anderson, B., 315, 321
- Anderson, C. L., 315-321, 315, 321
- Anderson, C. W., 781, 790
- Andersson, B., 272, 275, 284, 710, 717, 764, 770
- Andersson, J., 147-158, 147, 148, 149, 150, 153, 157, 163, 164, 164, 179, 182, 217, 225, 227-236, 227, 228, 230, 232, 235, 236, 248, 249, 250, 255, 259, 754, 758
- Andersson, L. C., 430, 439, 492, 495
- Anderton, B. H., 386
- Andrews, E. P., 61
- Anfinsen, C. B., 295, 305, 306, 670, 674
- Ansari, A. A., 677-686, 683, 684, 685
- Anteunis, A., 314
- Anundi, H., 329, 331-339, 331, 332, 338, 339, 363, 368, 377, 411, 413
- Aoki, T., 31, 408, 413, 814
- Appella, E., 326, 329, 341-342, 341, 342, 349, 357, 361, 371, 372, 650, 658, 677-686, 685, 686, 691, 696, 697, 731, 733, 830, 837, 838, 839, 845
- Arbeit, R. D., 250, 374, 377
- Arce-Gomez, B., 443-455, 451, 453
- Armerding, D., 24, 31, 119, 126, 364, 368, 369, 377, 469, 474, 489, 492, 493, 495, 496, 502, 503, 623, 625, 626
- Armstrong, D. W., 251, 259
- Arnaiz-Villena, A., 418, 419, 426
- Arndt, R., 59, 61
- Arnold, R. R., 215
- Arnon, R., 623, 672, 674
- Arnzel, L. H., 675
- Arquilla, E. R., 898, 901
- Arrenbrecht, S., 95, 101, 102
- Artzt, K., 339, 588
- Aschinazi, G., 204, 214
- Asherson, G. L., 105, 106, 109, 111
- Askonas, B. A., 37, 44, 115, 117, 167, 173, 193, 195, 196, 198, 199, 245, 250, 276, 284, 726, 733, 749-759, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 777, 779
- Asofsky, R., 113, 117, 137, 145, 172, 173, 182, 183, 199, 272, 432, 440
- Asterano, A., 314
- Atkins, J. F., 790
- Atkins, R. C., 527, 540, 542, 544, 561
- Atkinson, P. H., 386, 402, 411, 413, 454
- Atwell, J. L., 199, 273, 284, 718, 710, 711, 713, 716, 717
- Augustin, A., 285, 293, 709-718, 710, 711, 713, 716, 717
- Austin, C. M., 182, 791
- Avey, H., 645, 675, 835
- Aviv, H., 836
- Avrameas, S., 309, 314, 679, 685, 790
- B**
- Baas, P. D., 856, 862
- Babinet, C., 338, 338
- Bach, F. H., 83, 349, 351, 361, 418, 421, 426, 427, 429-441, 429, 430, 432, 433, 434, 436, 437, 438, 439, 439, 440, 441, 527, 535, 536, 574, 578, 587, 609
- Bach, M. L., 349, 361, 427, 429-441, 429, 439, 440, 441, 536
- Bächi, Th., 284
- Backman, K., 862
- Baglioni, C., 874, 883, 888
- Bailey, D. W., 293, 345, 348, 441, 463, 474, 519, 521, 526, 527, 594, 594, 736, 740, 845, 846
- Bain, B., 429, 440
- Baird, S., 9-21, 20
- Baldi, I., 877, 886, 888
- Balfour, B. M., 207, 214
- Balner, H., 427, 463
- Baltimore, D., 8, 63-72, 63, 65, 70, 72, 164, 774, 778, 818, 834
- Bangasser, S. A., 704, 706, 722, 724
- Bank, A., 874
- Bankhurst, A. D., 102, 102, 142, 144, 272
- Barclay, A. N., 51-61, 54, 55, 56, 57, 58, 59, 61, 408, 410, 413, 414
- Bargellesi, T., 182
- Barnes, D. W. H., 136
- Barnstable, C., 329, 361, 379-386, 385, 426, 443-455, 453, 454
- Barondes, S. H., 61
- Barron, A. L., 530, 533, 536
- Barry, D. W., 80, 82
- Barstad, P., 172, 654, 658, 662, 665, 725, 731, 733, 744, 748, 817-836, 823, 826, 827, 829, 834, 835, 838, 839, 841, 845, 847, 852
- Barton, M., 256, 257, 258, 259
- Basch, R. S., 6, 8, 8, 65, 72
- Baserga, R., 234, 236
- Basham, T., 400
- Basten, A., 93-103, 93, 94, 95, 96, 101, 102, 103, 114, 115, 117, 126, 126, 251, 257, 259, 307, 314, 315, 317, 321, 579, 580, 582, 587, 625, 626
- Batchelor, J. R., 323, 329
- Battisto, J. R., 21, 105, 111
- Baumal, R., 763, 770, 781, 783, 786, 787, 790, 791, 803
- Bauminger, S., 590, 595
- Baur, S., 200, 339
- Bazin, H. G., 202, 213, 214, 273
- Bean, M. A., 31
- Bechtol, K. B., 114, 117, 126, 126, 377, 489, 496, 543, 544, 598, 607, 608, 613, 615, 617, 621, 622
- Becka, L. N., 645
- Becker, M., 288, 292, 645, 741
- Beckwith, J., 787, 790
- Bell, C., 678, 685
- Bell, G. I., 765, 770
- Ballanti, J. A., 215
- Belman, S., 111
- Belo, M., 145
- Benacerraf, B., 23, 25, 30, 31, 88, 91, 102, 116, 117, 119,

- 126, 275, 284, 285, 292, 293, 295, 298, 305, 306, 344, 349, 358, 361, 369, 377, 402, 443, 454, 463, 465-475, 465, 466, 467, 472, 473, 474, 475, 486, 487, 489, 496, 501, 503, 504, 505, 510, 522, 527, 539, 542, 544, 553, 556, 559, 561, 563-570, 563, 564, 569, 570, 578, 579, 580, 582, 584, 587, 597, 607, 608, 609, 611, 612, 613, 614, 622, 623, 763, 764, 770, 898, 902
- Benck, L., 236
 Bengtsson, B., 454
 Benike, C. J., 440, 441
 Bennette, D., 51, 61, 339, 407, 413, 588, 814, 814, 896, 901
 Bennett, J. C., 61, 368, 855, 862, 863, 874
 Bennett, M., 511, 513, 514, 517
 Ben-Sasson, S. Z., 572, 578, 622
 Berek, C., 284, 285-294, 286, 287, 293, 544, 608, 624, 842, 843, 845
 Berg, R. B., 73, 82
 Berggård, I., 326, 329, 339, 357, 361, 368, 645, 674
 Bernardini, A., 779, 836, 853, 862, 883, 886, 887, 888
 Bernoco, D., 425, 426, 441, 551, 556
 Bernoco, M., 426
 Bernstein, D., 697
 Bernstein, S. E., 137
 Berzofsky, J. A., 295-306, 297, 298, 305, 306
 Betlach, M. C., 888
 Beutner, K. R., 215
 Bevan, M. J., 21, 29, 31, 61, 408, 411, 413, 414, 519-527, 519, 520, 521, 522, 523, 526, 527, 529, 536, 539, 544, 554, 555, 556, 559, 561, 579, 587, 597, 608, 614, 622
 Beverley, P. C. L., 83, 102, 113-118, 114, 115, 116, 117, 587
 Bianco, C., 284, 307, 314
 Bias, W. B., 463
 Bieber, D., 878, 888
 Bienenstock, J., 201, 213, 215
 Bierhorst-Eijlander, A., 440
 Bijnen, A., 417, 418, 426
 Bilofsky, H., 853
 Binz, H., 29, 30, 31, 116, 117, 261, 271, 275-284, 275, 276, 277, 278, 280, 281, 282, 283, 284, 300, 306, 508, 510, 543, 544, 559, 561, 585, 586, 587, 597, 608, 612, 618, 619, 624, 714, 717, 812, 814
 Biozzi, G., 755, 758
 Birnbaumer, L., 270, 271
 Birshtein, B., 758, 781, 785, 790, 791, 803
 Bishop, J. M., 862, 888
 Bishop, J. O., 866, 867, 872, 874, 888
 Bismuth, A., 368, 556
 Bjaring, B., 411, 413
 Björk, I., 333, 338, 674, 897, 901
 Black, P. H., 82, 82
 Black, P. L., 457, 463
 Black S. J., 33-45, 284, 285-294, 285, 286, 287, 293, 503, 543, 544, 597, 608, 624
 Blackman, M., 103
 Blaese, R. M., 249, 250
 Blake, J. T., 31, 306, 578
 Blakesley, R. W., 856, 862
 Blanden, R. V., 82, 243, 505, 506, 507, 509, 510, 519, 526, 536, 544, 554, 556, 561, 587, 597, 608, 622
 Blandova, Z. K., 345, 348
 Blank, K. J., 519, 527, 597, 608
 Blankenhorn, E. P., 51, 61
 Blease, R. M., 103
 Blitstein-Willinger, E., 37, 44
 Blobel, G., 789, 790
 Bloch, K. J., 293
 Blomberg, B., 172, 286, 293, 645, 658, 700, 706, 743-748, 743, 744, 745, 748, 802, 814, 835, 841, 843, 845, 852, 862, 888
 Blomgren, H., 536
 Bloom, A. D., 788, 789, 790
 Bloom, B. R., 73-83, 73, 74, 75, 78, 82, 83, 105, 111
 Bluestein, H. G., 305, 306, 397, 402
 Blume, M. R., 83
 Blussé van Oud Alblas, A., 396, 427
 Blyth, J. L., 561
 Blythman, H. E., 215
 Bobrow, M., 414, 449, 453, 454
 Boccoardo, R., 440, 527
 Bochert, G., 157
 Bockman, D. E., 144, 182, 202, 211, 213, 250
 Bode, W., 636
 Bodmer, J., 379, 385, 386, 426, 443-455, 443, 444, 445, 453, 454
 Bodmer, W. F., 329, 339, 343, 348, 348, 361, 367, 368, 372, 377, 379-386, 379, 385, 386, 412, 414, 426, 443-455, 443, 444, 445, 451, 452, 453, 453, 454, 455, 678, 685
 Bokisch, V. A., 697, 852
 Bolhuis, R. L. H., 144, 182, 190, 199
 Bollum, F. J., 63, 72
 Bona, C., 307-314, 307, 308, 309, 314
 Bondevik, H., 422, 426
 Bonnard, G. D., 426
 Bonner, T. I., 872, 874
 Boone, C. W., 590, 595
 Bordenave, G., 756, 758
 Borel, Y., 106, 111, 189, 190, 251, 259, 316, 321
 Borthistle, B. K., 315-321
 Bosma, G. C., 810, 814
 Bosma, M. J., 755, 758, 810, 814
 Botstein, D., 790, 803
 Bourgois, A., 172, 193-200, 663, 664, 665, 827, 834
 Bouteille, M., 790
 Bouthillier, Y., 758
 Bownern, N., 243, 510, 536, 556
 Boyce, C. R., 837, 845
 Boyden, S. V., 315, 321
 Boyer, H. W., 888
 Boyer, M. L., 395
 Boyer, S. H., 393, 395
 Boylston, A. W., 262, 263, 264, 271, 272
 Boyse, E. A., 5-8, 6, 8, 23-32, 23, 24, 25, 27, 29, 31, 34, 44, 61, 72, 78, 82, 83, 103, 116, 117, 137, 162, 245, 250, 339, 343, 362, 368, 407, 411, 413, 414, 429, 432, 440, 492, 496, 504, 556, 559, 561, 584, 587, 588, 590, 607, 608, 609, 805, 809, 811, 812, 814, 815, 895, 901
 Boyum, A., 444, 454, 699, 706
 Bozzo, L., 215
 Bradley, B. A., 417-427, 419, 421, 422, 426, 429, 430, 440
 Bradshaw, R. A., 636, 675, 814, 835, 874, 888
 Brand, A., 5-8, 5, 7, 8
 Braun, D. G., 168, 172, 649, 650, 656, 658, 666, 690, 696, 724, 726, 733, 756, 758
 Braun, V., 157, 236
 Brenner, S., 818, 834
 Bretscher, M. S., 354, 361, 410, 414
 Bretscher, P. A., 217, 225, 256, 259, 270, 271, 433, 440, 508, 510, 743, 748
 Brew, K., 636
 Brezin, C., 682, 685, 687, 688, 690, 696
 Briand, P.-A., 862, 888
 Bridgen, J., 326, 329, 359, 361, 382, 384, 385, 443, 453, 454
 Bridges, S. H., 700, 706
 Brient, B. S., 719, 724
 Briles, D. E., 726, 732, 733, 748, 845, 848, 852
 Britten, R. J., 867, 868, 869, 871, 872, 874
 Brochier, J., 314
 Broder, S., 103
 Bronzdz, B. D., 520, 527, 535, 536
 Brouet, J. C., 44, 145, 182, 191
 Brown, B. A., 261, 271
 Brown, G. D., 214, 595
 Brown, J. L., 343-349, 343, 344, 345, 346, 347, 348, 356, 361, 371, 373, 377
 Browne, W. J., 635, 636
 Brownlee, G. G., 697, 835, 862, 877, 886, 887, 888
 Brunner, K. T., 83, 440, 556
 Buchanan, P. D., 791
 Buckner, C. D., 83
 Buckton, K. E., 82, 82
 Buell, D. N., 173, 183
 Bull, F. G., 386
 Bullock, W. W., 113, 117, 150, 157, 182, 225, 228, 236, 250
 Burakoff, S. T., 548, 550, 554, 556
 Burckhardt, J. J., 261, 265, 271
 Burkholder, P. M., 441
 Burnet, F. M., 237, 242, 243, 351, 361, 586, 587, 762, 770, 892, 901
 Burrows, P., 139
 Burstein, Y., 847, 853
 Bussard, A. E., 314
 Byrd, W. J., 15, 21
 Byrt, P., 569
- C**
- Calkins, C. E., 86, 91
 Callahan, G. N., 364, 368
 Callard, R., 93-103
 Calne, R. Y., 426, 440
 Cambier, J., 162, 185-191, 189, 190, 190
 Campbell, J. H., 733, 748, 835, 852
 Campbell, R., 127, 496, 609
 Campbell, S., 202, 211, 214
 Canelakis, E. S., 72
 Cannon, L. E., 645, 647-659, 649, 652, 655, 656, 658, 659, 682, 685
 Cantor, H., 8, 11, 21, 23-32, 23, 24, 25, 26, 27, 29, 31, 34, 44, 72, 78, 82, 86, 87, 91, 94, 103, 113, 114, 116, 117, 118, 190, 407, 414, 429, 432, 440, 487, 492, 496, 504, 559, 561, 584, 587, 607, 608, 609, 811, 812, 814, 815
 Capaldi, R., 392, 395
 Capra, J. D., 339, 349, 362, 363-368, 366, 367, 368, 377, 455, 641, 645, 647, 654, 658, 687, 688, 691, 693, 694, 696, 700, 706, 731, 732, 733, 781, 790, 818, 822, 826, 827, 848, 834, 847-853, 847, 848, 850, 851, 852, 852, 853, 883, 888
 Carbonara, A. O., 214
 Carlson, B., 214
 Carpenter, C. B., 454
 Carson, D., 744, 746, 748, 826, 834, 838, 841, 845
 Carswell, E. A., 61
 Carta-Sorcini, M., 677-686, 685, 686
 Carter, P. B., 202, 213
 Cartwright, E. M., 835, 862, 887, 888
 Cavaillon, J. M., 314

- Cazenave, P. A., 307-314, 682, 685, 687, 688, 690, 696
 Ceбра, J. J., 106, 111, 176, 182, 193, 194, 199, 201-215, 201, 203, 205, 207, 208, 209, 213, 214, 215, 496, 644, 644, 654, 658, 659, 781, 790
 Cecka, J. M., 369-377
 Celada, F., 679, 685
 Ceppellini, R., 343, 422, 426, 441, 556
 Cerottini, J.-C., 83, 120, 126, 440, 556
 Cesari, I. M., 643, 645, 734, 748, 815, 827, 835, 837, 845, 846, 862, 889
 Cesla, R., 475
 Chambon, P., 888
 Chan, E. L., 102, 250
 Chan, P. L., 321
 Chang, L. M. S., 63, 72
 Chanock, R. M., 215
 Chao, N., 27
 Chaperon, E. A., 902
 Chardonnens, X., 772, 778
 Charlemagne, J., 262, 270, 271
 Chase, M. W., 47, 50, 82, 105, 111
 Chasin, L., 409, 414
 Chedid, L., 314
 Chen, B. L., 377, 627, 636, 637, 639-645, 639, 640, 643, 645, 659, 666, 675, 835
 Chen, F. W., 647, 653, 658
 Chen, K. C. S., 650, 658, 678, 685, 692, 693, 696
 Chen, S. H., 272
 Cheng, W. D., 647, 658
 Cherry, M., 293, 348, 487, 556, 846
 Chersi, A., 658, 696, 697
 Chesebro, B. W., 622, 709, 717, 720, 724
 Chess, L., 67, 72, 386, 395, 396, 441
 Chia, E., 93-103, 314, 321
 Chiappino, G., 888
 Chiller, J. M., 103, 226, 315-321
 Chin, A. F., 8, 136
 Chiorazzi, N., 623
 Chism, S. E., 103, 588
 Chiu, Y. Y., 639-645
 Choi, Y. S., 411, 414
 Cholun, J. J., 455
 Chou, P. Y., 636, 636
 Christian, G. D., 673, 675
 Christie, G. H., 172
 Churchill, W. H., 191
 Cicurel, L., 724
 Cieplinski, W., 781-791
 Cinader, B., 257, 259, 314
 Ciorbaru, R., 314
 Cisar, J., 744, 748
 Citronbaum, R., 272
 Clafin, J., 167, 172, 661, 662, 664, 665, 710, 717, 725-734, 725, 726, 727, 728, 730, 731, 732, 733, 733, 734, 763, 770, 809, 810, 811, 814
 Clagett, J., 52, 61
 Claman, H. N., 105-111, 105, 106, 111, 770, 891, 902
 Clancy, R., 213
 Clarkson, B., 234, 236
 Clem, L. W., 273
 Cleve, H., 59, 61, 182
 Click, R. E., 229, 236
 Clift, R. A., 83
 Cline, M. J., 74, 82, 317, 321
 Codington, J. F., 534, 536
 Coelho, I. M., 266, 273
 Coffino, P., 755, 758, 781, 785, 786, 788, 790, 793, 799, 802
 Cohen, B. E., 622
 Cohen, E., 411, 415, 787, 788, 789, 791, 833, 835
 Cohen, G. H., 8, 137, 637, 645, 659, 666, 686, 835
 Cohen, J. E., 902
 Cohen, N., 261, 271, 771, 776, 778, 779
 Cohen, P., 622
 Cohen, S., 840, 845
 Cohn, M., 167, 170, 171, 172, 173, 217, 225, 256, 259, 270, 271, 285, 293, 294, 433, 440, 508, 510, 519, 526, 642, 644, 645, 650, 658, 661, 665, 666, 687, 688, 688, 733, 734, 743-748, 743, 744, 748, 761, 762, 770, 797, 802, 807, 814, 815, 818, 821, 826, 831, 834, 835, 837, 840, 845, 846, 847, 852, 857, 858, 862, 879, 881, 887, 882, 889
 Colberg, J. E., 213
 Coleman, M. S., 63, 64, 67, 72
 Coligan, J. E., 286, 293
 Colle, A., 339
 Collie, M. H., 771, 779
 Collins, F. M., 202, 213
 Colman, P., 636, 645, 674, 674
 Colomb, M., 667, 674
 Colombani, J., 122, 126, 447, 454, 478, 479, 487, 497, 503
 Colombani, M., 126, 487, 503
 Colon, S. M., 329, 339, 414
 Condomine, H., 338
 Cone, J. L., 339, 487, 500, 501, 502, 504
 Cone, R. E., 148, 157, 199, 261, 262, 263, 265, 266, 272, 273, 284
 Cooley, M. A., 440
 Coombs, R. R., 313, 314, 455
 Coons, A. H., 127, 273, 609
 Cooper, E. L., 261, 271, 771, 772, 778
 Cooper, M. D., 38, 44, 130, 137, 139-145, 140, 141, 142, 144, 145, 158, 159, 160, 162, 182, 191, 194, 197, 199, 202, 211, 213, 213, 243, 248, 250
 Cooper, N. R., 454
 Cooper, S. M., 641, 645
 Coppo, F., 426
 Coppola, E. D., 202, 214
 Cornell, R., 215
 Corte, G., 182
 Cosenza, H., 173, 182, 191, 205, 214, 285, 293, 563, 569, 661, 665, 701, 706, 707, 709-718, 709, 710, 711, 713, 716, 717, 718, 719, 722, 723, 724, 725, 733
 Cotton, R. G. H., 755, 758, 788, 790, 793, 797, 801, 802, 803, 853
 Court-Brown, W. M., 82
 Courtenay, B. M., 172
 Coutinho, A., 147, 152, 157, 217, 218, 219, 220, 221, 223, 225, 226, 227-236, 227, 229, 235, 236, 248, 249, 250, 256, 259, 314, 752, 758
 Coutsogeorgopoulos, C., 72
 Cowan, N. J., 645, 665, 793-803, 793, 795, 796, 797, 802, 803, 853, 887
 Crabbé, P. A., 201, 202, 214
 Craig, S. W., 194, 199, 201, 207, 213, 214
 Cramer, M., 168, 172, 285-294, 726, 733
 Crandall, C. A., 201, 214
 Crandall, R. B., 214
 Cresswell, P., 324, 326, 328, 329, 333, 338, 339, 353, 361, 384, 385, 387, 394, 395, 395
 Crichton, R., 433, 440
 Crichton, W. B., 454
 Crone, M. M., 275, 284
 Cronlund, M., 659
 Crook, N. E., 595
 Cross, A. M., 175, 182
 Cross, J., 449, 453
 Crowle, A. J., 103
 Crumpton, M. J., 55, 61, 329, 339, 361, 379-386, 379, 383, 384, 385, 386, 426, 443-455, 443, 444, 454, 455
 Cuatrecasas, P., 47, 50, 295, 301, 305, 306
 Cuchens, M., 273
 Cudkowicz, G., 511-518, 511, 512, 513, 514, 516, 517, 518
 Cullen, S. W., 336, 337, 338, 339, 343, 349, 351, 355, 356, 361, 363, 364, 368, 374, 377, 384, 385, 386, 395, 395, 397, 400, 402, 402, 403, 443, 450, 454, 455, 477-487, 477, 478, 487, 555, 556
 Cunningham, A. J., 119, 126, 170, 172, 252, 259, 540, 544, 710, 717, 749, 758, 761-770, 763, 764, 765, 766, 767, 768, 770
 Cunningham, B. A., 326, 329, 339, 349, 351-362, 351, 357, 361, 363, 368, 377, 412, 414, 454, 510, 556, 645, 807, 814
 Curman, B., 331-339
 Curry, J. L., 129, 136
 Curtis, S. K., 771, 778
 Curtoni, E. S., 385, 426, 441, 454
 D
 Dahl, D., 396
 Damais, C., 314
 D'Amaro, J., 427
 Dart, G., 441
 Daugharty, H., 307, 314
 Dausset, J., 343, 349, 387, 396, 418, 427, 430, 440, 447, 452, 454, 527
 Davenport, L. M., 215
 David, C. S., 45, 119-127, 122, 126, 127, 250, 297, 306, 314, 336, 339, 368, 369, 374, 377, 386, 395, 395, 396, 425, 426, 427, 440, 443, 449, 455, 469, 474, 475, 477-487, 477, 478, 479, 480, 485, 486, 487, 489, 491, 492, 496, 497, 498, 499, 500, 501, 502, 503, 504, 520, 527, 595, 609, 626
 David, G. S., 690, 696
 Davidson, E. H., 867, 868, 869, 871, 872, 874
 Davidson, R. L., 782, 790
 Davie, J. M., 142, 144, 172, 661, 662, 664, 665, 717, 725, 726, 732, 733, 733, 734, 748, 764, 770, 845
 Davies, A. J. S., 14, 21, 172
 Davies, D. A. L., 535, 536
 Davies, D. R., 627-637, 627, 628, 636, 637, 645, 648, 659, 661, 666, 683, 684, 685, 686, 743, 748, 828, 834, 835, 893, 902
 Davis, F. M., 787, 789, 790
 Dawson, J. R., 328, 329, 333, 338, 353, 361
 Day, N. K., 426
 Day, R., 213
 Dayhoff, M. O., 628, 636, 640, 645, 818, 823, 832, 835
 Deak, B. D., 474, 496, 503, 504
 Debré, P., 23, 25, 31, 471, 472, 473, 474, 501, 503
 Decker, J. M., 261-273, 273, 773, 778, 779
 Decleve, A., 20, 21
 Decreusefond, C., 758
 DeFranco, A. L., 329, 394, 396
 DeGroot, M. L., 463
 Deisenhofer, J., 674
 De La Croix, F., 126, 474
 Delaney, N. L., 454
 Delaney, R., 645
 Delespesse, G. J., 463
 DeLisi, C., 765, 770
 Delovitch, T. L., 44, 364, 368, 377, 485, 489-496, 496, 497, 504, 623, 883, 888
 DeLuca, D., 261-273, 273
 de Luca, F., 214
 Demant, P., 487

- Denk, H., 673, 674
 Denman, A. M., 102, 102
 Denman, E. J., 102
 Dennert, G., 535, 536
 de Petris, S., 160, 162, 183, 556, 787, 790, 880
 de Preval, C., 172, 665, 743-748
 Desaynard, C., 609
 de Sousa, C. M., 475
 D'Eustachio, P., 142, 144, 763, 770, 895, 902
 Deutsch, H. F., 627, 636
 Devinsky, O., 31, 44
 de Weck, A. L., 105, 111, 398, 402, 578
 Dewey, A. F., 173
 Dharmgrongartama, B., 781-791, 781
 Diamantstein, T., 37, 44, 147, 157
 Diamond, R., 631, 636, 639, 645
 Dick, H., 447, 454
 Dickler, H. B., 249, 250, 307, 314, 315, 321, 337
 Diener, E., 251-259, 251, 252, 253, 254, 255, 256, 257, 258, 259, 611
 Diggelman, H., 862
 Dimuzio, H., 454, 569, 570, 623
 Dine, M. S., 487, 504
 Dintzis, H. M., 645
 Di Pauli, R., 764, 770
 Doenhoff, M., 272
 Doherty, P. C., 26, 30, 31, 31, 73, 82, 101, 102, 116, 118, 351, 362, 369, 377, 439, 441, 451, 453, 454, 505-510, 505, 506, 507, 508, 509, 510, 522, 526, 526, 527, 529, 534, 536, 537, 539, 540, 543, 544, 545, 547, 548, 553, 554, 555, 556, 557, 559, 560, 561, 568, 570, 571, 577, 578, 579, 582, 584, 587, 597, 609, 613, 614, 622, 624
 Dolejš, L., 853
 Doniach, D., 103
 Donnelly, N., 6, 8, 771, 778, 779
 Dooley, N., 250
 Dore, C. F., 207, 214
 Dorf, M. E., 31, 295, 297, 304, 306, 361, 427, 454, 457, 463, 465-475, 465, 466, 467, 468, 469, 472, 473, 474, 475, 501, 503, 503, 510, 544, 556, 569, 570, 578, 609, 623, 902
 Doria, F., 213
 Dorrington, K. J., 637
 Dossetor, J. B., 427
 Doughty, R. A., 168, 172
 Douglas, S. D., 102
 Douglas, T. C., 51, 53, 61, 408, 414
 Dray, S., 213, 677, 678, 685, 686, 687-688, 687, 688, 690, 696, 697
 Dresser, D. W., 101, 102, 195, 199, 257, 259, 735, 741, 750, 758, 776, 779
 Dreyer, W. J., 835, 855, 862, 863, 874, 881, 888
 Dube, S., 779, 836, 853, 862, 888
 Dubiski, S., 314, 696, 803
 duBois, M. J. G. J., 440
 Duc-Nguyen, H., 73, 82
 Duffus, W. P. H., 162, 556
 Dugan, E., 250, 314, 487, 504, 627, 636, 659, 807, 814, 881, 888
 Dunkley, M., 102, 117, 587
 Dunlap, R. C., 82
 Dunlop, M. B. C., 510, 526
 Dunn, D. C., 426, 440
 Dunn, P., 758, 770
 Du Pasquier, L., 262, 270, 272, 763, 770, 771-779, 771, 772, 773, 774, 778, 778, 779
 Dupont, B., 396, 420, 426, 430, 432, 440, 454
 Duprez, V., 527
 Durante, M. L., 182
 Durda, P. J., 805-815, 812, 813, 814, 814
 Durdick, J., 611
 Durham, T., 466, 469, 475
 Durin, M., 103
 du Toit, E. D., 426
 Dutton, R. W., 24, 31, 86, 91, 124, 126, 252, 259, 273, 569, 597-609, 598, 604, 605, 608, 609, 625, 626, 750, 758
 Dwek, R. A., 634, 636
- E**
- Eardley, D. D., 85-91, 86, 87, 91
 Early, P., 817-836
 Eastlake, A., 296, 300, 306
 Eaton, B., 817-836
 Ebers, G., 455
 Eckerstorfer, R., 674
 Eckhardt, L., 39
 Edelhoeh, H., 388, 395
 Edelman, G. M., 144, 158, 170, 172, 173, 175, 182, 265, 268, 270, 271, 272, 273, 288, 290, 293, 339, 349, 351-362, 351, 361, 368, 372, 377, 388, 395, 395, 396, 413, 414, 451, 453, 454, 510, 547-557, 547, 548, 552, 553, 556, 586, 587, 640, 645, 667, 670, 674, 687, 688, 763, 770, 779, 789, 790, 805, 806, 808, 812, 814, 815, 817, 818, 821, 835, 847, 852, 882, 888, 891-902, 893, 895, 896, 898, 900, 902
 Edelman, R., 73, 76, 82
 Edidin, M., 429, 440
 Edmundson, A. B., 333, 339, 628, 636, 636, 637, 639, 642, 645, 659, 674, 674, 675
 Edwards, G. E., 147, 157
 Edwards, J. M., 426, 440
 Eernisse, J. G., 427
 Efstratiadis, A., 869, 874
 Eggers, H. J., 53, 61
 Egorov, I. K., 345, 348
 Ehrenfield, E., 83
 Ehrlich, P., 709, 717
 Eichmann, K., 29, 30, 31, 93, 101, 102, 116, 117, 249, 250, 261, 272, 284, 285-294, 285, 286, 287, 288, 292, 293, 300, 306, 315, 321, 503, 544, 585, 586, 587, 597, 608, 619, 622, 624, 658, 693, 697, 701, 702, 704, 706, 714, 716, 717, 719, 723, 724, 725, 726, 733, 733, 735, 740, 756, 758, 777, 778, 812, 814, 821, 835, 842, 843, 845, 847, 848, 852, 885, 888
 Eijsvooegel, V. P., 418, 426, 429, 440
 Eisen, H. N., 105, 111, 170, 172, 285, 293, 317, 318, 321, 627, 634, 636, 637, 665, 675, 712, 717, 719-724, 719, 720, 721, 722, 723, 724, 763, 770, 814, 835, 874, 888
 Elfenbein, G. J., 190, 763, 770
 Elgin, S. C. R., 733, 748, 835, 852
 Elliot, B., 25
 Elliott, E. V., 11, 21
 Elliott, H. L., 214
 Ellis, A. E., 262, 270, 272
 Ellman, L., 397, 402
 Ellner, J. J., 31, 306
 Elsasser, W. M., 769, 770
 Elson, C. J., 98, 102, 209, 214
 Elves, M. W., 14, 21
 Ely, K. R., 339, 636, 637, 645, 659, 674, 675
 Emmrich, F., 262, 270, 272
 Enders, J. F., 73, 83
 Enein, A. A., 214
 Engelhard, M., 47-50
 Engers, H. D., 440
 Ephrussi, B., 450, 454
 Epp, O., 627, 631, 636, 645
 Epstein, S., 812
 Erb, P., 113-118, 113, 114, 115, 117, 119, 126, 255, 259, 539, 544, 559, 561, 563, 568, 569, 579, 587, 597, 608, 611, 622, 625, 626
 Ertl, H., 369, 377, 505, 510, 529-537, 529, 530, 535, 536, 547, 556
 Eshhar, Z., 623, 626
 Espinosa, L., 455
 Esselman, W. J., 59, 61
 Esteban, M., 535, 536
 Estes, J. D., 463
 Evans, E. P., 136
 Evans, J., 454
 Evans, P. D., 511-518
 Evrin, P. E., 331, 339, 446, 454
 Ewenstein, B. M., 343-349, 344, 346, 348, 354, 358, 359, 361, 365, 366, 368, 369, 371, 372, 377
- F**
- Fagen, G., 321
 Fairbanks, G., 389, 396
 Fairwell, T., 329, 341-342, 342
 Falkoff, R., 31, 626
 Fan, K., 788, 789, 791
 Fanger, M. W., 677, 685
 Farace, M. G., 852, 855, 862, 883, 885, 888
 Farnsworth, V., 658, 678, 685, 692, 693, 697, 748, 834, 845, 862
 Farr, A., 618, 619
 Fasman, G. D., 636, 636
 Fasold, H., 339
 Fatham, C. G., 11, 21, 295-306, 295, 300, 306
 Faulk, W. P., 45, 200, 202, 214
 Faulkes, R. A., 61
 Faust, C. H., 855, 862, 888
 Fefer, A., 83
 Fehllhammer, H., 636, 636, 644, 645
 Feinstein, A., 803
 Feizi, T., 102, 102, 144, 182
 Feldman, J. D., 61, 75, 82, 83
 Feldman, M., 527, 536
 Feldmann, M., 34, 44, 96, 101, 102, 103, 113-118, 113, 114, 115, 116, 117, 118, 119, 126, 183, 251, 253, 254, 255, 257, 258, 259, 261, 264, 272, 539, 544, 559, 561, 563, 568, 569, 579, 584, 587, 597, 608, 611, 622, 625, 626, 763, 770, 888
 Feldmann, R. J., 270, 271, 273
 Fellous, M., 338, 338, 339
 Fellows, R. E., 645
 Fernstedt, Y., 339
 Ferrarini, M., 176, 177, 182, 182
 Ferrone, S., 368, 452, 454
 Festenstein, H., 385, 418, 419, 426, 454
 Fett, J. W., 627, 636
 Fields, R., 688
 Fiers, W., 862
 Fink, G., 790, 803
 Finkelman, F. D., 266, 267, 271, 272, 402
 Finn, J., 898, 901
 Finstad, J., 272
 Fischetti, V., 82
 Fitch, F. W., 284, 724
 Fitch, M. W., 688, 815, 836, 874
 Flaherty, L., 814, 814
 Fleischman, J. B., 655, 658
 Florent, G., 683, 685
 Fog, T., 454
 Fong, C., 722, 723
 Fontino, M., 426
 Ford, C. E., 136
 Ford, W. L., 276, 284, 520, 527, 540, 542, 544, 559, 561
 Fordham, S. A., 765, 766, 770

- Forman, J., 185-191, 191, 345, 348, 439, 440, 519, 521, 527, 529, 536, 547, 548, 554, 556, 613, 614, 622
- Forni, L., 44, 50, 145, 163, 164, 164, 175-183, 183, 191, 199, 200, 243, 272, 273, 401, 402, 791, 803
- Forsgren, A., 76, 82, 158, 221, 225
- Fotino, M., 463
- Fougereau, M., 171, 172, 665, 666, 827, 834
- Fox, C. F., 57, 61
- Fradelizi, D., 430, 440
- Fraker, P. J., 706, 722, 723, 724
- France, C. M., 214
- Francis, S. H., 627, 628, 636, 664, 665, 827, 835
- Franek, F., 848, 852, 853
- Frangione, B., 645, 795, 802
- Frank, L., 791, 803
- Frank, M. M., 190, 314, 321
- Franklin, E. C., 293, 645, 795, 802
- Franks, D., 426, 440
- Fraser, B. A., 686, 689-698, 697, 815, 853
- Fraser, B. F., 659
- Fraser, K. J., 658, 659, 675
- Frazier, W. A., 61,
- Freed, J. H., 117, 126, 343-349, 348, 361, 368, 377, 386, 402, 454, 487, 608, 622
- Freedman, H. A., 527, 608
- Freedman, M. H., 726, 733
- Frelinger, J. A., 250, 314, 369, 377, 426, 477-487, 478, 483, 484, 487, 499, 500, 501, 503, 504, 611
- Freter, R., 201, 214
- Frey, J. R., 105, 106, 111
- Fridman, W. H., 320, 321
- Friedberg, S. H., 21
- Friedenson, B., 644, 645, 700, 706
- Friedman, S., 637
- Friend, C., 163, 164, 517
- Friend, P., 417, 426
- Froland, S. S., 200
- Fu, S. M., 47-50, 50, 143, 144, 177, 182, 185, 186, 190, 193, 199, 200, 261, 263, 270, 272, 354, 361, 395, 395, 396, 426, 455
- Fuccilo, D. A., 82
- Fuchs, S., 306
- Fudenberg, H. H., 102, 102, 214, 294, 595, 710, 717, 791
- Fuhrman, J., 817-836
- Fujiwara, M., 257, 259
- Fuke, M., 878, 888
- G**
- Gabb, B. W., 427
- Gachelin, G., 338
- Gahmborg, C., 812, 814
- Galanos, C., 157, 236
- Gall, W. E., 645, 667, 670, 674, 847, 852
- Gallagher, M. T., 137, 518
- Gally, J. A., 170, 172, 175, 182, 351, 361, 372, 377, 395, 395, 453, 454, 586, 587, 687, 688, 789, 790, 795, 803, 805, 808, 812, 815, 818, 835, 882, 888, 895, 898, 902
- Gambino, R., 865, 874
- Gamble, J., 31, 103, 118, 314, 321, 455, 475, 544, 561, 569, 578, 587, 588, 623
- Garbarino, C. A., 31, 118, 361, 527, 536, 545, 556, 561, 570, 578, 587, 609
- Gardner, I. D., 505, 510, 526, 529, 536, 547, 556
- Gardner, M. B., 457-463, 458, 462, 463
- Gardner, R. L., 9-21
- Gathings, W. E., 137, 139, 143, 144, 145, 158, 162, 191, 243, 250
- Gavish, M., 667-675, 674
- Gearhart, P. J., 165-173, 165, 167, 172, 173, 201-215, 204, 205, 206, 213, 214, 215, 645, 685, 716, 717, 718, 725, 727, 733, 835
- Geckeler, W. R., 172, 293, 645, 658, 706, 743-748, 748, 802, 807, 814, 835, 845, 852, 862, 888
- Geczy, A. F., 397, 398, 401, 402, 572, 578
- Geczy, C. I., 772, 778
- Geftter, M. L., 781-791, 782, 787
- Geier, M. D., 697, 853
- Geiser, S. S., 384, 385, 387, 394, 395, 395
- Geiger, M. D., 674
- Geleick, H., 111
- Gelfand, M. C., 166, 172, 187, 190
- Gell, P. G. H., 267, 268, 273, 308, 314, 657, 659, 888
- Gerald, L., 688
- Gerald, P. S., 782, 790
- Gerber, H., 45, 200
- Gerday, C., 357, 361
- Gergely, J., 791
- Germain, R. N., 351, 361, 505, 510, 547, 548, 556, 898, 902
- Gershon, R. K., 27, 31, 36, 43, 44, 85-91, 85, 86, 87, 88, 90, 91, 106, 111, 170, 172, 615, 622, 749, 758, 763, 770
- Gesteland, R. F., 781, 790, 796, 803
- Gewurz, H., 50
- Ghanta, V., 272
- Gibbons, R. J., 201, 214
- Gibson, D. J., 452, 454, 809, 810, 811, 815
- Gilbert, W., 860, 861, 862
- Giles, C. M., 426
- Gill, T. J., III, 272, 273
- Gilleter, R., 595
- Gilman, A. M., 687, 688
- Gilman, J. G., 373, 377
- Gilman-Sachs, A., 688, 690, 697
- Gilmour, D. G., 5-8, 7, 8, 273
- Giphart, M., 387-396
- Girling, R. L., 636, 637, 645, 659, 675
- Gisler, R. H., 321
- Givol, D., 294, 627-637, 627, 628, 634, 636, 637, 667-675, 667, 672, 673, 674, 675
- Glaser, M., 634, 636
- Glass, D., 454
- Glaudemans, C. P., 665, 666, 748, 835
- Glazer, A. N., 834, 835
- Glimcher, L., 26
- Glover, J. S., 272
- Glucksberg, H., 83
- Goding, J. W., 33-45, 38, 39, 40, 44, 190, 190, 237-243, 237, 238, 240, 241, 243, 261, 262, 263, 264, 266, 267, 270, 271, 272
- Goetzl, E. J., 627, 634, 637
- Goidl, E. A., 623, 763, 770
- Golan, D. T., 106, 111
- Gold, E., 710, 717
- Goldberg, E., 496
- Goldblum, R. M., 207 214
- Goldman, J. N., 369, 377
- Goldman, M. G., 369, 377
- Goldstein, A. L., 8, 21, 137
- Goldstein, B., 765, 770
- Goldstein, D. J., 645
- Goldstein, G., 5-8, 5, 6, 8, 8, 65, 72, 176, 182, 203, 213, 407, 414
- Goldstein, I. J., 228, 236
- Golstein, P., 514, 517, 520, 527, 529, 531, 534, 536
- Golub, E. S., 611
- Gomard, E., 519, 527
- Good, R. A., 137, 426
- Goodfellow, P., 329, 339, 361, 379-386, 385, 386, 412, 414, 425, 426, 443, 444, 446, 447, 451, 453, 454, 455
- Goodfleish, R., 685, 697
- Goodfriend, L., 463
- Goodman, J. R., 214
- Goodman, M., 639, 645
- Goodman, S. A., 194, 199
- Gorzynski, R. M., 124, 126, 126, 137
- Gordon, J., 315, 321
- Gordon, R. D., 29, 31, 519, 521, 522, 527, 529, 536, 539, 544, 554, 555, 556, 559, 561, 614, 622
- Gordon, S., 444, 689-698
- Gorer, P. A., 343, 349
- Gosselin-Rey, C., 361
- Gottlieb, A. B., 47-50
- Gottlieb, P. D., 72, 645, 663, 665, 805-815, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 814, 815, 842, 845
- Götze, D., 485, 487, 500, 501, 502, 503, 510, 587
- Gough, J., 21
- Goulmy, E., 427
- Gowans, J. L., 168, 172, 202, 214, 215, 891, 902
- Graff, R. J., 521, 527
- Granato, D. D., 722, 724
- Grant, J. A., 819, 835
- Graves, H. E., 272, 778
- Graves, M., 454, 569, 578, 623
- Graves, P. N., 790
- Gray, W. R., 825, 835, 888
- Greaves, M., 263, 268, 272, 590, 595, 750, 752, 758
- Green, C., 773, 778
- Green, I., 145, 164, 191, 200, 306, 321, 397, 402, 403, 474, 578, 585, 587, 770
- Green, J., 314
- Green, M., 786, 790, 814, 815
- Green, P. C., 778
- Greenberg, A. A., 307, 314
- Greenblatt, J. J., 690, 697
- Greene, A. E., 455
- Greene, P. J., 880, 888
- Greenspan, S., 18
- Greenwood, F. C., 264, 265, 272, 331, 339
- Greenwood, M. F., 72
- Grefrath, S. P., 59, 60, 61
- Gregory, C. J., 137
- Gregory, W., 396
- Greineder, D. K., 31, 306
- Grey, H. M., 190, 193, 199, 315-321, 315, 320, 321, 326, 329, 331, 339, 368, 377, 414
- Griffith, I. P., 590, 595
- Grillot-Courvalin, C., 439
- Grisafi, P., 790, 803
- Griscelli, C., 202, 206, 214
- Gronowicz, E., 147, 148, 150, 152, 157, 218, 220, 223, 225, 226, 228, 230, 235, 236, 752, 758
- Gross, E., 345, 349
- Gross, L., 163, 164
- Gross-Bellard, M., 878, 888
- Grossberg, A., 45
- Grossberg, N., 779
- Grosse-Wilde, H., 427
- Grossi, C. E., 139-145, 141, 144, 145
- Grubb, R., 689, 697
- Grumet, F. C., 297, 306, 491, 496, 501, 503, 622
- Grunnet, N., 440
- Guggesberg, F., 271
- Guidotti, G., 393, 396
- Guimezanes, A., 321
- Günther, E., 466, 470, 474, 559, 561
- Gurdon, J. B., 781, 790
- Gurner, B. W., 314, 455
- Gustafson, G. T., 158
- Gutman, G. A., 11, 21, 33-45, 243, 250
- Guy-Grand, D., 202, 205, 206, 214
- Gyongyossy, M. I. C., 321
- H**
- Haas, R., 772, 778
- Haas, W., 237, 238, 243, 507, 510, 523, 527, 539-545,

- 541, 545, 547, 548, 553, 557
 Haskill, J. S., 134, 137, 563, 569
 Hass, L., 137
 Hathcock, K. S., 518
 Hauptfeld, M., 361, 440, 457-463, 462, 463, 556
 Hauptfeld, V., 354, 361, 377, 425, 426, 427, 440, 458, 463, 500, 503, 547, 551, 555, 556
 Hausman, S. J., 755, 758
 Haustein, D., 238, 243, 261, 262, 263, 264, 265, 272, 273, 275, 284, 812, 815
 Hayakawa, K., 127
 Hayman, M. J., 55, 61, 379, 386, 455
 Häyry, P., 430, 439, 495
 Hayward, J. A., 307, 314
 Heber-Katz, E., 114, 117, 542, 544, 559-561, 560, 561, 569, 569, 577, 578, 598, 608, 608, 613, 615, 622
 Heinrich, G., 157, 236, 758
 Helenius, A., 335, 339
 Helgesen, A., 427
 Hencin, R., 622
 Henderson, B. E., 463
 Henin, Y., 527
 Henkart, P. A., 249, 250, 396
 Henle, W., 73, 82
 Henley, W. L., 273
 Henney, C. S., 78, 83, 429, 440
 Henning, R., 344, 349, 351-362, 351, 354, 358, 361, 365, 366, 368, 369, 371, 372, 377, 453, 454, 547-557, 547, 551, 552, 556
 Henriksen, O., 341-342, 341, 342
 Henry, C., 202, 214, 236, 599, 609, 623, 751, 758, 902
 Herberman, R., 321, 517, 517, 531, 536
 Heremans, J. F., 201, 202, 214
 Heritage, J., 449
 Herrmann, H., 329, 386, 396
 Hersh, E. M., 74, 82
 Herzenberg, L. A., 21, 23, 24, 31, 33-45, 33, 34, 35, 36, 38, 39, 40, 44, 45, 93, 102, 117, 122, 125, 126, 126, 127, 147, 158, 182, 187, 190, 199, 203, 214, 236, 249, 250, 293, 303, 306, 307, 314, 317, 321, 475, 487, 497-504, 497, 499, 501, 502, 503, 504, 518, 544, 606, 608, 609, 622, 706, 709, 717, 842, 845
 Herzenberg, L. A., 31, 33-45, 44, 102, 127, 190, 250, 303, 306, 475, 487, 497-504, 501, 503, 504, 609, 845
 Hess, M., 686
 Heusser, C. H., 315-321
 Hewgill, D., 33-45
 Hijmans, W., 144, 182, 190, 194, 199, 200
 Hildemann, W. H., 261, 268, 270, 272, 771, 772, 778
 Hill, R. L., 636, 639, 645
 Hill, S. W., 470
 Hirsch, M. S., 82, 82
 Hirschberg, H., 421, 426, 427, 430, 440
 Hirschhorn, K., 429, 440
 Hirst, J. A., 31, 83, 587, 626
 Hitamura, T., 536
 Hochman, J., 637, 667-675, 667, 669, 670, 674, 675
 Hodes, R. J., 515, 518
 Hoecker, G., 343
 Hoffman, T., 47, 50, 200
 Hoffmann, M. K., 8, 31, 83, 137, 587, 599, 609, 626
 Hogg, N. M., 117, 263, 272, 626
 Holden, H. T., 517, 536
 Holland, J. G., 164
 Holland, P., 72
 Holley, R., 413, 414
 Holmes, E. C., 590
 Honjo, T., 734, 852, 855-862, 855, 856, 857, 858, 859, 862, 877, 888
 Hood, L., 171, 172, 331, 339, 343, 344, 349, 351, 352, 358, 359, 360, 361, 363, 365, 366, 368, 369-377, 370, 371, 372, 373, 377, 398, 401, 402, 403, 411, 414, 453, 455, 523, 527, 627, 628, 636, 637, 650, 658, 665, 682, 685, 686, 688, 688, 697, 730, 731, 733, 744, 748, 762, 770, 815, 817-836, 818, 819, 820, 821, 822, 824, 832, 833, 834, 835, 836, 838, 839, 840, 841, 845, 847, 852, 856, 862, 874, 888
 Hooper, J. A., 137
 Hooper, R. S., 8
 Hopper, J. E., 285, 293, 314, 725, 733, 791
 Horibata, K., 781, 790, 793, 794, 803
 Horn, R. G., 578
 Horng, W. J., 682, 685, 687-688, 687, 688, 690, 697
 Hors, J., 452, 454
 Horta-Barbosa, L., 82, 82
 Horton, J. D., 771, 778, 779
 Horton, T. L., 778
 Horwitz, D. A., 199
 Hough, B. R., 874
 Houssaint, E., 145
 Howard, J. C., 15, 21, 326, 329, 372, 377, 455, 527, 559-561, 560, 561
 Howard, J. G., 167, 172
 Howe, M. L., 15, 21, 83
 Howe, S. C., 803
 Howie, S., 113-118
 Hozumi, N., 852, 877-889, 877, 882, 884, 888
 Hsia, J. C., 637
 Hsia, S., 427
 Hsu, S. H., 451, 454, 463
 Huang, P. C., 269, 272
 Huang, R. C., 269, 272, 862, 888
 Hubbard, L., 250
 Huber, B., 23, 24, 25, 26, 30, 31, 34, 44
 Huber, R., 636, 674
 Hubert, J., 817-836, 830
 Huchet, R., 763, 770
 Hudson, L., 118, 127, 314, 321, 540, 543, 545, 567, 570, 609, 624
 Huebner, R. J., 463
 Huetteroth, T. H., 182
 Hug, K., 45, 145, 183, 191, 200, 243, 273
 Hughes R. C., 60, 61
 Humayun, M. Z., 862
 Humphrey, J. H., 168, 172
 Humphrey, R. L., 645
 Humphrey, W., 173, 214, 293, 487, 665, 717, 724, 734, 748, 758, 845, 852
 Humphreys, R. E., 329, 339, 386, 387, 394, 395, 396
 Hünig, T., 755, 758
 Hunt, S. M., 272
 Hunt, S. V., 264, 268, 272
 Hunter, I. R., 44, 145, 190, 199
 Hunter, P., 625, 626
 Hunter, W. M., 272, 331, 339
 Hurme, M., 740
 Hurst, M. M., 272
 Hurwitz, E., 636, 637
 Huser, H., 654, 658
 Huston, J. B., 667, 674
 Hutton, J. J., 72, 815
 Hylton, M. B., 137, 182
 Hyman, R., 59, 61, 407-415, 407, 408, 409, 410, 411, 412, 413, 414, 521, 522, 526, 527, 536
 Hyshka, L., 427
- I**
- Ihde, D., 454
 Illmensee, K., 781, 790
 Imai, H. T., 889
 Imanishi, T., 289, 290, 293, 735, 736, 740, 741, 756, 758, 764, 770, 779, 842, 845
 Inbar, D., 634, 637, 667-675, 674
 Inman, J. K., 536, 609, 710, 717, 731, 733, 834, 835, 838, 839, 845
 Inqué, M., 883
 Iritani, C. A., 814
 Isac, R., 127, 377
 Ishizaka, K., 34, 44, 124, 126, 248, 250
 Israels, M. C. G., 21
 Isselbacher, K. J., 215
 Itakura, K., 805, 814, 812, 815
 Ito, M., 530, 533, 536
- J**
- Jackson, D. C., 510, 556, 608
 Jackson, L., 306
 Jackson, R. L., 61, 361
 Jackson, S. A., 659, 686, 697, 748, 853
 Jacob, F., 338, 339, 588
 Jacobs, D. M., 219, 225
 Jacobs, J. W., 358, 361, 901, 902
 Jacobsen, B., 441

- Jacobson, M. W., 441
 Jamieson, J., 411, 414
 Jandinski, J., 23, 24, 25, 31, 89, 91, 189, 190, 483, 487
 Janeway, C. A. J., Jr., 275, 284, 314, 590, 594, 595, 611, 616, 618, 619, 622, 713, 717, 719-724, 719, 720, 721, 722, 723, 724
 Janossy, G., 272, 752, 758
 Jansz, H. D., 862
 Jaramillo, S., 427
 Jarrett, E., 463
 Jarrett-Toth, E., 440
 Jarvis, J. M., 835, 862, 874, 887, 888
 Jasek, T., 791, 803
 Jatón, J.-C., 306, 496, 650, 655, 658, 666, 683, 685, 690, 696, 697, 756, 758, 778
 Jazwinski, S. M., 900, 902
 Jeanes, A., 747
 Jefferis, R., 195, 199
 Jeffrey, A., 862
 Jehn, U. W., 755, 758
 Jenkins, V. K., 137
 Jenner, E., 73, 83
 Jensen, F. B., 83
 Jerne, N. K., 1-4, 29, 30, 31, 33, 44, 93, 99, 102, 149, 155, 157, 228, 236, 249, 250, 285, 293, 505, 507, 510, 526, 527, 677, 685, 695, 697, 710, 716, 717, 722, 724, 797, 803, 818, 835, 887, 888, 892, 902
 Jersild, C., 396, 426, 440, 452, 454
 Jimenez, L., 73-83, 73, 74, 78, 82, 83
 Johnson, B. J., 61
 Johnson, B. M., 103, 189, 191, 560, 561
 Johnson, F. L., 83
 Johnson, N., 817-836
 Johnson, P., 102, 126
 Johnston, M. F. M., 723, 724
 Johnstone, A. P., 655, 658, 689-698, 690, 691, 697
 Joklik, W. H., 529, 530, 536
 Jolley, M. E., 662, 665, 666, 748, 835
 Jonal, U., 214
 Jondal, M., 80, 83, 518
 Jones, E. A., 379, 380, 385, 386, 414, 425, 426, 443-455, 443, 449, 451, 453, 454
 Jones, P. P., 44, 178, 182, 193, 199, 201, 202, 213, 214
 Jones, T. L., 202, 214
 Jones, V. E., 263, 270, 272, 777, 778
 Jonker, M., 417-427, 422, 426
 Jonsson, S., 397, 402
 Jordan, R. K., 129-137, 137
 Jørgensen, F., 419, 426
 Joslin, F. G., 685, 852
 Jotereau, F. V., 131, 137, 145
 Ju, G., 73-83
 Ju, S.-T., 699-707, 703, 706, 707, 853
 Julin, M., 645, 741
 Julius, M. H., 35, 44, 228, 236, 288, 293, 483, 487, 515, 518, 540, 544, 598, 609, 704, 706, 709-718, 709, 713, 717
 Jurd, R. D., 772, 773, 778
 Jutila, J. W., 178, 182
 Juy, D., 307-314, 308, 314
- K**
- Kaakinen, A., 426, 440
 Kabat, D., 395, 396, 882, 888
 Kabat, E. A., 171, 173, 294, 627, 636, 637, 641, 642, 645, 647, 648, 649, 651, 658, 659, 661, 662, 665, 666, 687, 688, 731, 734, 743, 748, 807, 815, 818, 828, 836, 837, 838, 839, 846, 851, 853
 Kacian, D., 874
 Kadish, A., 83
 Kafatos, F. C., 874
 Kagnoff, M. F., 202, 211, 214
 Kahane, I., 361
 Kaji, H., 595
 Kamat, R., 78, 83, 201-215, 213
 Kamin, R. M., 211, 214
 Kamisaku, H., 611, 613, 615, 617, 624
 Kan C., 440
 Kanamaru, A., 518
 Kano, S., 73-83, 75, 78, 82, 83
 Kantor, F. S., 597, 609
 Kaplan, H. S., 21
 Kapp, J. A., 23, 25, 31, 95, 102, 119, 125, 126, 471, 473, 474, 475, 501, 503, 504, 563-570, 563, 569, 570, 578, 609, 618, 619, 622, 623
 Kappler, J. W., 31, 598, 599, 609, 618, 622, 623, 626
 Kapsalis, A. A., 706
 Karakawa, W. W., 697
 Karjalainen, K., 735-741, 736, 740
 Karkinen-Jaaskelainen, M., 137
 Karlsbad, G., 787, 790
 Karlsson, F. A., 667, 670, 674
 Karniely, Y., 491, 496
 Kärre, K., 518
 Kasakura, S., 15, 21
 Kask, A. M., 377, 397-403, 402, 402
 Katagiri, C., 771, 779
 Katagiri, M., 368
 Kates, J., 535, 536
 Kato, K., 339, 348, 349, 361, 377, 403
 Katz, D. H., 23, 24, 27, 30, 31, 114, 116, 117, 119, 126, 202, 214, 275, 284, 292, 293, 344, 349, 358, 361, 368, 369, 377, 443, 451, 454, 465, 470, 474, 486, 487, 491, 493, 495, 496, 503, 505, 510, 522, 527, 539, 542, 544, 553, 556, 559, 561, 563, 564, 568, 569, 571, 577, 578, 579, 580, 582, 584, 587, 597, 598, 607, 608, 609, 611-624, 611, 612, 613, 614, 615, 617, 618, 619, 620, 622, 623, 625, 626
 Katz, L. R., 623
 Katz, S. I., 427, 454, 455
 Kaufman, J. F., 387-396, 387, 394
 Kawata, T., 518
 Kay, M. M. B., 60, 61
 Kearney, J. F., 38, 44, 139-145, 140, 141, 142, 144, 150, 157, 176, 178, 181, 182, 194, 197, 229, 230, 236, 248, 249, 250, 749, 750, 753, 758
 Keeler, K. D., 199
 Kehoe, J. M., 367, 368, 641, 645, 691, 693, 696, 822, 834, 847, 848, 851, 852, 852, 853, 883, 888
 Keightley, R. G., 144
 Kelly B., 113, 118
 Kelly, T., 781-791
 Kelus, A. S., 314, 657, 659, 803, 888
 Kemler, R., 338
 Kemper, B., 361, 902
 Kemshead, J. T., 751
 Kennett, R. H., 447, 451, 454, 455
 Keren, D. F., 209, 214
 Kessler, S. W., 148, 157, 267, 272
 Kettman, J. R., 31, 162, 185-191, 189, 190, 191, 609, 625, 626, 755, 758
 Keuning, J. J., 396, 419, 420, 426, 427, 440, 452, 454, 455
 Khorana, H. G., 72
 Kibler, R., 531, 536
 Kidder, G. M., 773, 778, 778
 Kiefer, H., 288, 293
 Kiessling, R., 517, 518
 Kilbrick, S., 83
 Kilburn, D., 117
 Kim, B. S., 687, 688, 690, 697
 Kim, J. H., 162
 Kim, Y., 426
 Kimura, A., 284
 Kincade, P. W., 144, 159, 162, 178, 182, 199, 213, 245-250, 245, 247, 248, 250
 Kindred, B., 539, 544, 579, 587, 611, 614, 618, 623
 Kindt, T. J., 285, 293, 650, 657, 658, 659, 677, 682, 685, 686, 687, 688, 689-698, 689, 690, 692, 693, 694, 696, 697, 731, 733, 756, 758, 781, 790, 815, 818, 828, 834, 842, 845, 847, 848, 851, 852, 853
 Kipp, D. E., 304, 306, 470, 474
 Kirov, S. M., 243
 Kishimoto, T., 34, 44, 124, 126, 127, 248, 250
 Kisielow, P., 31, 78, 83, 584, 587
 Kissmeyer-Nielsen, F., 379, 386, 426, 440, 443, 445, 447, 454
 Kitajima, K., 753
 Kitamura, Y., 511, 518
 Klapper, D. G., 339, 349, 362, 363-368, 368, 377, 455, 659, 847-853, 852
 Klareskog, L., 329, 331-339, 339, 377
 Klaus, G. G. B., 168, 172, 195, 199
 Klein, D., 463, 503
 Klein, E., 518, 787, 788, 790
 Klein, G., 80, 83, 411, 413, 453
 Klein, J., 331, 337, 339, 343, 345, 348, 349, 351, 354, 359, 360, 361, 362, 363-368, 368, 369, 371, 373, 374, 375, 377, 418, 425, 426, 427, 429, 438, 439, 439, 440, 455, 457-463, 457, 458, 462, 463, 474, 497, 499, 501, 503, 504, 506, 510, 520, 521, 524, 527, 536, 547, 551, 554, 556, 559, 561, 587, 597, 609, 625-626, 809, 812, 814, 815, 897, 902
 Klein, K., 426
 Klein, P., 61, 550, 556
 Klein, W. H., 874
 Kleppe, K., 71, 72
 Kleppe, R., 72
 Klinman, N. R., 140, 141, 142, 144, 145, 160, 162, 165-173, 165, 166, 167, 168, 170, 171, 172, 173, 189, 191, 204, 205, 206, 209, 214, 215, 245, 250, 489, 490, 491, 496, 504, 563, 570, 598, 609, 613, 614, 623, 644, 645, 677, 685, 704, 706, 717, 718, 726, 733, 763, 770, 818, 821, 822, 835
 Kluskins, L., 719, 723, 724
 Knapp, W., 143, 144, 175, 176, 182, 185, 186, 190, 193, 199
 Knight, E. J., 202, 214
 Knight, K. L., 183, 199, 685, 687-688, 687, 688, 697
 Knopf, P., 414
 Knott, J. C. A., 636
 Knowles, B. B., 377, 790, 802
 Knudson, K. C., 202, 214
 Kobayashi, H., 590, 595
 Kobel, H. R., 774, 778
 Koch, C., 284
 Kodama, T., 595
 Köhler, G., 175, 182, 781, 789, 790, 793-803, 793, 794, 797, 798, 799, 801, 803
 Köhler, H., 145, 162, 173, 191, 205, 214, 661, 665, 701, 706, 707, 709, 710, 717, 718, 719, 722, 723, 724, 725, 733
 Kohn, H. I., 455, 510, 527
 Kohne, D. E., 867, 869, 874
 Koller, R. D., 395, 396
 Koller, P. C., 21
 Komuro, K., 6, 8, 8, 65, 72, 137

- Kondo, K., 91, 763, 770
 Konigsberg, W. H., 273, 639, 640, 658, 665, 724, 733, 748, 779, 835, 853
 Kontiainen, S., 102, 113-118, 113, 114, 117, 118, 587
 Koo, P. H., 496, 644, 658
 Kook, A. I., 133, 137
 Kopycinski, C. F., 214
 Koren, H. S., 70, 72, 536, 609
 Kornfeld, S., 393, 396
 Koshland, M. E., 674, 697, 853
 Koski, I., 250
 Koszinowski, U., 369, 377, 505, 510, 529-537, 529, 530, 531, 535, 536, 547, 556
 Kourilsky, F. M., 361, 368, 556
 Kourilsky, P., 874
 Kovithavongs, T., 426, 427
 Kraft, N., 259
 Krakow, J. S., 63, 72
 Krammer, P. H., 264, 272, 317, 321
 Krans, M. L., 271
 Krause, R. M., 658, 690, 685, 696, 697, 732, 733, 756, 758, 848, 852
 Krawinkel, U., 282, 283, 284, 285-294, 288, 289, 290, 291, 292, 293
 Krejei, J., 111
 Kreth, H. W., 167, 173, 726, 734
 Kristensen, T., 429, 440
 Kronenberg, M., 817-836
 Kronvall, G., 267, 272, 397, 402
 Krueger, R. G., 881, 888
 Kubo, R. T., 185, 186, 190, 193, 199, 329, 339, 368, 377, 413, 414
 Kucich, U. N., 59, 61
 Kuehl, W. M., 791, 803
 Kuettner, M. G., 699, 706, 732, 734, 850, 852
 Kuhn, L., 214
 Kuhn, T. S., 769, 770
 Kung, P. C., 63-72, 63, 64, 65, 66, 67, 69, 70, 72
 Kunkel, H. G., 47-50, 47, 50, 102, 144, 182, 190, 199, 200, 263, 272, 285, 293, 307, 314, 354, 361, 395, 396, 422, 426, 427, 455, 682, 685, 689, 697, 736, 741, 848, 852, 853
 Kuperman, O. J., 429-441, 436, 437, 440
 Kurland, J. I., 245, 248, 250
 Kurnick, J. T., 193, 199
 Kvist, S., 331-339
- L**
- Labaw, L. W., 645
 Lachmann, P. J., 452, 454
 Lackland, H., 658
 Ladoulis, C. T., 261, 272, 273
 Laemmli, U. K., 380, 386
 Lafferty, K. J., 433, 437, 438, 440, 441
 LaFleur, L., 137, 139, 144, 156, 157, 164, 758
 Lahat, N., 262, 273
 Laing, R., 272
 Lake, P., 589-595, 593, 595
 Lamm, L. U., 426
 Lamm, M. E., 145, 160, 162, 182, 183, 190, 191, 199, 200, 214, 250
 Lamon, E. W., 264, 272
 Lampkin, B., 72
 Lance, E. M., 86, 91
 Landucci-Tosi, S., 677-686, 678, 679, 680, 681, 685, 686
 Landvall, P., 221
 Lane, I., 164
 Langman, R. E., 251, 253, 259, 526
 Laskov, R., 781, 786, 787, 790
 Lattman, E. E., 636, 645
 Lawrin, D. H., 517
 Lawson, Y., 127
 Lawton, A. R., 38, 44, 132, 137, 139-145, 139, 140, 142, 144, 145, 150, 157, 158, 160, 162, 176, 178, 181, 182, 191, 194, 197, 199, 213, 229, 230, 236, 243, 248, 250, 749, 750, 753, 758
 Layton, J. E., 237-243, 237, 238, 239, 241, 243, 250, 257, 259, 271
 Lazarides, E., 387, 396
 Lebowitz, H. E., 645
 Leder, P., 725, 734, 836, 848, 852, 855-862, 855, 857, 862, 883, 888
 Lederberg, J., 160, 162, 237, 243
 Le Douarin, N. M., 131, 133, 137, 141, 145
 Leduc, E. H., 787, 790
 Lee, G., 247
 Lee, K.-C., 251-259, 251, 252, 253, 254, 259
 Lee, W., 167, 173, 206, 214
 Lee, W. M. F., 145, 162, 191, 707, 718
 Leech, S., 590, 595
 Lees, R. K., 321
 Lefebvre, J. C., 313, 314
 Lefkovits, I., 155, 157, 235, 236, 717, 778, 779
 Legrand, L., 387, 396
 Lehtonen, E., 137
 Le Lievre, C. S., 133, 137
 Lemieux, S., 307, 314
 Lennox, E., 414, 687, 688, 847, 852
 Leon, M. A., 661, 664, 665, 666, 722, 724, 725, 734, 837, 845
 Lerner, K. G., 83
 Leserman, L. D., 563, 569
 Lesley, J. F., 31, 532, 536, 626
 Leslie, G. A., 732, 734
 Leslie, R. G. Q., 636, 665, 835
 Letarte-Muirhead, M., 51-61, 52, 54, 55, 56, 57, 59, 61, 408, 413, 414
 Leuchars, E., 21, 172
 Levi, G., 213
 Levin, R., 14, 21
 Levine, B. B., 295, 306, 397, 402, 457, 463
 Levine, H., 72
 Levine, S. L., 14, 21
 Lewis, W. R., 74, 83
 Levy, J., 113, 117, 118, 527
 Levy, R., 14, 21
 Lewis, H., 273, 791
 Lewis, J. B., 790
 Liao, J., 748
 Lichtenberg, L., 617, 623
 Lichten, E. A., 697
 Lidin-Janson, G., 214
 Lieberman, M., 21
 Lieberman, R., 167, 172, 173, 203, 205, 206, 214, 215, 285, 286, 293, 321, 486, 487, 622, 661, 662, 664, 665, 666, 686, 688, 709, 710, 717, 719, 721, 722, 724, 725, 726, 727, 730, 732, 733, 734, 736, 741, 744, 748, 755, 756, 758, 835, 837, 842, 843, 845, 848, 852
 Liebhaber, S. A., 86, 91, 622
 Lightbody, J. J., 535, 536
 Lilly, F., 361, 527, 556, 590, 591, 592, 595, 608
 Lin, P. K., 182
 Lindahl, K. F., 351, 361, 520, 521, 527, 559
 Lindahl-Kiessling, K., 433, 440
 Lindblom, J. B., 329, 339, 349, 361, 368
 Lindenmann, J., 275, 284, 508, 510, 590, 595, 608
 Linthicum, D. S., 598, 609
 Lipman, L. N., 314
 Lipsky, P. E., 31, 306, 587
 Lisco, H., 455
 Lisowska-Bernstein, B., 162, 185, 186, 190
 Lister, T. A., 595
 Little, J. R., 171, 173, 637, 700, 706, 724, 833, 835
 Littlefield, J. W., 791, 798, 803
 Litwin, S. D., 175, 182
 Liu, S. H., 491, 496
 Livnat, S., 582, 587
 Loblay, R., 93-103
 Lobo, P. I., 193, 199
 Loh, E., 172, 817-836, 822, 823, 824, 825, 835, 838, 839, 840, 845
 Loken, M. R., 33-45
 Lomant, A. J., 389, 396
 Lonai, P., 299, 306, 492, 496, 520, 527, 536
 Loor, F., 67, 72, 137, 263, 272, 273, 778
 Lord, E., 666, 734
 Los, W. R. T., 426
 Lotzová, E., 511, 513, 517, 518
 Lowenstein, L., 440
 Lozner, E. C., 295, 296, 306
 Lucas, S. J., 82
 Lüderitz, O., 236
 Luther-Davies, S. M., 778
 Lutter, L. C., 332, 339
 Luzzati, A. L., 175-183, 504, 624
 Lydyard, P. M., 139-145, 141, 144, 145
 Lynch, R. G., 675, 835, 874
 Lyon, M. F., 781, 791
- M**
- MacDermott, R. P., 72
 MacDonald, A. B., 127, 314
 MacDonald, H. R., 75, 78, 83, 137, 430, 440, 514, 518
 Mach, B., 847, 852, 862, 874, 877, 886, 888
 MacLennan, I. C. M., 307, 314
 Mack, C., 272, 608
 MacKay, I. R., 103
 Mage, R. G., 677-686, 677, 678, 679, 682, 683, 685, 686, 687, 688, 692, 696, 697, 698, 733, 818, 835, 842, 845
 Maia, L. C. S., 475
 Maizel, J. V., 750, 758
 Maizels, N. M., 860, 862
 Maizels, R., 198, 752
 Mäkelä, O., 175, 182, 215, 261, 273, 288, 289, 290, 292, 293, 644, 645, 659, 734, 735-741, 735, 736, 737, 738, 739, 740, 741, 755, 756, 758, 764, 770, 779, 842, 845, 882, 888, 892, 902
 Mäkelä, P., 407, 414
 Makinodan, T., 758
 Malawista, S. E., 785, 791
 Malenka, D., 386, 396
 Mandel, T. E., 243, 250, 284, 321
 Mandy, W. J., 678, 686, 697, 803, 842, 845
 Maniatis, T., 874
 Manjula, B. N., 661, 665
 Mann, D. L., 323-329, 329, 339, 342, 349, 361, 368, 377, 379, 386, 387-396, 387, 395, 396, 403, 425, 427, 449, 452, 454, 455
 Mannik, M., 170, 173, 741
 Manning, D. D., 178, 182, 248, 250
 Manning, M. J., 771, 778, 779
 Mans, R., 273
 Manuel, Y., 368, 556
 Maoz, A., 113-118
 Marbrook, J., 559, 561, 569
 Marchalonis, J. J., 193, 199, 243, 261-273, 261, 262, 263, 264, 265, 266, 267, 268, 271, 272, 273, 275, 284, 325, 329, 392, 396, 585, 587, 779, 812, 815
 Marchesi, V. T., 59, 60, 61, 361
 Marcus, P. I., 82
 Margolies, M., 627, 628, 644, 645, 647-659, 648, 649, 650, 654, 655, 658, 659, 685
 Margulies, D. H., 781-791, 781, 782, 783, 784, 785, 786, 789, 791

- Marks, P. A., 874
 Maron, E., 623
 Marr, K., 395
 Marrack, P., 599, 605, 609, 618, 622, 623
 Marsh, D. G., 457, 463, 636
 Mashak, A., 561
 Marshall-Clark, S., 763
 Martel, J. L., 425, 427
 Martin, J. W., 402
 Mason, D. W., 168, 172, 187, 190
 Mason, S., 272
 Masters, D., 272, 608
 Masuda, T., 21
 Mathews, M. B., 697
 Mathies, M., 113-118
 Mathieson, B. J., 556
 Mathieu, F., 172
 Matthyssens, G., 848, 852, 877-889
 Mattioli, C. S., 207, 214
 Maurer, P. H., 31, 306, 457-463, 457, 462, 463, 474, 475, 504, 544, 623
 Maurer, R., 862
 Mauve, G., 496, 503
 Maxam, A., 860, 862, 874
 Mayhew, B., 111
 Mayor, K. S., 137, 758
 Mazauskas, C., 408, 410, 412, 414
 McBride, R. A., 590, 595
 McBroom, C. R., 590, 595
 McCaffrey, R. P., 63-72, 63, 71, 72
 McCalmon, R., 414
 McCarthy, M. M., 569
 McCarty, M., 286, 293
 McCluskey, R. T., 214
 McConnachie, P. R., 427
 McConnell, I., 185, 191
 McCormick, J. N., 45, 200, 214, 487, 503
 McCullagh, P. J., 95, 102
 McCulloch, E., 129, 137, 415
 McCune, J. M., 323, 329, 339, 386, 396
 McDavitt, H. O., 23, 31, 34, 44, 117, 126, 127, 275, 284, 295, 298, 299, 305, 306, 364, 368, 369, 374, 375, 377, 379, 386, 452, 455, 465, 474, 475, 487, 489-496, 489, 490, 491, 492, 496, 497-504, 497, 500, 501, 502, 503, 504, 543, 544, 595, 597, 608, 613, 622, 623, 845, 898, 902
 McDonald, J., 623
 McGarry, M. P., 137
 McGhee, J. R., 145, 215
 McInnes, J., 790
 McIntire, K. R., 845
 McKean, D., 627, 628, 631, 637, 661, 665, 824, 825, 831, 835, 838, 839, 845, 862, 878, 885, 888
 McKearn, T. J., 261, 273, 280, 284, 719, 723, 724
 McKenny, J. A., 733
 McKenzie, J., 407, 414
 McKeough, M., 441
 McKusick, V. A., 417, 418, 427, 454
 McLaughlin, A. C., 636
 McLaughlin, C. L., 645, 667, 675, 686
 McMaster, P. R. B., 103
 McMichael, A. J., 736, 741, 749, 756, 758, 763, 770, 777, 779
 McMillan, M., 369-377, 398
 McWilliams, M., 145, 182, 183, 190, 191, 199, 200, 202, 206, 214
 Meera Khan, P., 426, 455
 Mees, J. R., 455
 Megson, M., 137, 145, 158, 161, 162, 191, 243, 250
 Meier, H., 845
 Meinesz, A., 440
 Melcher, U., 143, 145, 176, 182, 183, 185, 190, 191, 194, 199, 200, 365, 368
 Melchers, F., 139, 145, 147-158, 147, 148, 149, 150, 152, 153, 155, 156, 157, 158, 160, 161, 162, 163, 164, 164, 182, 187, 191, 227-236, 228, 229, 230, 231, 232, 235, 236, 249, 250, 288, 410, 414, 754, 758
 Melchers, I., 470, 474, 486, 487, 501, 503, 504
 Melief, C. J. M., 521, 527
 Melli, M., 866, 867, 874, 885, 888
 Melnick, J. L., 83
 Melvold, R. W., 527
 Mempel, W., 418, 419, 427
 Menck, H., 463
 Meo, T., 427, 440, 469, 474, 487, 492, 496, 503, 527, 544
 Merchant, B., 717, 763, 770
 Merler, E., 791
 Merryman, C. F., 457-463, 457, 458, 459, 462, 463, 466, 468, 474, 475, 501, 503, 504
 Mestecky, J., 215
 Metcalf, D., 9, 21, 129, 137, 229, 236, 237, 239, 243, 245, 247, 248, 250, 321
 Metcalf, E. S., 140, 141, 145, 160, 162, 165-173, 165, 168, 172, 189, 191
 Metz, D. H., 535, 536
 Metzger, H., 627, 634, 637, 709, 717, 720, 724, 727, 734
 Metzler, C. M., 44, 88, 126, 503
 Meyer, B., 862
 Michael, A., 426
 Michaelides, M. C., 723, 724
 Michaelsen, T. E., 200
 Michalek, S., 145, 207, 215
 Michel, M., 307, 314, 657, 659, 736, 741, 756, 758
 Mickelson, E., 426
 Miggianno, V. C., 414, 426, 440, 441, 448, 454, 455, 474, 527, 544
 Milgrom, F., 466, 470, 475
 Milili, M., 666
 Miller, A., 306, 474
 Miller, E. J., 697
 Miller, F., 727, 734
 Miller, G., 73, 83, 443, 444, 455
 Miller, H. C., 59, 61, 214
 Miller, J. F. A. P., 30, 31, 102, 103, 113, 116, 118, 126, 236, 243, 250, 273, 314, 321, 451, 455, 474, 475, 539, 540, 544, 559, 560, 561, 568, 569, 577, 578, 579-588, 579, 580, 582, 583, 584, 585, 587, 588, 611, 618, 619, 621, 623, 891, 902
 Miller, O. J., 453
 Miller, R. G., 126, 135, 136, 137, 144, 157, 518
 Miller, S. D., 105-111, 105, 106, 107, 111
 Miller, T. B., 454
 Milner, R. J., 349, 351-362, 361, 368, 377, 454, 547-557, 550, 556
 Milstein, C., 175, 182, 641, 644, 645, 664, 665, 686, 695, 697, 758, 781, 787, 788, 789, 790, 793-803, 793, 794, 795, 796, 797, 798, 799, 801, 802, 803, 818, 819, 833, 834, 835, 840, 845, 847, 853, 855, 856, 862, 863, 874, 877, 885, 886, 887, 888
 Milstein, C. P., 803
 Minowada, J., 447, 455
 Mintz, B., 781, 790, 901, 902
 Mishell, R. I., 86, 91, 252, 259, 569, 750, 758
 Misra, D. N., 272, 273
 Mitchell, G. F., 95, 101, 102, 113, 118, 255, 257, 259, 496
 Mitchison, N. A., 85, 91, 257, 259, 589-595, 590, 592, 595, 891, 902
 Miura, M., 814
 Miyakawa, Y., 341, 342
 Miyake, T., 127
 Miyazawa, M., 31, 814
 Modabber, F., 273, 609
 Mohit, B., 788, 789, 791
 Mole, L. E., 348, 361, 368, 377, 655, 659, 667, 674, 682, 684, 686, 690, 691, 697, 743, 748, 847, 852, 853
 Molineux, I., 72
 Möller, E., 150, 157, 221, 225, 226, 228, 236
 Müller, G., 85, 91, 147, 157, 217-226, 217, 218, 219, 220, 221, 224, 225, 226, 227, 236, 248, 249, 250, 256, 259, 268, 270, 273, 461, 462, 463, 519, 527, 752, 755, 758
 Moloney, J. B., 163, 164
 Molony, W. C., 191
 Monahan, J. J., 856, 862
 Montgomery, P. C., 637, 763, 770, 777, 779
 Montgomery, R., 57, 61
 Monty, K. J., 380, 386
 Moore, G. E., 183, 455
 Moore, G. W., 639, 645
 Moore, M. A. S., 9, 21, 129, 131, 134, 137, 245, 248, 250
 Moorhead, J. W., 105-111, 105, 108, 109, 111, 770
 Morag, A., 215
 Morling, N., 427
 Moroz, C., 262, 273
 Morris, J. E., 658
 Morris, R. J., 51-61, 51, 52, 53, 61, 408, 414
 Morrison, D. C., 219, 225, 226
 Morrison, M., 901, 902
 Morrison, S. L., 781-791, 781, 786, 787, 791, 793, 803
 Morse, H. C., 823
 Mortensen, R. F., 48, 50
 Morton, D. L., 590
 Moscona, A., 131, 137
 Moseley, J. M., 261-273
 Mosier, D. E., 88, 91, 97, 103, 189, 191, 560, 561
 Moss, K., 534, 536
 Moulin, A., 172
 Mouton, D., 758
 Mowbray, J. F., 262, 263, 264, 271
 Moyer, S., 413
 Mozes, E., 125, 127, 251, 259, 296, 306, 369, 377, 469, 475, 491, 496, 587, 617, 618, 619, 623, 624
 Mudgett, M., 656, 659, 678, 686, 695, 697, 810, 815, 847, 852, 853
 Mullen, H. B., 167, 173
 Müller, A., 61
 Müller-Eberhard, H. J., 314, 452, 455
 Munkres, K. D., 345, 347, 349
 Munro, A. J., 23, 31, 118, 119, 125, 127, 275, 284, 295, 304, 306, 369, 377, 451, 455, 469, 470, 475, 496, 504, 545, 585, 587, 609, 624, 625, 626
 Muramatsu, T., 411, 414
 Murgita, R. A., 315, 321, 726, 734
 Murphy, D. B., 36, 44, 44, 123, 125, 127, 371, 374, 377, 472, 475, 478, 479, 480, 482, 483, 485, 486, 487, 492, 496, 497-504, 498, 499, 501, 502, 504
 Muschel, R., 82
 Mushinski, E. B., 173, 214, 293, 661-666, 665, 666, 706, 707, 717, 724, 734, 748, 758, 835, 845, 852
 Myers, H., 845

N

- Nabholz, M., 25, 439, 440, 455, 474, 510, 521, 523, 527, 540, 544, 545, 624
 Nachtigal, D., 95, 103

- Nahmias, A. H., 73, 83
 Naidorf, K. F., 85-91, 87
 Nakamura, F. T., 788, 789, 790
 Nakamura, I., 202, 215
 Nakamuro, K., 326, 329, 331, 339, 341, 342, 351, 361
 Nakashima, Y., 639, 640
 Narashimikas, S., 414
 Nash, D. R., 214
 Nathans, D., 860, 862
 Nathenson, S. G., 324, 329, 337, 338, 339, 343-349, 343, 346, 348, 349, 351, 355, 356, 361, 363, 368, 377, 386, 395, 402, 403, 414, 454, 487, 527, 532, 535, 536, 556, 595, 790, 802
 Natori, T., 343, 346, 349, 361, 363, 368
 Natvig, J. B., 47, 50, 200, 685
 Nau, M., 734, 852, 862, 888
 Neauport-Sautes, C., 321, 354, 361, 365, 368, 551, 555, 556
 Nehlsen, S., 137
 Neiman, P. E., 83
 Nelson, D. L., 454, 455
 Neville, D. M., 783, 791
 Newell, J., 658
 Newman, C., 536
 Newton, J. T., 803
 Niall, H. D., 8, 361, 902
 Nichols, W. W., 455
 Nicholson, G. L., 270, 273, 410, 414
 Niederhuber, J. E., 249, 250, 307, 314, 377, 477-487, 478, 482, 483, 487, 500, 503, 504
 Nielsen, L. S., 441
 Nilson-Hamilton, M., 408
 Nilsson, B. S., 151, 158
 Nilsson, K., 339, 446, 454
 Nisbet, N. W., 559, 561
 Nishizawa, Y., 127
 Nisizawa, T., 343-349
 Nisonoff, A., 285, 293, 307, 314, 645, 658, 688, 696, 699-707, 699, 700, 703, 706, 707, 719, 722, 724, 725, 733, 734, 791, 834, 847-853, 850, 851, 852, 853
 Nordin, A. A., 177, 182, 236, 245, 250, 710, 717, 797, 803, 902
 Nordling, S., 137, 495
 Norman, B., 734, 852, 862, 888
 North, A. C. T., 636
 North, J. R., 193, 198, 199, 749-759, 749, 750, 751, 752, 758
 Nossal, G. J. V., 115, 117, 139, 140, 141, 145, 148, 157, 160, 162, 162, 166, 173, 177, 182, 189, 191, 236, 237-243, 237, 238, 239, 241, 242, 243, 249, 250, 251, 257, 259, 262, 272, 273, 441, 755, 758, 783, 791, 892, 894, 902
 Notani, G., 293
 Nottenburg, C., 38, 172, 835, 845
 Novotny, J., 848, 852, 853
 Nowakowski, M., 73-83, 75, 77, 82, 83
 Nowell, P. C., 15, 21, 29, 30, 31, 284, 455, 527, 561
 Nowinski, R. C., 550, 556
 Noyes, A. N., 395
 Nunn, M. E., 517, 536
 Nussenzweig, V., 284, 314
 Nutt, N. B., 777, 779
- O**
- O'Brien, C., 441
 O'Daly, J. A., 201, 215
 O'Donnell, J., 874
 Oettgen, H. F., 31, 83, 587
 O'Farrell, P. H., 387, 396
 Ogra, P. L., 201, 215
 Ohms, J. J., 658
 Ohno, S., 847, 853, 882, 888
 Ohnuma, T., 455
 Ojeda, A., 306, 402, 609
 Okada, Y., 797, 803
 Okumura, K., 31, 33-45, 34, 35, 36, 37, 44, 125, 126, 127, 190, 475, 487, 497-504, 498, 501, 502, 503, 504, 609
 Okuyama, T., 252, 259
 Olander, J., 171, 173, 833, 835
 Old, L. J., 31, 61, 159, 162, 407, 411, 413, 414, 814, 815
 Olding, L. B., 80, 83
 Oldstone, M. B. A., 83
 Olins, D. E., 388, 396
 Olive, C., 21
 O'Malley, B. W., 862
 O'Malley, K. A., 790
 Oppenheim, J. J., 74, 83
 Orbach-Arbouys, S., 91
 Ordal, J. C., 491, 496
 Oriol, R., 666
 Orkin, S. H., 787, 788, 791
 Orleans, E., 272, 778
 Orme, T., 595
 Orr, K. B., 315, 321
 Orris, L., 111
 Ortlandel, F., 339
 Ortsuka, E., 72
 Osborn, M., 353, 362
 Osborne, B. A., 33-45
 Osborne, D. P., Jr., 612, 622, 623
 Osmand, A. P., 50
 Osmond, D. G., 134, 137, 139, 145, 162, 162, 241, 243, 249, 250
 Östberg, L., 329, 331-339, 331, 338, 339, 360, 361, 363, 368, 377, 411, 413, 414
 Osterland, C. K., 690, 697, 724
 Oudet, P., 888
 Oudin, J., 285, 293, 307, 314, 657, 659, 682, 686, 687, 688, 689, 690, 697, 736, 741, 756, 758
 Ovary, Z., 293, 770
 Owen, F. L., 699-707
 Owen, J. J. T., 38, 44, 129-137, 130, 131, 132, 134, 137, 145, 156, 158, 159, 160, 161, 162, 191, 243, 250, 407, 411, 414, 803
 Ozer, H., 215
- P**
- Packman, S., 734, 852, 862, 888
 Padlan, E. A., 627-637, 627, 628, 636, 637, 645, 648, 659, 661, 666, 683, 684, 685, 686, 734, 748, 818, 835, 902
 Paetkau, V. H., 252, 253, 259
 Palade, G., 411, 414
 Palm, W., 636, 674
 Palmer, J., 253, 259, 563, 570
 Panagiotopoulos, N., 339, 645, 674
 Pantelouris, E. M., 132, 137
 Papaioannou, V. E., 9-21
 Paranjpe, M., 595
 Paraskevas, F., 315, 321
 Parham, P., 323-329, 324, 325, 329, 332, 339, 342, 349, 361, 368, 377, 386, 396, 455
 Parish, C. R., 34, 44, 237, 243, 307, 314
 Park, W., 273
 Parker, D. C., 248, 250
 Parker, J. C., 463
 Parkhouse, R. M. E., 44, 143, 144, 176, 182, 185, 186, 187, 190, 191, 193-200, 193, 194, 195, 199, 262, 266, 270, 271, 272, 365, 368, 383, 386
 Parkman, R., 72, 787, 788, 791
 Parlevliet, J., 426, 427, 455
 Passmore, H. C., 377
 Patrick, R., 314
 Paul, W. E., 23, 31, 36, 44, 103, 142, 144, 145, 170, 172, 190, 191, 200, 272, 295, 306, 314, 377, 398, 401, 402, 402, 403, 474, 475, 487, 571-587, 578, 587, 590, 595, 622, 623, 719, 720, 722, 723, 724, 763, 764, 770
 Pauling, L., 631, 637
 Pawlak, L. L., 286, 293, 700, 701, 702, 706, 707
 Payne, R., 343
 Pearson, P. L., 453
 Pearson, T., 799
 Peavy, D. L., 31, 91, 190, 487
 Pecht, I., 627-637, 627, 634, 637, 667-675, 674, 675
 Peck, A. B., 439, 440, 527
 Pellegrino, M., 426, 454
 Pemberton, R., 874
 Pena, A. S., 454
 Perey, D. Y. E., 202, 213, 214, 215
 Perham, R. M., 837, 845
 Periman, P., 788, 799, 791, 803
 Perkins, E. H., 755, 758
 Perlmann, H., 314
 Perlmann, P., 313, 314
 Pernis, B., 38, 39, 42, 44, 143, 145, 163, 164, 164, 175-183, 175, 176, 177, 178, 180, 182, 182, 183, 185, 191, 194, 199, 200, 243, 266, 273, 783, 791, 802, 803, 882, 888
 Perramon, A., 686
 Persijn, G. G., 426
 Persson, U., 221, 225, 226
 Pestka, S., 790
 Peter, H. -H. 61
 Peterson, J. A., 785, 791
 Peterson, P. A., 326, 328, 329, 331-339, 331, 332, 333, 337, 338, 339, 349, 351, 361, 363, 368, 372, 377, 413, 414, 639, 645, 674
 Petitprez, A., 314
 Petranyi, G., 518
 Petz, L. D., 595
 Pfizenmaier, K., 507, 510, 523, 527, 529, 536, 541, 545, 547, 553, 556
 Pflumm, M. N., 814
 Phanuphak, P., 105, 106, 111
 Phillips, D. C., 636
 Phillips, D. R., 901, 902
 Phillips, J. M., 195, 199, 307, 314, 735, 741, 750, 758, 776, 779
 Phillips, R. A., 126, 136, 137, 144, 145, 147-158, 147, 156, 157, 158, 162, 236, 518
 Phillips-Quagliata, J., 145, 182, 183, 191, 199, 200, 214
 Phizackerley, R. P., 377, 637, 639-645, 645, 659, 666, 675, 835
 Piazza, A., 430, 441
 Pickard, A., 173
 Pickel, H. G., 272, 608
 Pickeral, S., 402, 571-578
 Pierce, C. W., 25, 30, 31, 88, 91, 102, 126, 142, 145, 168, 173, 178, 183, 190, 198, 199, 474, 474, 475, 483, 487, 504, 563-570, 563, 564, 565, 566, 567, 569, 570, 577, 578, 597, 607, 609, 618, 619, 622, 623
 Pierce, N. F., 202, 215
 Pierce, S. K., 145, 165-173, 168, 173, 491, 496, 563, 570, 598, 608, 609, 613, 614, 618, 623
 Pierson, G. R., 561
 Piessens, W. F., 185, 191
 Piette, L. H., 637
 Pike, B. L., 139, 140, 141, 145, 148, 157, 160, 162, 166, 173, 189, 191, 237-243, 894, 902
 Pilarski, L. M., 764, 765, 766, 767, 768, 770
 Pincus, J. H., 697, 733
 Pink, J. R. L., 167, 173, 777, 778, 779

- Pinkerton, W., 778
 Pirofsky, B., 190, 199
 Pisano, J. J., 342
 Pisetsky, D. S., 295-306
 Plata, F., 547, 556
 Platt, T., 396
 Platz, P., 427, 441
 Playfair, J. H. L., 321, 763
 Ploem, J. S., 427
 Pohl, S. L., 271
 Polak, L., 106, 111
 Polisky, B., 535, 536
 Poljak, R. J., 372, 377, 627, 628, 632, 635, 636, 637, 639-645, 639, 640, 642, 643, 644, 644, 645, 647, 648, 649, 658, 659, 661, 666, 673, 675, 743, 748, 818, 833, 834, 835
 Polsky, F., 862
 Pontecorvo, G., 782, 791
 Pope, H., 118, 545, 609, 624
 Porter, L., 441
 Porter, R. R., 307, 314, 659, 667, 674, 686, 697, 748, 853
 Poskus, E., 802
 Pospisil, M., 426
 Potter, M., 67, 70, 72, 163, 164, 173, 205, 214, 215, 285, 293, 294, 627, 634, 636, 637, 645, 658, 659, 661-666, 661, 662, 663, 664, 665, 666, 686, 688, 706, 707, 709, 717, 719, 724, 725, 727, 730, 731, 733, 734, 735, 736, 741, 744, 748, 755, 758, 790, 794, 803, 811, 815, 821, 822, 826, 830, 835, 836, 837, 840, 845, 852, 862, 888, 889
 Potts, J. T., 361, 902
 Poulik, M. D., 329, 339, 357, 361, 363-368, 363, 392, 396, 426, 695, 697
 Poulsen, K., 667, 675
 Poulton, P., 609
 Prael, J. W., 690, 691, 697, 762, 770
 Pratt, D. M., 691, 697
 Premkumar, E., 68, 72, 163, 164, 883, 888
 Prendergast, R. A., 215
 Press, E. M., 636, 667, 673, 675
 Press, J. L., 44, 142, 144, 165, 166, 168, 170, 172, 204, 206, 214, 245, 250, 377, 489-496, 489, 490, 491, 492, 496, 501, 502, 504, 613, 615, 617, 622, 623, 645, 685, 718, 726, 733, 763, 770, 818, 821, 822, 835
 Pressman, D., 45, 183, 329, 339, 341-342, 342, 349, 361, 368, 675, 779
 Preud'homme, J.-L., 178, 183, 755, 758, 790, 791, 803
 Price, N. C., 636
 Primi, D., 224, 225
 Pritchard-Briscoe, H., 93-103
 Pross, H., 518
 Pross, S. H., 773, 779
 Proudfoot, N. J., 835, 862, 888
 Ptak, W. P., 85-91, 87, 88, 91, 105, 111
 Ptashne, M., 860, 861, 862
 Purcell, R. H., 215
 Pye, J., 259, 314, 321, 587
- Q**
- Quintans, J., 235, 236, 717
- R**
- Rabbitts, T. H., 793, 803, 833, 835, 847, 853, 855, 862, 863, 869, 874, 883, 885, 888
 Rabellino, E., 236
 Rabstein, L. S., 163, 164
 Race, R., 410, 414, 417, 427
 Radl, J., 144, 182, 190, 199
 Radola, B. J., 700, 707
 Radovich, J., 441
 Radzimski, G., 658
 Raff, M. C., 11, 21, 29, 31, 44, 51, 61, 86, 91, 130, 135, 136, 137, 139, 140, 145, 147, 155, 156, 158, 159-162, 159, 160, 161, 162, 162, 175, 183, 189, 191, 241, 243, 248, 250, 407, 410, 411, 414, 556, 882, 888
 Raich, P. C., 441
 Rajewsky, K., 29, 30, 31, 98, 103, 116, 117, 261, 272, 284, 285-294, 285, 286, 287, 288, 289, 290, 292, 293, 300, 306, 315, 321, 470, 474, 486, 487, 501, 503, 504, 544, 585, 586, 587, 597, 608, 612, 618, 619, 622, 624, 714, 717, 812, 814
 Ralph, P., 245-250, 250, 414
 Ramachandran, G. N., 628, 637
 Ramakrishnan, C., 628, 637
 Ramasamy, R., 249, 250
 Ramirez, F., 874
 Ramseier, H., 275, 284, 285, 293, 508, 510, 811, 815
 Ramshaw, I. A., 556
 Rao, D. N., 661-666, 663
 Rao, K. V., 874, 888
 Rapson, N. T., 595
 Raschke, W., 9-21, 20, 172, 645, 658, 748, 802, 814, 835, 845, 852, 862, 888
 Rask, C. S., 377
 Rask, L., 226, 329, 331-339, 331, 332, 333, 337, 338, 339, 343, 349, 361, 363, 368, 377, 413, 414
 Rassulin, Y. A., 536
 Raushwerger, J. W., 511, 518
 Ravitch, M. M., 102, 250
 Rawls, W. E., 83
 Ray, A., 215, 644, 658
 Read, S. E., 272
 Reempsma, K., 426
 Reese, R. T., 106, 111
 Rehn, T. G., 31, 118, 361, 511-518, 527, 529, 534, 536, 545, 556, 561, 570, 578, 587, 598, 609, 624
 Reichert, A. E., 297, 306
 Reif, A. E., 51, 52, 53, 59, 61, 163, 164, 407, 414
 Reinisch, C. L., 190
 Reinsmoen, N., 426
 Reinfeld, R. A., 368, 503, 686, 695, 697
 Reisner, H., 791
 Reitherman, R. W., 60, 61
 Rejnek, J., 677-686, 686
 Reske, K., 349
 351-362, 361, 368, 377, 454, 556
 Revillard, J. P., 314
 Reynolds, J. A., 59, 60, 61
 Rhim, J. S., 402
 Riblet, R. J., 102, 147, 151, 158, 172, 218, 226, 248, 250, 286, 293, 645, 647, 658, 659, 725, 734, 748, 802, 814, 821, 835, 837-846, 841, 843, 845, 846, 852, 862, 888
 Rice, S. A., 293
 Rich, R. R., 483, 486, 487, 607, 609, 611, 624
 Rich, S. S., 486, 487, 607, 609
 Richards, F. F., 636, 644, 658, 723, 724, 777, 779, 834, 834, 835, 847, 853
 Richards, F. M., 380, 382, 384, 386, 387, 389, 396
 Richardson, A., 497, 504
 Richardson, D. C., 645
 Richardson, J. S., 639, 645
 Richardson, M., 874, 888
 Richter, R. F., 272
 Richter, W., 225
 Rieber, E. P., 262, 263, 273
 Riesen, W. F., 665, 666
 Riethmüller, G., 262, 263, 273
 Rijder, L. P., 427
 Rijnbeek, A., 474, 527, 544
 Rimmer, T. T., 778
 Ringden, O., 221, 226
 Rittenberg, M. B., 102, 598, 609
 Risso, A., 182
 Rivat, C., 686
 Rivat, L., 678, 686
 Robb, R., 323-329, 326, 329, 339, 386, 396
 Robberson, D. L., 862
 Robbins, J. B., 201, 213
 Robbins, J. H., 74, 83
 Roberts, I. M., 102, 103
 Robertson, S. M., 201-215, 201, 208, 209, 213, 215
 Robineaux, R., 314
 Robinson, J. H., 129-137, 134, 137
 Robinson, P. J., 380, 386
 Robyns, E., 361
 Rocca-Serra, J., 172, 663, 664, 666
 Roche, R. S., 675
 Rockey, J. H., 634, 637
 Rodbell, M., 271
 Rodkey, L. S., 285, 293, 719, 723, 724
 Rodkey, S., 685, 697
 Rodt, H., 510, 527, 536, 545, 556
 Roelants, G. E., 37, 44, 67, 72, 134, 137, 262, 273, 758
 Roger, J. H., 425, 427
 Rogers, J., 396
 Roholt, O. A., 658, 675
 Roitt, I. M., 103, 314, 386
 Rolley, R. T., 267, 273
 Röllinghoff, M., 441, 510, 527, 536, 545, 556
 Romano, T., 81
 Rongey, R. W., 463
 Ropartz, C., 686
 Rosan, R. C., 83
 Rose, N. R., 99, 103
 Roseblatt, M., 658, 659, 685
 Rosen, S. D., 61
 Rosenberg, N., 70, 72, 163, 164
 Rosenberg, S. A., 393, 396
 Rosenstein, R. W., 724, 779, 835, 853
 Rosenstreich, D. L., 74, 83, 572, 578
 Rosenthal, A. M., 74, 83
 Rosenthal, A. S., 23, 24, 27, 30, 31, 300, 306, 474, 475, 522, 527, 539, 545, 563, 568, 570, 571-578, 571, 574, 576, 577, 578, 578, 579, 587, 597, 607, 609, 611, 613, 624
 Rosenthal, M. S., 73, 82
 Rossi, G. B., 513, 517
 Rossow, P., 787, 790
 Roth, J. A., 590
 Roth, J. R., 790, 803
 Rougeon, F., 852, 869, 874
 Roux, M. E., 758
 Rowe, D. S., 39, 45, 143, 145, 175, 176, 183, 185, 186, 191, 193, 200, 240, 243, 266, 273
 Rowe, W. P., 72, 164
 Rowlands, D. T., 773, 779, 821, 835
 Rowley, D. A., 145, 162, 191, 707, 718
 Royal, S., 144
 Ruben, L. N., 261, 273, 778
 Ruben, T. J., 94, 103
 Rubin, A. S., 126, 127
 Rubin, B., 517, 618, 619, 645
 Rubinstein, A., 82
 Rubinstein, P., 426, 427
 Rude, E., 466, 470, 474
 Rudikoff, S., 173, 214, 293, 627, 637, 645, 658, 659, 661-666, 661, 662, 663, 665, 666, 686, 724, 725-734, 725, 727, 730, 731, 733, 734, 744, 748, 758, 827, 830, 835, 845, 852
 Rudzik, O., 207, 213, 215
 Ruhl, R., 157
 Russell, A. S., 102
 Russell, E. S., 137
 Russell, P., 259
 Russell, W. C., 530, 536
 Rutishauser, U., 158, 173, 288, 290, 293, 645, 779, 902

- Ryan, J. L., 249, 250
 Ryden, A., 137, 273
 Ryder, L. P., 441
 Rynbeek, A., 440
 Ryser, J. E., 139, 145
- S**
- Sachs, D. H., 221, 249, 250, 294, 295-306, 295, 296, 300, 304, 305, 306, 307, 314, 315, 321, 339, 377, 384, 386, 474, 479, 480, 487, 496, 500, 501, 502, 503, 504, 536, 591, 595, 734, 758, 815, 836
 Sachs, J., 385, 454
 Sado, T., 611, 613, 615, 617, 624, 758
 Säfwenberg, J., 331, 433, 440
 Saito, H., 595
 Sakato, N., 712, 717, 719-724, 719, 720, 721, 722, 723, 724
 Salaman, M. R., 734
 Salsano, P., 193, 200
 Samelson, L. E., 31, 527, 536, 544, 556, 561, 622
 Samurat, C., 307, 314
 Sandberg, L., 331-339, 331
 Sanders, E., 835
 Sanderson, A. R., 47, 50, 323, 329, 339
 Sandford, B. H., 534, 536
 Sanger, R., 417, 427
 Sano, Y., 536
 Santer, V., 273
 Sarma, V. R., 639, 645
 Sarvas, H., 740
 Satake, K., 252, 259
 Sato, S., 707, 853
 Sato, T., 164
 Sato, V. L., 31, 36, 44, 500, 504
 Sato, W., 398, 402
 Sauer, R. T., 862
 Saul, F., 377, 636, 637, 639-645, 644, 645, 658, 659, 666, 675, 834, 835
 Saxen, L., 129, 137
 Schachner, M., 396, 595
 Schachter, H., 414
 Schacter, B. Z., 454
 Scharff, M., 410, 415, 755, 758, 763, 770, 781-791, 781, 783, 785, 786, 787, 790, 791, 793, 802, 803
 Schechter, A. N., 295-306, 305, 306
 Schechter, I., 593, 595, 847, 853, 877, 886, 888
 Scheid, M. P., 5-8, 5, 8, 53, 61, 67, 72, 133, 136, 137, 407, 414
 Schellekens, P. Th. A., 426, 440
 Schendel, D., 83, 361, 433, 434, 439, 439, 440, 536, 607, 609
 Scher, C. D., 72, 163, 164
 Scher, W., 164
 Schier, P. H., 191
 Schierman, L. W., 590, 595
 Schiff, C., 172
 Schiffer, M., 339, 628, 636, 637, 642, 645, 649, 659, 673, 674, 675
 Schilling, J., 817-836
 Schimpl, A., 115, 117, 118, 124, 126, 127, 625, 626, 750, 758
 Schirrmacher, V., 249, 250, 307, 314, 517, 585, 587
 Schlesinger, D. H., 5, 8
 Schlesinger, M., 407, 414
 Schlessinger, J., 667-675, 670, 671, 672, 674, 675
 Schlossman, S., 31, 72, 102, 190, 395, 396, 441, 474, 504, 540, 543, 545, 567, 570
 Schmitt-Verhulst, A.-M., 511-518, 535, 536, 624
 Schnute, W. C., 293
 Schoenberg, L. M., 144, 145
 Schrader, J. W., 37, 45, 251, 259, 351, 354, 361, 505, 508, 510, 547-557, 547, 548, 550, 551, 552, 553, 554, 556
 Schramm, H. J., 636
 Schreiber, R. D., 452, 455
 Schrek, R., 14, 21
 Schreuder, I., 426
 Schroer, J., 733, 733, 734
 Schuit, H. R. E., 427, 455
 Schulenberg, E. P., 667, 675, 827, 835, 863, 874
 Schuller, R., 877-889, 883, 888
 Schulof, R. S., 8, 137
 Schultz, L. D., 814, 815
 Schur, P. H., 454, 673, 675
 Schwaber, J., 787, 788, 789, 791, 833, 835
 Schwager, P., 636, 645
 Schwartz, B. D., 333, 339, 343, 349, 353, 361, 374, 377, 384, 386, 397-403, 397, 398, 399, 401, 402, 402, 403, 443, 455, 478, 487, 532, 535, 536, 556, 571, 572, 578
 Schwartz, M., 473, 475
 Schwartz, R. H., 23, 31, 295-306, 295, 299, 306, 402, 470, 475, 515, 517, 598, 608
 Schwartz, R. S., 527
 Scott, R. E., 61
 Scudeller, G., 556
 Seal, U. S., 272
 Sears, D. W., 343-349
 Secher, D. S., 645, 665, 758, 793-803, 794, 795, 796, 802, 803, 848, 853
 Seeger, R. D., 74, 83
 Segal, D. M., 627, 631, 636, 637, 641, 645, 647, 648, 659, 661, 662, 663, 666, 683, 686, 748, 835, 902
 Segal, G. P., 173
 Segal, S., 489, 503
 Segall, M., 440
 Sege, K., 329, 331-339, 339, 377
 Segrest, J. P., 55, 61, 270, 271, 273, 354, 361
 Seide, R. K., 685, 697, 852
 Seidman, J., 855-862, 856, 857
 Sekhon, G. S., 455
 Sela, M., 288, 293, 295, 306, 465, 474, 475, 496, 580, 587, 617, 623, 624, 637, 672, 674, 898, 902
 Self, S., 144
 Seligmann, M., 44, 145, 178, 182, 183, 191
 Sell, S., 182, 267, 268, 273, 308, 314, 609
 Sendo, F., 595
 Senik, A., 73-83, 78
 Seon, B. K., 667, 675
 Sercarz, E. E., 306, 474, 773, 778
 Sever, J. L., 82
 Shamborant, O. G., 536
 Sharon, J., 667-675, 667, 675
 Sharrow, S. O., 595
 Shaw, A., 259
 Shearer, G. M., 26, 30, 31, 116, 118, 251, 259, 295, 305, 306, 351, 361, 369, 377, 496, 508, 510, 511-518, 511, 512, 513, 518, 519, 527, 529, 534, 536, 539, 540, 543, 545, 548, 552, 555, 556, 559, 561, 568, 570, 571, 577, 578, 579, 587, 597, 609, 613, 614, 617, 623, 624
 Sheehy, M., 421, 426, 427, 430, 440, 441
 Shek, P. N., 314
 Shelanski, M. L., 396
 Shelton, E., 261, 273
 Shelton, K. R., 269, 273
 Shen, F.-W., 23, 25, 31, 44, 103, 504, 588, 598, 609, 812, 815
 Shen, L., 314
 Sheppard, H. W., Jr., 267, 273
 Sher, A., 167, 173, 294, 661, 666, 725, 734, 826, 835
 Sherwin, W. K., 821, 835
 Shevach, E. M., 164, 299, 306, 317, 321, 377, 397-403, 397, 401, 402, 402, 403, 474, 475, 522, 527, 539, 545, 563, 568, 570, 571-578, 571, 573, 574, 576, 577, 578, 578, 587, 597, 607, 609, 611, 613, 624
 Shih, C. Y., 441
 Shiku, H., 23, 31, 83, 587
 Shimada, A., 323, 329, 346, 349
 Shinnick, C. J., 368
 Shiozawa, C., 251-259, 259, 611
 Shirai, T., 595
 Shoffner, P., 487, 504
 Shortman, K., 236, 250, 253, 259, 563, 570
 Shortmann, K., 441
 Shoyab, M., 888
 Shreffler, D. C., 83, 126, 250, 297, 306, 314, 331, 336, 339, 343, 351, 354, 359, 361, 368, 369, 371, 374, 377, 395, 395, 396, 418, 425, 426, 427, 440, 443, 449, 455, 469, 470, 474, 475, 477-487, 477, 486, 487, 489, 491, 492, 496, 497, 499, 501, 503, 504, 520, 527, 539, 544, 579, 587, 595, 611, 614, 623
 Siddoway, L. A., 387-396, 387
 Sidman, C. L., 140, 145, 156, 158, 159, 160, 162, 189, 191, 241, 243, 248, 250
 Siegel, L. M., 380, 386
 Siegler, R., 163, 164
 Sigal, N. H., 165-173, 165, 166, 167, 172, 173, 204, 214, 215, 645, 685, 716, 717, 718, 733, 821, 835
 Silver, J., 331, 339, 343, 344, 348, 349, 351, 352, 358, 359, 360, 361, 363, 365, 366, 368, 369-377, 370, 371, 372, 373, 377, 398, 401, 402, 403, 411, 414, 453, 455, 523, 527, 682, 686
 Silvers, W. K., 284
 Silverstein, A. M., 894, 902
 Silverstone, A. L., 8, 8, 63-72, 65, 67, 68, 72
 Silverton, E. W., 637, 645, 659
 Silvestre, D., 361, 556
 Siminovitich, L., 137, 409, 414, 415
 Simmonds, S. J., 284, 527, 561
 Simms, E. S., 636, 675, 724, 814, 835, 874, 888
 Simons, K., 335, 339
 Simonsen, M., 284, 520, 527, 561
 Simpson, E., 31, 44, 94, 103, 114, 118, 236, 293, 487, 518, 527, 536, 544, 556, 561, 595, 609, 622, 706, 717
 Sinclair, N. R., 315, 321
 Singer, P. A., 72, 164
 Singer, S., 410, 414, 634, 636
 Singh, B., 251-259
 Singh, U., 129-137, 134, 137
 Sinsheimer, R. L., 862
 Sirisinha, S., 285, 293, 719, 720, 722, 724
 Siskind, G. W., 170, 172, 755, 758, 763, 764, 770
 Sjöberg, O., 157, 225, 236, 252, 259
 Sjöquist, J., 148, 158
 Skehel, J. J., 395, 396
 Skidmore, B. J., 218, 226, 620
 Skinner, M. A., 559, 561
 Sklar, M. D., 72, 163, 164
 Slater, R. J., 689, 697
 Sly, W. S., 444, 455
 Small, M., 21
 Smith, C. B., 201, 215
 Smith, D. F., 341-342, 342
 Smith, E., 219, 225, 226, 529, 536
 Smith, G. P., 688, 688, 805, 815, 820, 836, 863-875, 870, 872, 874
 Smith, H. O., 860, 862

- Smith, M. J., 867, 868, 869, 871, 874
 Smith, N., 261, 273
 Smith, P., **261-273**
 Smith, P. G., 82
 Smith, W. I., 262, 263, 267, 273
 Smithies, O., 357, 361, 363, 368, 392, 396, 688, 688, 817, 836
 Smoler, D. F., 72
 Smyth, D. G., 677, 685
 Snary, D., 329, 333, 339, 361, **379-386**, 379, 380, 384, 385, 385, 386, 426, **443-455**, 443, 447, 454, 455
 Snegerova, A. E., 536
 Snell, G. D., 343, 348, 349, 407, 414, 474, 478, 487, 497, 504, 524, 527, 530, 536
 Sogn, J. A., 693, 694, 697
 Sohl, A., 214
 Solheim, B. G., 365, 368, 422, 426, 427
 Solliday, S. M., 145, 173, 183, 199, 570
 Solliday-Rich, S., 611, 624
 Sollinger, H. W., **429-441**, 438, 441
 Solomon, A., 215, 645, 667, 675, 686
 Solomon, E., 414, 453, 454
 Sondel, P. M., 427, **429-441**, 429, 430, 432, 433, 434, 435, 436, 439, 439, 440, 441
 Sopori, M. L., 429, 440, 441
 Sordat, B., 83
 Sorg, C., 268, 273
 Sorkin, E., 315, 321
 Sorvari, T., 624
 Soteriades-Vlachos, C., 317, 321
 Southern, E.M., 870, 874
 Spande, T., 637
 Spear, P. G., 149, 158, 166, 173, 773, 779, 894, 895, 902
 Speirs, R. S., 137
 Spiegelberg, H. L., 194, 200
 Spiro, R., 410, 414
 Spiva, D., 162
 Sprent, J., 114, 118, 127, 137, 273, 314, 321, 507, 510, 523, 527, **539-545**, 539, 540, 542, 543, 544, 544, 545, **559-561**, 560, 582, 588, 609, 618, 621, 624
 Springer, T., **323-329**, 323, 326, 327, 328, 329, 339, 374, 376, 386, **387-396**, 387, 388, 389, 391, 392, 394, 396, 401, 403
 Staats, J., 519, 527, 809, 810, 815
 Stadler, J. K., 782, 791
 Stafford, D. W., 878, 888
 Staines, N. A., 127, 496, 609
 Stallings, V., 408, 409, 411, 412, 414, 522, 527
 Stankus, R. P., 732, 734
 Stanley, P., 410, 414
 Stanton, T. H., 363, 368
 Stark, O., 559, 561
 Stark, R., 52, 61
 Starzinski-Powitz, A., 510, 527, 536, 545, 556
 Staskawicz, M. O., 91
 Staub-Nielsen, L., 427, 440
 Stavnezer, E., 862, 888
 Stavnezer, J., 855, 862, 877, 888
 Steck, T. L., 57, 59, 60, 61, 331, 333, 339
 Steel, C. M., 454
 Stefani, S., 14, 21
 Steigemann, W., 636, 645
 Stein, G., 269, 273
 Stein, J., 273
 Steinberg, A. G., 645, 678, 686
 Steinberg, C., 779, 836, 853, 862, 882, 888
 Steinberg, I.-Z., **667-675**, 674, 675
 Steinberg, M., 158
 Steinberger, H., 674
 Steiner, L. A., 763, 770, 778
 Stember, R. H., 463
 Stern, C., 185, 191
 Stern, P. L., 53, 61
 Sterzl, J., 245, 250, 894, 902
 Stevens, S. M., 778
 Stevenson, G. T., 772, 778
 Stiffel, C., 758
 Stiller, C. R., 321
 Stimpfling, J. H., 297, 306, 343, 361, 439, 463, 466, 469, 474, 475, 487, 497, 503, 504, 511, 517, 536, 590, 595
 Stitt, D., 455
 Stocker, B., 407, 414
 Stocker, J. W., **237-243**, 237, 238, 241, 243, 243, 250, 261, 264, 273
 Stockert, E., 162, 250, 414, 814
 Stolen, J. S., 261, 273
 Stolenheim, G., 158
 Stone, H. A., 8
 Stoner, G., **73-83**, 82, 83
 Storb, R., 83
 Storb, U., 855, 862, 883, 888
 Storrie, B., 6, 7, 8
 Stout, R. D., 34, 38, 39, 45, 307, 314, 317, 321, 499, 500, 502, 504
 Straus, N. A., 872, 874
 Strausbauch, P. H., 636
 Strayer, D. S., 140, 145, 160, 162, 189, 191, 701, 707, 710, 718
 Streisinger, G., 803
 Strober, S., 15, 21, 168, 173, 489
 Strober, W., 103, 427, 454, 455
 Strominger, J. L., **323-329**, 326, 327, 328, 329, 333, 339, 342, 349, 361, 368, 377, 384, 385, 386, **387-396**, 387, 388, 389, 391, 392, 393, 394, 396, 403, 455
 Strosberg, A. D., 645, 649, 650, 655, 656, 658, 659, 678, 682, 686, 693, 695, 697, 698, 810, 815, 847, 853
 Stuart, F. P., 284, 724
 Studier, F. W., 387, 396
 Stutman, O., 91, 134, 137
 Suci-Foca, N., 418, 426, 427
 Sugita, A., 803
 Sullivan, J. L., 82
 Sultzer, B. M., 151, 158, 225
 Summers, D. F., 83, 413
 Sutcliffe, S., 73, 83
 Sutherland, D. J. A., 130, 137
 Svasti, J., 797, 801, 802, 803, 885, 888
 Svejgaard, A., 385, 426, 427, 440, 441, 453, 454
 Svedjelund, A., 82, 225
 Svedmyr, E., 430, 441, 527, 536
 Swain, S., 263, 273, **597-609**, 598, 599, 605, 606, 609
 Swan, D., 734, 833, 836, 852, **855-862**, 862, 888
 Swank, R. T., 345, 347, 349
 Sweet, G. H., 699, 707
 Sweet, V. C., 74, 82
 Szenberg, A., 119, 126, 182, 252, 259, 266, 268, 273, 540, 544, 710, 717, 791
- T**
- Tacey, S. E., 717
 Tacier-Eugster, H., 182
 Tack, B. F., 685, 690, 697
 Tada, T., 23, 30, 31, 33, 36, 45, 106, 111, **119-127**, 119, 121, 122, 124, 127, 275, 284, 369, 377, 469, 472, 473, 475, 478, 479, 480, 482, 485, 487, 489, 496, 499, 502, 504, 611, 618, 619, 624, 625, 626
 Tadakuma, T., 31, 91, 190, 487
 Tagaya, I., 529, 530, 535, 536
 Takagi, N., 183
 Takahashi, M., 175, 183
 Takahashi, T., 31, 408, 413
 Takasugi, M., 425, 427
 Takemori, T., 31, 111, 119, 121, 127, 275, 284, 475
 Talmage, D. W., 438, 441, 688, 723, 724, 821, 835
 Tanford, C., 333, 338, 674, 897, 901
 Tanigaki, N., 329, 339, **341-342**, 342, 349, 361, 368
 Taniguchi, M., 31, 33, 36, 45, 111, **119-127**, 119, 120, 121, 123, 124, 127, 369, 377, 475, 487, 489, 496, 502, 504, 611, 618, 619, 624, 625, 626
 Taniuchi, H., 305
 Tannenber, W. J. K., 755, 758
 Tans, E. M., 215
 Tappimer, G., 674
 Tarikas, H., 661, 666
 Taussig, M. J., 23, 31, 119, 125, 126, 127, 257, 259, 275, 284, 295, 304, 306, 369, 377, 451, 455, 469, 470, 475, 489, 492, 496, 502, 504, 585, 587, 598, 608, 609, 618, 619, 624, 625, 626
 Taylor, B. A., 293, 842, 843, 845
 Taylor, R. B., 98, 101, 102, 103, 158, 159, 162, 209, 214, 555, 556
 Teherani, J., 678, 686
 Teorey, T., 874, 874
 Terasaki, P. I., 343, 449
 Terhorst, C., **323-329**, 325, 329, 336, 339, 341, 342, 344, 349, 359, 360, 361, 367, 368, 371, 372, 377, 386, **387-396**, 387, 388, 392, 393, 395, 396, 443, 453, 455
 ter Meulen, V., 531, 536
 Termijtelen, A., **417-427**, 422, 426, 427, 440, 455
 Ternynck, T., 679, 685
 Terry, W. D., 145, 191, 200, 645, 686, 688, 835, 845
 Thiele, H.-G., 52, 61
 Thierfelder, S., 427
 Thomas, C. A., Jr., 878, 888
 Thomas, D. W., **571-578**, 576, 577, 578
 Thomas, E. D., 81, 83, 426
 Thomas, K. A., 645
 Thomsen, M., 385, 420, 426, 427, 430, 440, 441, 453, 454
 Thomssen, R., **529-537**, 529, 531, 536
 Thorbecke, G. J., 273
 Thorsby, E., 365, 368, 418, 422, 426, 427, 430, 440, 441
 Thrall, C., 273
 Thunberg, A. L., 659, 692, 697, 851, 852, 853
 Till, J. E., 137, 415
 Tillack, T. W., 61
 Tochinnai, S., 771, 779
 Todd, C. W., 685, 690, 696, 697, 803
 Toivanen, A., 624
 Toivanen, P., 611, 614, 624
 Tokuhisa, T., 127
 Tomasi, T. B., 201, 207, 214, 215
 Tomasz, A., 709, 718
 Tomita, M., 59, 60, 61
 Tonegawa, S., 725, 734, 778, 779, 821, 833, 836, 838, 839, 846, 847, 852, 853, 855, 862, 863, 864, 865, 866, 867, 868, 870, 875, **877-889**, 877, 878, 882, 883, 884, 885, 886, 887, 888
 Tonnelle, C., 339
 Torrigiani, G., 102, 102, 103, 203, 215
 Tosi, R. M., **677-686**, 679, 685, 686
 Tournefier, A., 262, 270, 271
 Tourville, D. R., 201, 215
 Toy, S. T., 73, 83
 Tracey, D., 518

- Trainin, N., 133, 137
 Travis, M., 21
 Trefts, P. E., 597-609, 599, 605, 606, 609, 751, 758
 Trenkner, E., 248, 250, 843, 846
 Trentin, J. J., 129, 136, 137, 518
 Trinchieri, G., 369, 377, 429, 441, 510, 556, 587
 Triplett, R. F., 902
 Tripp, M., 454
 Trishmann, T. M., 654, 659
 Trotter, J., 631, 637
 Trowbridge, I. S., 11, 21, 59, 61, 407-415, 407, 408, 409, 409, 410, 412, 414, 523, 527
 Trucco, M., 385, 454
 Tse, H. Y.-S., 597-609, 598, 604, 605, 609
 Tseng, J., 201-215, 213
 Tsu, T. T., 44
 Tumilowicz, J., 447, 455
 Tung, A. S., 293, 645, 658, 699, 700, 703, 706, 707, 733, 834, 847-853, 848, 850, 851, 852, 853
 Turk, J. L., 106, 111
 Turner, M. J., 324, 329, 339
 Turner, R. S., 771, 779
 Twarog, F. J., 103
 Twigg, M. B., 474
 Tyan, M. L., 147, 158, 249, 250
- U**
- Ueda, Y. A., 530, 535, 536
 Uhr, J. W., 61, 145, 162, 176, 182, 183, 185-191, 185, 190, 191, 198, 199, 200, 240, 241, 243, 261, 266, 270, 271, 273, 284, 307, 314, 339, 349, 362, 363-368, 365, 368, 377, 414, 455
 Unanue, E. R., 120, 126, 140, 145, 156, 158, 159, 160, 162, 189, 191, 241, 243, 248, 249, 249, 250, 563, 569, 570, 618, 619, 623
 Underdown, B. J., 637
 Unkeless, J. C., 317, 318, 321
- V**
- Vada, M. A., 31, 97, 103, 118, 455, 475, 492, 544, 561, 569, 578, 579-588, 579, 580, 581, 582, 583, 584, 585, 587, 588, 623
 Vaerman, J. P., 201, 214
 Vainio, O., 624
 Valentine, E. A., 426, 430, 440, 441
 Van Acker, A. M., 852
 Vanaman, T. C., 636
 van Boxel, J., 143, 145, 175, 183, 185, 191, 193, 200, 272, 313, 314
 van den Tweel, J. G., 419, 427
 van der Hoven, A., 273
 Vanderkooi, G., 392, 395
 van der Loo, W., 33-45, 679, 682, 685, 686, 697, 815, 853
 Van de Vorde, A., 862
 van Heyningen, V., 414, 454
 van Hoegaerden, M., 650, 655, 659
 van Hooff, J. P., 427, 454
 van Leeuwen, A., 396, 417-427, 418, 422, 425, 426, 426, 427, 443, 444, 454, 455
 Vann, D., 31, 626
 van Rood, J. J., 343, 387, 392, 396, 417-427, 417, 418, 422, 423, 425, 426, 427, 429, 430, 440, 450, 454, 455
 van Someren, H., 443, 455
 van Vreeswijk, W., 427
 Varga, J. M., 636, 644, 658, 724, 779, 834, 835, 853
 Vas, M. R., 440
 Vas, S. I., 726, 734
 Vassalli, P., 139, 145, 185, 186, 190, 214, 724, 852, 862, 888
 Vaz, N. M., 466, 475
 Venkatchalam, C. M., 631, 637
 Vesterberg, O., 387, 396
 Viale, G., 182
 Vicari, G., 286, 294
 Villarejo, M., 409, 415
 Virella, G., 266, 273
 Vitetta, E. S., 59, 61, 143, 145, 160, 162, 176, 182, 183, 185-191, 185, 186, 187, 188, 190, 191, 193, 194, 198, 199, 200, 240, 241, 243, 261, 266, 270, 271, 273, 275, 284, 331, 338, 339, 344, 349, 358, 359, 360, 362, 363-368, 363, 364, 365, 366, 368, 369, 371, 372, 377, 411, 414, 427, 453, 455, 586, 588
 Vives, J., 544
 Vogt, W., 157
 Volkens, W. S., 426
 Volpe, E. P., 771, 778
 von Boehmer, H., 15, 21, 114, 118, 126, 127, 137, 145, 157, 162, 236, 507, 510, 523, 527, 539-545, 539, 540, 541, 542, 543, 544, 545, 547, 548, 553, 557, 582, 588, 598, 607, 609, 613, 615, 617, 618, 621, 624
 Von Eschen, K. B., 315-321
 von Fellenberg, R., 271
 von Pirquet, C., 73, 83
 Vos, G. H., 590, 595
 Vossen, J. M., 194, 200
 Vrana, M., 661-666, 663, 665, 666, 744, 748
 Vriesendorp, H. M., 470
- W**
- Wabl, M. R., 763, 770, 771-779, 773, 778
 Waddington, C. H., 769, 770
 Wagner, H., 113, 118, 432, 441, 510, 527, 531, 536, 545, 556
 Wagner, R. M., 609
 Waksal, H., 511-518
 Waksal, S. D., 45, 504
 Waksman, B. H., 202, 211, 215
 Waldmann, H., 114, 118, 543, 545, 598, 608, 609, 613, 615, 617, 618, 624
 Waldmann, T. A., 93, 103
 Waldron, J. A., 571, 578
 Walker, J. G., 758, 770
 Walker, K. Z., 440
 Walker, W. A., 202, 215
 Walker, W. S., 318, 321
 Wallis, E., 21
 Waltenbaugh, C., 472, 474, 475
 Walters, C. S., 193, 198, 200, 763, 770
 Walzer, P. D., 144, 182
 Wang, A. C., 783, 791
 Wang, A. L., 158, 173, 706, 734, 779, 852, 902
 Wang, J. L., 361, 368, 902
 Wang, K., 380, 382, 384, 386, 387, 389, 396
 Wank, R., 427, 440
 Ward, S. M., 697
 Warner, N. L., 33-45, 44, 47, 50, 142, 144, 190, 236, 243, 250, 261, 262, 268, 272, 273, 314, 321, 587, 791
 Warner, T. F. C. S., 881, 888
 Warr, G. W., 44, 190, 243, 261-273, 261, 262, 263, 264, 265, 266, 270, 271, 272, 273, 777, 779
 Warren, L., 388, 396
 Wartiovaara, J., 137
 Wasserman, R. W., 834, 848, 852, 853
 Watanabe, T., 127, 227-236
 Waterfield, E., 226
 Waterfield, J. D., 225, 226
 Waterfield, M. D., 329, 395, 396, 690, 697, 852
 Watkins, W., 410, 415
 Watson, J., 147, 151, 158, 218, 226, 270, 271, 273
 Waxdal, M. J., 265, 273, 398, 401, 645
 Webb, S. R., 141, 145
 Weber, K., 353, 362, 387, 396
 Wecker, E., 115, 117, 118, 124, 126, 127, 625, 626, 750, 758
 Wegmann, T. G., 622
 Weiden, P. L., 250
 Weigert, M., 172, 285, 293, 294, 642, 643, 644, 645, 658, 659, 677, 686, 706, 725, 726, 733, 734, 735, 741, 743, 744, 746, 748, 756, 757, 758, 802, 805, 807, 810, 814, 815, 821, 824, 826, 827, 834, 835, 836, 837-846, 837, 838, 839, 840, 841, 845, 846, 847, 852, 855, 862, 879, 881, 885, 888, 889
 Weigle, W. O., 61, 93, 101, 103, 226
 Weimann, B. J., 888
 Weinbaum, F. I., 261, 273
 Weiner, A. M., 388, 396
 Weiner, F., 787, 788, 790
 Weiss, M. C., 785, 791
 Weiss, N., 272, 771, 772, 778, 779
 Weissman, I. L., 9-21, 9, 11, 12, 14, 15, 16, 20, 21, 23, 29, 31, 61, 414, 527
 Weitzman, S., 410, 415, 781, 785, 791
 Wekerle, H., 527, 529-537, 529, 530, 534, 536
 Wells, J. V., 285, 294
 Wells, R. D., 856, 862
 Welstead, J. L., 758
 Weltman, J. K., 325, 329, 392, 396
 Werblin, T. P., 622
 Wernet, D., 590, 591, 592, 595
 Wernet, P., 102, 396, 422, 427
 Westerveld, A., 455
 Westervelt, F. B., 199
 Westholm, F. A., 636
 Wetmur, J. G., 872, 875
 Wheeler, T. B., 790
 Wheelock, E. F., 73, 76, 82, 83
 White, A. I., 636
 White, B. J., 164
 White, D. W., 595
 White, E., 243
 Whitelaw, A. M., 31, 103, 118, 454, 475, 544, 561, 569, 578, 587, 588, 623
 Whitfield, C., 874, 888
 Whitsett, C., 426
 Whitten, H. D., 272
 Whittingham, S., 103
 Wide, L., 339
 Widmer, M. B., 345, 349, 429, 441
 Wiemann, B., 68, 163-164
 Wigzell, H. N., 29, 30, 31, 82, 116, 117, 193, 198, 200, 225, 261, 271, 275-284, 275, 276, 277, 278, 280, 281, 282, 283, 284, 300, 306, 339, 361, 368, 414, 508, 510, 517, 518, 527, 543, 544, 559, 561, 585, 586, 587, 597, 608, 612, 618, 619, 624, 714, 717, 812, 814, 883, 889
 Wilborn, F. L., 699, 707
 Wilchek, M., 636
 Wilde, C. D., 793-803
 Wildermann, G., 674
 Wilkinson, J. M., 655, 659, 686, 690, 691, 697, 698, 748, 847, 853
 Wilkes, C. F., 214
 Willcox, H. N. A., 129-137, 193-200, 195, 199, 749, 756, 758, 763, 770
 Willems, F. T. C., 73, 83
 Williams, A. F., 51-61, 51, 52, 53, 55, 61, 187, 202, 215, 264, 272, 413, 414
 Williams, C. A., 47, 50
 Williams, H., 127

- Williams, R.C., Jr., 272, 741, 848, 853
 Williamson, A.R., 167, 173, 199, 250, 726, 727, 733, 734, 735, 741, 749, 755, 756, 757, 758, 759, 763, 770, 773, 777, 779, 888
 Williamson, D.H., 536
 Williston, C.S., 631, 637
 Wilson, A.B., 314
 Wilson, A.D., 444, 455
 Wilson, D.B., 15, 21, 29, 30, 31, 114, 117, 276, 284, 452, 455, 520, 527, 542, 544, 559-561, 559, 560, 561, 569, 569, 577, 578, 598, 608, 608, 613, 615, 622
 Wilson, G.A., 878, 889
 Wilson, J.H., 835
 Wilson, J.W., 250
 Wilson, S.K., 791
 Winchester, R.J., 47, 50, 144, 182, 190, 193, 199, 200, 272, 387, 395, 396, 427, 452, 455, 852
 Winfield, J.B., 693, 697, 698
 Winzler, R. J., 59, 60, 61
 Wissler, F. C., 314
 Witte, O. N., 15, 16, 18, 20, 21
 Wittig, B., 82
 Wofsy, L., 623
 Wolcott, M. J., 368
 Wolf, B., 144, 145
 Wolf, M. N., 137
 Wolfner, M., 790, 803
 Wong, L. T. L., 634, 637
 Wood, D. D., 570
 Wood, M. K., 645
 Wood, S. L. C., 862
 Wood, W. B., 835
 Woodland, R., 173
 Woodruff, J. F., 73, 83
 Woodruff, J. J., 73, 83
 Woods, F. R., 455
 Woody, J., 113-118, 114, 116, 117
 Woolnough, J., 440
 Wortis, H. H., 132, 137
 Wright, B. E. G., 199, 250, 733
 Wright, C., 627-637
 Wu, A., 407, 415
 Wu, C.-Y., 86, 91
 Wu, T. T., 171, 173, 627, 636, 637, 641, 642, 645, 647, 648, 649, 651, 658, 659, 661, 662, 665, 666, 687, 688, 731, 734, 743, 748, 807, 815, 818, 828, 836, 837, 838, 839, 846, 851, 853
 Wunderlich, J. R., 72
- Y**
- Yachnin, S., 590, 595
 Yagi, Y., 183, 342
 Yahara, I., 270, 271, 273
 Yamamura, Y., 127
 Yamane, K., 535, 536
 Yang, R. C. A., 856, 862
 Yardley, J. H., 214
 Yarmush, M. L., 697
 Yeger, H., 733
 Yen, S.-H., 394, 396
 Yin, E., 758
 Yocum, D., 261, 273
 Yocum, R. R., 329
 Yoffey, J. M., 214
 Yonkovich, S. J., 645, 734, 748, 815, 846, 862, 889
 Yoshida, T. H., 879, 881, 889
 Yoshida, T. O., 275, 284, 315, 321
 Young, D., 385, 453, 454
 Young, F. E., 878, 889
 Young, G. O., 688, 696, 845
 Young, H., 440, 527, 544
 Young, N. M., 664, 665, 722, 724, 725, 734, 845
 Young-Cooper, G. O., 677-686, 686, 697
 Yount, W. J., 791
 Ysern, X., 639-645
 Yu, A., 411, 415
 Yuan, D., 185-191, 185
 Yunis, E. J., 137, 426
 Yussa, T., 536
 Yutoku, M., 38, 45
- Z**
- Zabin, I., 409, 415
 Zabriskie, J., 455
 Zajdel, S., 164
 Zakut, R., 627, 628
 Zaleski, M., 466, 470, 475, 561
 Zan-Bar, I., 103
 Zarling, J. M., 439, 441
 Zauderer, M., 749, 750, 752, 753, 755, 758
 Zeeuws, R., 693, 698
 Zehavi-Willner, T., 790
 Zembala, M., 106, 109, 111
 Zeylemaker, W. P., 440
 Zier, K. S., 430, 439, 440, 441
 Ziffer, J. A., 351-362
 Zigelbaum, S. D., 201, 215
 Zimmerman, A., 590, 595
 Zimmerman, S. C., 341, 342
 Zinkernagel, R. M., 26, 30, 31, 31, 82, 101, 102, 116, 118, 351, 362, 369, 377, 439, 441, 451, 453, 454, 505-510, 505, 506, 507, 508, 509, 510, 522, 523, 526, 526, 527, 529, 536, 537, 539, 541, 543, 544, 545, 547, 548, 553, 554, 555, 556, 557, 561, 568, 570, 571, 577, 578, 587, 597, 609, 613, 614, 620, 622, 624
 Zoalberg, O. B., 455
 Zoschke, D. C., 574, 578
 Zweerus, R., 427

Subject Index

A

- Abelson murine leukemia virus-transformed mouse lymphoma cells, induction of immunoglobulin synthesis in, 163-164
- Activation
 B cell, mechanism of, 217-225, 251-259
 lymphocyte, role of surface immunoglobulin in, 268-271
 T cell, macrophage-lymphocyte interactions in, 571-587
- Adherent cells, role of in B-cell triggering and in tolerance induction, 253-259
- Alloantigens, B cell
 genetic studies of, 422-426
 immunologic and chemical characterization of, 387-395
- Allogenic effect factor (AEF), analysis of Ia determinants on, 492-495
- Allogenic effect, negative, suppression of T-B collaboration between allogenic cells by, 600-608
- Allograft rejection, role of LD and CD antigens in, 437-438
- Allotypes, rabbit immunoglobulin, 677-695
- Allotype suppression, 35-37
- Altered-self hypothesis, to explain genetic restriction of
 cytotoxic T-cell responses, 505-509, 519-541, 547-556
 macrophage-lymphocyte interactions, 568-578, 582-584
 T-B collaborative interactions, 542-544, 611-622
- Amphibians, anuran, ontogenesis of the immune response in, 771-778
- Antibody. *See also* Immunoglobulin
 anti-allotype, enhancement of antibody-dependent cell-mediated cytotoxicity by, 308-311
 anti-Ia
 inhibition of in vitro primary antibody response by, 484-485
 regulation of clonal B-lymphocyte proliferation by, 245-249
 xenogenic, specificity and properties of, 446-448
 anti-idiotypic
 anti-staphylococcal nuclease idiotypes, 300-304
 enhancement of antibody-dependent cell mediated cytotoxicity by, 311-314
 raised against T cell receptors, 275-283
 reactivity of with helper T cells, 285-288, 714-717
 suppression of idiotype production by, 701-721
 anti-immunoglobulin
 activation of rabbit lymphocytes by, 268-269
 functional inactivation of immature B lymphocytes by, 139-141, 159-161
 inhibition of B-cell mitogen reactivity by, 153-156
 regulation of clonal B-lymphocyte proliferation by, 245-249
 anti-p-azophenylarsonate, idiotype composition of, 699-706, 848-851
 antiphosphorylcholine, idiotype composition of, 726-730
 clonal
 constancy of, 755-758
 variation in, 765-766
 conformational changes subsequent to antigen binding, 671-674
 diversity, generation of
 in anuran amphibians, 773-778
 following antigenic stimulation, 761-770
 via multiple germ-line genes, 647-658, 725-748, 773-778, 817-852, 863-871, 886-887
 nucleic acid hybridization studies of, 832-833, 855-887
 possible molecular mechanisms of, 833-834
 restriction-modification model of, 860-861
 via somatic mutations, 647-658, 761-770, 793-797, 817-861, 882-886
 domains, interactions between, 667-674
 elicited, amino acid sequences of, 647-658
 formation, in B-cell cultures stimulated by LPS, 752-755
 gene families, 817-834
 germ-line, 840-842
 heteroclitic, 735-740
 response
 in anuran amphibians, 772-773
 to $\alpha(1,3)$ dextran, genetic analysis of, 743-748
 genetic restriction of macrophage-lymphocyte interactions in, 563-569
 genetic restriction of T-B collaborative interactions in, 123-126, 542-544, 597-622
 IgA, by Peyer's patch lymphocytes, 201-213
 polyclonal, 217-225
 primary IgM, role of macrophage Ia determinants in, 484-486
 regulatory effects of T-cell subclasses on, 27-30, 89-91. *See also* T-B interactions
 role of soluble factors in the regulation of, 95, 113-126
 role of T-T interactions in the regulation of, 85-91, 113-116
 to streptococcal hyperimmunization, 689-696
 suppression of, 30-31, 93-102, 119-123, 471-473
 secretion, IgG, requirement for cellular proliferation preceding, 750-755
 synthesis, regulation of in myeloma cells, 781-790
- Antibody-combining site, three-dimensional structure of, 627-644
- Antibody-dependent, cell-mediated cytotoxicity, enhancement of by anti-allotype and anti-idiotypic sera, 307-314
- Antigen. *See also specific antigens such as* H-2; Ia; Thy-1; etc.
 cell surface, regulation of immune responses to, 589-594
 presentation, role of in B-cell triggering, 255-259
 role of in diversification of B-cell specificity repertoire, 167-172
 thymus-independent, as polyclonal B-cell activators, 217-225
 viral, association with H-2 determinants on virus-infected cells, 550-556
- Antigen-binding cells, generation of in the bursa of Fabricius, 141-142
- Antigen-binding site, three-dimensional structure of, 627-644
- Antigenic competition, between H-2 and Thy-1, 592-593
- Antigenic modulation, of surface immunoglobulin on B cells by anti-immunoglobulin, 159-160

B

B cell

- activation factors, 625
- activation, mechanism of, 217-225, 251-259
- adherent cell interaction with, role of in B-cell triggering and tolerance induction, 251-259
- alloantigens
 - chemical and immunologic characterization of, 387-395
 - genetic studies of, 422-426
- clonal proliferation of, regulation by anti-Ig or anti-Ia antibodies, 245-249
- clones, antibody produced by
 - constancy of, 755-758
 - variation in, 765-766
- differentiation
 - changes in class of immunoglobulin receptors during, 185-190, 197-198
 - in gut-associated lymphoid tissue, 211-213
 - induced by hormones and pharmacologic agents, 5-8, 133-134
 - in vitro models for the study of, 129-136
 - in ontogeny, 139-162, 165-172
 - surface markers of cells in, 33-44
- hapten-specific, enrichment and cloning of in vitro, 237-239
- immature
 - cytoplasmic IgM in, 135-136, 139, 161-162
 - functional inactivation by modulation with anti-Ig, 139-141
 - induction of tolerance in, 159-161, 168-170, 188-190
- memory
 - differentiation of, 36-39
 - immunoglobulin receptors on, 195-199
 - surface markers of, 34
- Peyer's patch, secretory IgA response by, 201-213
- primary and secondary, properties of, 168
- receptor
 - immunoglobulin classes of, 176-199, 240-241
 - modulation of following interaction with specific antigen, 239-240
 - role of in B-cell activation, 218-225
- specificity repertoire, diversification of during development, 165-172
- subpopulations, expression of Ia antigens on, 489-491
- surface immunoglobulin
 - during ontogeny, 149-150
 - phylogeny of, 266-268
- triggering. *See* B cell, activation mechanism of

- Bone marrow cells, terminal transferase in, 64-67
- Bone marrow graft rejection, F₁ antiparental, 511-517
- Bursa-equivalent, mammalian, 159
- Bursa of Fabricius, generation of antigen-binding cells in, 141-142
- Bursopietin, 5-8

C

- C-determinant (CD) antigens
 - CML tolerance induction resulting from neonatal injection of, 436-437
 - role of in allograft rejection in vivo, 437-438
 - role of in the generation of cytotoxic T lymphocytes in vitro, 432-433
- Cell interactions. *See specific type of interaction such as* Macrophage-lymphocyte; T-B; T-T; etc.
- Cell-mediated lympholysis, F₁ antiparental, 511-517
- Cells. *See specific type of cell such as* B cell; Cytotoxic T cell; Helper T cell; etc.
- Cellular interaction (CI) structures
 - possible role of in lymphocyte-macrophage interactions, 568-578, 582-584
 - possible role of in T-B collaborative interactions, 611-622
- Clonal selection theory, 2-3, 892-900
- Cloning
 - of hapten-specific B lymphocytes in vitro, 237-239
 - of normal lymphocytes in vitro, 227-236
- Concanavalin A, induction of cytotoxic T cells by, 519-520
- Contact sensitizers, mechanisms of tolerance to, 105-111
- Cyclic AMP, role of in T- and B-cell differentiation, 5-8, 133-134
- Cytotoxic T-cell response
 - H-2 restriction of, 505-509, 519-541, 547-556
 - to minor histocompatibility antigens, 519-526
 - suppression of by cells generated in mixed lymphocyte cultures, 433-436
 - to syngenic tumor cells, 547-550
 - to virus-coated cells, 552-556
 - to virus-infected cells, 505-509, 529-535
- Cytotoxic T cells
 - detection of by a virus plaque assay, 78-80
 - generation of
 - role of LD and CD antigens in, 432-433
 - role of T-cell subclasses in, 24-30
 - induction of by concanavalin A, 519-520
 - Ly phenotype of, 24-30

- virus-immune, specificity of, 505-509, 529-535

D

- Delayed-type hypersensitivity
 - genetic restriction of transfer of, 580-587
 - mediation of by Ly-1 T cells, 584
- $\alpha(1,3)$ Dextran, genetic analysis of antibody response to, 743-748
- Differentiation. *See* B cell, differentiation; Lymphocyte, differentiation; T cell, differentiation
- Dimethyl sulfoxide (DMSO), use of to induce immunoglobulin synthesis in lymphoma cells, 163-164
- DNA polymerases in lymphoid cells, 63-71
- Dual recognition hypothesis, to explain genetic restriction of, cytotoxic T-cell responses, 505-509, 519-526, 547-561
 - macrophage-lymphocyte interactions, 568-578, 582-584
 - T-B collaborative interactions, 613-622

E

- Enhancing T-cell factor, 123-125

F

- Factors
 - B-cell activation, 625
 - carrier-specific helper, role of in B-cell triggering, 256-259
 - enhancing T-cell, 123-125
 - genetically related (GRF), 113-116
 - soluble, role of
 - in the regulation of antibody responses, 95, 113-126
 - in suppression of contact sensitization, 109-111
 - suppressive T-cell, 119-123
- Fc receptor. *See* Receptor, Fc
- FV antibody fragments
 - denaturation and renaturation of, 669-671
 - preparation of, 667-668

G

- Generation of antibody diversity. *See* Antibody diversity, generation of
- Genetically related factor (GRF), 113-116
- Genetic restriction
 - of cytotoxic T-cell responses, 505-509, 519-541, 547-556
 - of macrophage-lymphocyte interactions, 114, 563-578, 582-584
 - of T-B collaborative interactions, 123-126, 542-544, 597-622
 - of transfer of delayed-type hypersensitivity, 580-587
- Germ-line theory of antibody diversity, 647-658, 725-748,

- Germ-line theory (*continued*)
773-778, 817-852, 863-871, 886-887
- Goldfish, surface immunoglobulins on lymphocytes of, 261-264
- GPLA B and S antigens, molecular structure of, 398-399
- Graft rejection
bone marrow F₁ antiparental, 511-517
role of LD and CD antigens in, 437-438
- H**
- H-2 antigens. *See also* Histocompatibility antigens, major association of with viral determinants on virus-infected cells, 550-556
molecular structure of, 343-374
possible genetic mechanisms in the evolution of, 371-374
regulation of antibody response to, 590-592
restriction of cytotoxic T-cell response by, 505-509, 519-541, 547-556
structural differences between mutant forms of, 343-348
- H-2* complex
genetic restriction of macrophage-lymphocyte interactions controlled by, 563-578, 582-584
genetic restriction of T-B collaborative interactions controlled by, 123-126, 542-544, 597-622
genetic restriction of transfer of delayed-type hypersensitivity controlled by, 580-587
I-A subregion of, enhancing T-cell factor determined by, 123-125
I-E subregion of, definition of, 478-482
I-J subregion of
control of macrophage function in primary *in vitro* antibody response by, 484-485
definition of, 497-499
mapping of *Ia* determinants on allotype suppressor T cells to, 497-499
mapping of *Ia* determinants on Con-A-responsive T cells to, 482-483
suppressive T-cell factor determined by, 121-123
- H-2 gene products, as self markers for T-cell surveillance, 509
- H-2K and H-2D antigens, comparison of molecular structures of, 343-345, 354-360, 370-374
- Heavy-chain genes
murine, 842-843
rabbit, 690-691
- Helper mechanisms, in the immune response to cell-surface antigens, 589-594
- Helper T cells. *See also* T-B interactions, helper cell interactions in the induction of, 113-116
collaborative responses with allogenic B cells, 542-544
expression of I-region determinants on, 500-501
Ly phenotype of, 23-29, 34
reaction of anti-idiotypic serum with, 285-288, 714-717
role of in antibody responses to alloantigens, 590-594
specificity of for class and allotype commitment of B cells, 34
surface markers on, 23-29, 34
- Hematopoietic stem cells, embryonic origin of, 9-11
- Hemopoietic-histocompatibility (Hh) genes, 511-517
- Hermaphrocyte, 85-91
- Histocompatibility antigens. *See also* GPLA B and S antigens; H-2 antigens; HL-A antigens
major
amino acid sequences of, 405
restriction of cytotoxic T-cell responses by, 505-509, 519-541, 547-556
minor, cytotoxic T-cell response to, 519-526
HL-A antigens, structure of, 323-336, 341-342
HL-A complex, genetics of, 417-419
HL-A D antigens, detection of, 429-432
HL-A D locus, genetic analysis of, 419-426
Homozygous typing cell (HTC) test, 429-430
Hybrid cells. *See* Somatic cell hybrids
Hypervariable regions of antibody molecules, 647-649, 654-655, 818-840, 847-852
- I**
- Ia* antigens
amino acid sequences of, 406
association with specific immune response genes, 400, 469
on B-cell subpopulations, 489-491
on concanavalin-A responsive T cells, 482-483
on helper T cells, 500-501
human, serologic characterization of, 445-448. *See also* HL-A D antigens
on macrophages, role of in primary antibody responses *in vitro*, 484-485
molecular structure of, 336-337, 374-401, 406
possible functions of, 451-453, 491, 501-503
possible role of in mediating IgM to IgG switch, 491
presence of determinants on suppressive and enhancing T-cell factors, 119-126
somatic cell genetics of, 448-451
on suppressor T cells, 96-97, 114-115, 497-501
on T-cell subpopulations, 482-483, 492, 497-501
in wild mouse populations, 457-463
- Ia.22* specificity, identification and use of to define *I-E* subregion of *H-2*, 478-482
I-A subregion of *H-2* complex. *See H-2* complex, *I-A* subregion
I_B peptide marker, 805-814
- Idiotypic
anti-*p*-azophenylarsonate, 699-706
antiphosphorylcholine, 709-733
antistaphylococcal nuclease, 300-304
autologous, antibody response to, 712-713, 719-724
-specific T cells, 704-706, 713-714, 721-722
suppression of production of by anti-idiotypic antibody, 701-721
T15, 709-724
T cell, genetic analysis of, 278-280, 286-287
use of as genetic markers, 693-694
- Idiotypic receptors, T cell antibodies to, 275-283
biochemical properties of, 276-278
use of to induce specific tolerance, 280-282
- I-E* subregion of *H-2* complex. *See H-2* complex, *I-E* subregion
- IgA, secretory, production of by Peyer's patch lymphocytes, 201-213
- IgD
allotypes in mice, 39-43
on memory B cells, 195-197
surface
antigen-binding specificity of, 241
on B cells during differentiation, 142-143, 185-190
on lymphoid cells simultaneously bearing IgM, 176-177, 240-241
- IgG
binding of subclasses of to lymphoid cells, 317-319
production of in B-cell cultures stimulated with LPS, 752-755
requirement for cellular proliferation preceding production of, 750-755
synthesis of by lymphocytes simultaneously synthesizing IgM, 177-182
- IgM
allotypes in mice, 39-43
cytoplasmic, in immature B cells, 135-136, 139, 161-162
surface
on B cells during differentiation, 149-150, 159-162, 185-190
on memory B cells, 195-197
modulation of on immature B cells, 159-162
synthesis of by Abelson murine leukemia virus-transformed lymphoma cells, 163-164

- IgM (continued)**
 synthesis of by lymphocytes simultaneously synthesizing other classes of immunoglobulin, 176-182
 IgM to IgG switch, possible role of Ia antigens in controlling, 491
 I-J determinants, cellular distribution of, 499-500
 I-J subregion of *H-2* complex. *See H-2* complex, I-J subregion
 Immune response gene product, possible expression of in macrophages, 578, 584-585
 Immune response genes
 association with specific Ia antigens, 400, 469
 complementation between, 465-471
 control of antibody responses to synthetic polypeptides by, 465-471
 control of immune response to staphylococcal nuclease by, 295-305
 role of in antibody response to α (1, 3)dextran, 747
 in wild-mouse populations, 457-463
 Immune suppressor genes, 471-473
 Immunoglobulin. *See also* Antibody; IgA; IgD; IgG; IgM
 allotypes, rabbit, 677-695
 amino acid sequences of, 647-665, 817-834, 847-852
 classes
 changes in on the surface of B cells during differentiation, 185-190, 197-198
 multiple, synthesis of by single lymphocytes, 175-182
 class heterogeneity, generation of, 142-143
 domains, interactions between, 667-674
 expression, regulation of in myeloma cells, 781-790
 fold, 639
 Fv fragments, 667-671
 heavy-chain
 framework, 655-656, 818-834
 hypervariable regions, 654-655, 818-834
 heavy-chain genes
 murine, 842-843
 rabbit, 690-691
 light-chain
 framework, 649-652, 818-834, 848-852
 hypervariable regions, 647-649, 818-840, 847-852
 light-chain genes, rabbit, 692-694
 surface
 on lymphocytes of anuran amphibians, 772
 phylogeny of, 261-271
 role of in lymphocyte activation, 268-271
 on T cells, 261-270
 synthesis
 during B-cell ontogeny, 148-150
 induction of in Abelson murine leukemia virus-transformed lymphoma cells, 163-164
 three-dimensional structure of, 627-644
 from T-lymphoma cells, 264-266
 V and C genes, joining of during ontogeny, 877-882. *See also* V-C integration
 V_H genes, 687-691, 735-740, 819-845
 V_K subgroups, associated with identical hypervariable regions, 847-852
 V_L genes, murine, 837-841, 857-858
 V_L genes, 805-814, 819-845
 V_L region, I_B peptide marker in, 805-814
 V-region subgroups, 818-834
 Immunoregulation, possible role of Fc receptors in, 315-317
 Immunosuppression, latent viral infection of lymphocytes and, 81
 I-region gene products, role of in regulating antibody responses, 119-126
 I-region of *H-2* complex, evidence for subdivision of, 477-486
 I-region loci, expression of in lymphocyte subpopulations, 497-503
- K**
- Kappa immunoglobulin antigen, on T and B lymphocytes, 47-50
- L**
- L-determinant (LD) antigens
 detection of, 429-432
 role of in allograft rejection in vivo, 437-438
 role of in the generation of cytotoxic T lymphocytes in vitro, 432-433
 Light-chain genes, rabbit, 692-694
 Lipopolysaccharide (LPS)
 development of B-cell reactivity to during ontogeny, 150-156
 induction of immunoglobulin synthesis by, 178-182, 187-188, 752-755
 use of to stimulate growth of B-cell clones in vitro, 233-236
 Ly-1 cells
 functional properties of, 23-31, 114-117
 mediation of delayed-type hypersensitivity by, 584
 Ly-1, 2, 3 cells, 25-31, 89-91, 114-117
 Ly-2, 3 cells
 immunosuppressive activity of, 24-31, 96-97, 114-117
 killer function of, 24-31, 114-117
 Ly-3 antigens, molecular nature of, 812-814
 Ly-3 locus, genetic linkage of to locus determining I_B peptide marker, 809-814
 Lymphocyte-macrophage interactions, genetic restriction of, 563-578, 582-584
- Lymphocytes**
 B. *See* B cell
 clones, growth of in vitro, 227-236
 differentiation
 role of major histocompatibility complex in, 611-622
 sites of, 130-131
 Fc-receptor-bearing, functional characterization of, 307-314. *See also* Receptor, Fc
 mitogen-reactive and MLC-reactive, generation of in organ cultures of embryonic thymus, 134-135
 Peyer's patch, secretory IgA response by, 203-215
 single, synthesis of multiple immunoglobulin classes by, 175-182
 subpopulations
 I-region determinants on, 497-503
 ontogeny of in anuran amphibians, 771-778
 phylogeny of, 261
 surface immunoglobulins, phylogeny of, 261-271
 T. *See* Cytotoxic T cells; Helper T cells; Suppressor T cells; T cells
 thymic
 maturational lineages and subpopulations of, 11-15
 terminal transferase in, 64
- M**
- Macrophage-lymphocyte interactions, genetic restriction of in antibody responses in vitro, 114, 563-569
 in delayed-type hypersensitivity, 582-584
 in T-lymphocyte proliferative responses, 571-578
 Macrophages. *See also* Adherent cells
 heat-killed, use of to block T-T interactions, 87-91
 possible expression of immune response gene product in, 578, 584-585
 role of in F₁ antiparental graft rejection and cell-mediated lympholysis, 513-514
 role of in helper-cell induction, 113-116
 role of Ia determinants on, in primary antibody responses in vitro, 484-485
 Major histocompatibility complex (MHC). *See H-2* complex; *HL-A* complex
 2-Mercaptoethanol, use of to support growth of lymphocyte clones in vitro, 228-229
 β_2 -Microglobulin
 amino acid sequence of, 357
 association of with blastocyst and sperm surface molecules, 337-338
 serum levels of following streptococcal immunization, 695
 as a subunit of *H-2* and *TL* antigens, 363-367

- β_2 -Microglobulin (*continued*)
 as a subunit of HL-A antigen, 324-336
- Mitogen. *See also* Concanavalin A; Lipopolysaccharide
 reactivities of B cells, development of during ontogeny, 150-156
 use of to stimulate growth of lymphocyte clones in vitro, 228-236
- Modified-self, role of T-cell subclasses in immune response to, 26-30
- MOPC-315, hapten-binding site of, 627-636
- Myeloma cells
 regulation of immunoglobulin expression in, 781-802
 somatic cell hybrids of, 781-802
 spontaneous mutations in, 793-797
- Myeloma proteins
 binding of different IgG subclasses of to lymphoid cells, 317-319
 hapten-binding, 826-830
 idiotypic similarity to induced antibodies of the same specificity, 661-662
 mutant forms of, 794-797
 NZB and BALB/c, differences between, 821-825
 primary structure of, 661-665
- N**
- Nuclear proteins, synthesis of during lymphocyte activation, 268-269
- Nuclease, staphylococcal, immune response to, 295-305
- Nucleic acid hybridization, use of to determine number of germ-line V genes, 832-833, 855-887
- O**
- One, nonspecific signal hypothesis of B-cell activation, 218-225
- Ontogeny, B-cell differentiation during, 139-162, 165-172
- Origin of antibody diversity. *See* Antibody diversity, generation of
- P**
- Peritoneal exudate cells, T-cell activation by, genetic restriction of, 571-578
- Peyer's patches, secretory IgA response by lymphocytes of, 201-213
- Phylogeny, of lymphocyte surface immunoglobulins, 261-271
- Polyclonal B-cell activators, 217-225. *See also* Lipopolysaccharide
- Pre-B cells, 139, 161-162
- Primed LD typing (PLT) test, 430-432
- Protein A of *Staphylococcus aureus*
 polyclonal activation of B cells by, 221-223
 use of in hemolytic plaque assays, 230
- Prothymocytes
 properties of, 7-8
 terminal transferase in, 65
- R**
- Receptor
 B-cell
 immunoglobulin classes of, 176-199, 240-241
 modulation of following interaction with specific antigen, 239-240
 role of in B-cell activation, 218-225
- Fc. *See also* Lymphocytes, Fc-receptor-bearing
 functional heterogeneity of, 315-321
 physicochemical properties of, 319-321
 possible role of in immunoregulation, 315-317
 for polyclonal B-cell activators, 221
- T cell
 idiotypes, 275-292, 714-717
 multiple, 559-561
 nature of, 116-117, 261-270, 275-292, 585-586, 714-717, 897
- S**
- Self-nonsel self discrimination, role of T and B cells in, 26-30, 224-225
- Soluble factors. *See* Factors
- Somatic cell hybrids
 myeloma cell \times myeloma cell, 781-802
 myeloma cell \times spleen cell, 797-802
- Somatic generation of antibody diversity, 647-658, 761-770, 793-797, 817-861, 882-886
- Staphylococcal nuclease, immune response to, 295-305
- Streptococcal hyperimmunization, antibody response to, 689-696
- Suppression
 allotype, 35-37
 of antibody responses
 control of by immune suppressor genes, 471-473
 effector cells responsible for, 24-31, 94-102. *See also* Suppressor T cells
 mechanism of, 30-31, 95-102, 119-123
 role of soluble mediator in, 95, 119-123
 of contact sensitization, mechanisms of, 108-111
 of cytotoxic T-cell responses, 433-436
 of idiotype production, by anti-idiotypic antibody, 701-721
 of in vitro immune responses, possible role of Fc receptors in, 315-317
- of T-B collaborative responses between allogenic cells, 600-608, 614-617
- Suppressive T-cell factor, 119-123
- Suppressor T-cells
 cell interactions in the induction of, 114-115
 for the cytotoxic T-cell response, generation of in mixed lymphocyte cultures, 433-436
- Ia determinants on, 96-97, 114-115, 497-499
- Ly phenotype of, 24-31, 96-97
- role of in tolerance to contact sensitizers, 105-111
- role of in tolerance to nonself and self antigens, 93-102
- surface markers on, 24-25, 36, 96-97, 114-115, 497-499
- suppression of T-B collaborative responses between allogenic cells by, 600-608
- T**
- T-B interactions
 genetic restriction of, 123-126, 542-544, 597-622
- helper
 between allogenic T and B cells, 542-544, 597-608
 role of soluble factor in, 123-126
 roles of T-cell subclasses in, 21-30
 in the production of IgA antibody responses, 203-204
- suppressive
 mechanism of, 30-31, 35-37, 98-102, 119-126
 role of soluble factor in, 119-126
 roles of T-cell subclasses in, 24-31, 96-97
- T-cell-replacing factor (TRF), 115
- T cells. *See also* Cytotoxic T cells; Helper T cells; Suppressor T cells
 activated, enumeration by means of a virus plaque assay, 73-82
 activation of by antigen-pulsed peritoneal cells, genetic restriction of, 571-578
- Con-A-responsive, genetic mapping of Ia determinants on, 482-483
- differentiation of, 5-8, 129-136
- idiotype-specific, 704-706, 713-714, 721-722
- Ly subclasses of, 23-31
- macrophage interactions with, genetic restriction of, 563-578, 582-584
- mediation of F, antiparental cell-mediated lympholysis by, 514-517
- multiple receptors on, 559-561
- proliferative response, genetic restriction of macrophage-lymphocyte interactions in, 571-578
- receptor
 idiotypes, 275-292, 714-717

- T-cells (*continued*)
- nature of, 116-117, 261-270, 275-292, 585-586, 714-717, 897
 - subpopulations, expression of Ia antigens on, 492
 - surface immunoglobulin on, 261-270
 - T₁ cells, role of in the regulation of antibody responses, 89-91
 - Terminal transferase, 63-71
 - T_HB antigen, 38-39
 - Thy-1 antigen
 - rat, tissue distribution and physicochemical properties of, 51-60
 - regulation of the antibody response to, 592-594
 - Thy-1⁻ variant cell lines, 407-411
 - Thymopoietin, 5-8
 - TL antigen, molecular structure of, 360, 363-367
 - TL⁻ variant cell lines, 411-413
 - T lymphoma cells
 - immunoglobulins from, 264-266
 - presence of surface receptors for murine leukemia viruses on, 15-21
 - Tolerance
 - B cell, use of polyclonal B-cell activators to detect, 223-225
 - to contact sensitizers, mechanisms of, 105-111
 - in cytotoxic T cells induced by neonatal injection of CD antigens, 436-437
 - induction of via clonal abortion mechanism, 241-242
 - induction of in immature B cells, 159-161, 168-170, 188-190
 - role of adherent cells in, 253-259
 - role of suppressor T cells in, 93-102, 105-111
 - self, modulation of surface IgM on immature B cells and, 159-161
 - transplantation, induced by autoimmunization with idiotypic receptor molecules, 280-282
 - Triggering, B cell. *See* Activation, B cell
 - T-T interactions
 - in the induction of helper cells, 113-116
 - in the induction of suppressor cells, 114-115
 - role of in the regulation of antibody responses, 85-91, 113-116, 125-126
 - Tumor cells, syngenic, H-2 restrictions of cytotoxic T-cell response to, 547-550
- U
- Ubiquitin, 5-8
- V
- V-C integration, mechanism of, 801-802, 860-861, 881-882
 - Viral surface antigens, early, role of in cytotoxic T-cell response to vaccinia virus, 533-535
 - Virus-coated cells, H-2 restriction of cytotoxic T-cell response to, 552-556
 - Virus-infected cells, specificity of cytotoxic T cells mediating lysis of, 505-509, 529-535
 - Virus infection of lymphocytes, latent or persistent, 77-82
 - Virus plaque assay for enumerating activated T cells, 73-82
 - V_H genes, 687-691, 735-740, 819-845
 - V_κ-1 locus, 809-814
 - V_I genes, 805-814, 819-845